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Human immunodeficiency virus type-1 (HIV-1) initiates infection by direct fusion of the 
virus membrane with the plasma membrane of the target cell. This fusion event is a 
multi-step process mediated by the envelope (Env) surface subunit gp120 and the 
transmembrane subunit gp41 which anchors gp120 into the viral membrane. First the 
surface subunit gp120 binds to the primary receptor CD4. This interaction promotes actin 
cytoskeletal rearrangements in the target membrane that bring the chemokine coreceptor, 
CCR5 or CXCR4, into close proximity for binding and induces conformational changes 
in gp120 that allow it to couple to the coreceptor. Formation of the gp120-CD4-
coreceptor complex triggers conformational changes in the transmembrane gp41 subunit 
that allows gp41 to insert into the target cell membrane, allowing lipid mixing or 
hemifusion, and pore formation. Previous studies from our lab have shown that 
reorganization of the actin cytoskeletal network is required for multiple steps in HIV-1 
fusion. Additional data from our lab show that HIV-1 Env induced activation of Rac is 
 iii 
critical for HIV-1-mediated membrane fusion. HIV-1 Env activates multiple signaling 
pathways that could potentially lead to Rac activation. In an effort to determine which 
signaling molecules were required both upstream and downstream of Rac activation, we 
utilized small interfering RNAs (siRNAs) and various small-molecule inhibitors to 
disrupt signaling pathways activated by HIV-1 Env through CD4 and coreceptors. 
Published data from our lab demonstrated that the Gαq pathway, activated by CCR5, is 
required for Env-mediated Rac activation and fusion. Further studies have shown that the 
downstream effectors of Rac that promote fusion are components of the Wave2 signaling 
complex and at least some of these signaling components are required at a post-
hemifusion step. Other studies from our lab and other labs, with mutant CD4 constructs, 
have shown that signaling through CD4 is also playing a role in membrane fusion, most 
likely at the step of forming the gp120-CD4-coreceptor complex. These results suggest a 
model in which gp120 signaling though CD4 promotes gp120 binding to and signaling 
through the coreceptor, which is necessary for full fusion and release of the viral 
nucleocapsid into the cell’s cytosol. 
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HIV AND AIDS 
Human immunodeficiency virus (HIV), a complex retrovirus and the etiologic agent of 
acquired immunodeficiency syndrome (AIDS), has infected more than sixty million 
people worldwide since its discovery in the early 1980s. AIDS was first identified in the 
United States (US) in 1981. Clinicians in New York and California noted an unusual 
clustering of rare diseases such as Kaposi sarcoma and other opportunistic infections in 
young homosexual men. It soon became apparent that there was a common 
immunological deficit in cell-mediated immunity, resulting from a loss of circulating 
CD4+ T cells in these patients. In 1983, a research team in France published data 
indicating an association between a retrovirus and AIDS. At the time there were two 
known retroviruses, human T-lymphotrophic virus (HTLV)-1 and HTLV-II that were 
recognized as viruses known to preferentially infect CD4+ T cells. The transmission 
pattern among individuals with HTLV was similar to that seen among AIDS patients. In 
1984 the French group and researchers at the National Institutes of Health (NIH) led by 
Robert C. Gallo published evidence that the virus known as HIV was the cause of AIDS 
(1).  
The discovery of HIV as the agent that causes AIDS led to intense research in the 
field of molecular virology that is still ongoing (1). This research has led to the 
development of potent antiretroviral drugs, 30 of which are currently approved by the 
Food and Drug Administration (FDA) to treat people infected with HIV. These drugs are 
prescribed in combination in a treatment known as highly active antiretroviral therapy 
(HAART). This treatment, although effective at suppressing the virus does not cure the 
infection so it must be maintained for life, and prolonged use often results in significant 
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toxicity. Any interruption in treatment results in the rapid rebound of replicating virus 
which can lead to drug resistance. An increase in heart disease, diabetes, liver disease, 
and many forms of cancer has also been observed in aging HIV-infected patients who are 
receiving treatment (2). Due to the high cost of HAART therapy and the lack of an 
adequate delivery method, it is not available in developing countries where it is most 
needed. According to the 2008 UNAIDS/WHO report, there are 33 million people 
estimated to be currently living with HIV/AIDS worldwide, with 22 million residing in 
sub-Saharan Africa.  Out of the 9.7 million people in immediate need of life-saving AIDS 
drugs, only 2.99 million (31%) are receiving the drugs.  This information clearly shows 
that current treatment strategies are not sufficient  and that understanding the molecular 
biology of HIV and its relationship with the host is imperative to further progress in drug 
discovery, vaccine development and prevention methods. 
HIV GENES AND THEIR PROTEIN PRODUCTS 
Lentiviruses are a separate genus of the family Retroviridae. They include equine 
infectious anemia virus, visna/maedi virus, caprine arthritis-encephalitis virus, bovine 
immunodeficiency virus, feline immunodeficiency virus, simian immunodeficiency virus 
(SIV), and HIV. There are two types of HIV, HIV-1 and HIV-2. HIV-1 is found globally, 
whereas HIV-2 is found predominantly in West Africa.  HIV-2 has a longer clinical 
latency period than HIV-1 and a lower morbidity rate. HIV-1 and HIV-2 have 40-60% 
genomic similarity and are thought to have evolved from SIV.  Lentiviruses possess a 
relatively large genome, with more genes than other retroviruses. Lentiviral genomes 
encode the three structural proteins common to all retroviruses, Gag, Pol, and Env, as 
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well as many additional auxiliary proteins. The gag gene encodes the 55kD Gag 
polyprotein precursor, and due to a ribosomal frameshift event, the 160kD Gag-Pol 
polyprotein that is cleaved to produce viral protease (PR), integrase (IN), and reverse 
transcriptase (RT). RT transcribes viral DNA from the viral RNA genome, IN catalyzes 
integration of viral DNA into the host chromosome, and during maturation of virus 
particles, PR cleaves the Gag polyprotein into matrix (MA), capsid (CA), and 
nucleocapsid (NC). The product of the env gene is a monomeric glycoprotein precursor 
(gp160) that is processed into the gp120 surface subunit and the gp41 transmembrane 
subunit (2-4).  
The auxiliary proteins, transcriptional activator (Tat) and regulator of viral gene 
expression (Rev), perform regulatory functions necessary for viral replication in vitro and 
in vivo. The negative effector (Nef), viral infectivity factor (Vif), viral protein R (Vpr), 
and viral protein U (Vpu), are not essential for viral replication in vitro, and are known as 
the accessory proteins. Tat and Rev are translated early in infection from multiply spliced 
RNA, so that they may function to stimulate transcription and facilitate mRNA export, 
respectively. The accessory protein Nef is also translated early from multiply spliced 
RNA, so that it may induce signaling pathways that enhance viral replication. Nef 
promotes the production and release of more infectious virions by activating T cells, 
activating expression of FasL which induces apoptosis in cytotoxic T cells that express 
Fas, and by downregulating expression of CD4 and major histocompatibility complex 
(MHC) class I molecules on the cell surface. Nef also inhibits apoptosis in the infected 
cell by inhibiting p53 and by blocking Fas and TNFR death signaling pathways (2, 3).  
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The rest of the accessory proteins, Vif, Vpr, Vpx, and Vpu are translated late in 
infection from singly spliced mRNAs. Vif is required early in infection to stabilize the 
reverse transciption complex (2, 3). Vpr is associated with the nucleocapsid of the virion 
and has multiple functions in the cell. Vpr promotes G2 cell cycle arrest,  plays a role in 
reverse transcription, promotes entry of viral DNA into the nucleus, regulates apoptosis 
and transactivates the HIV-LTR (5). The HIV-2 and SIV genomes encode the accessory 
protein Vpx in addition to Vpr.  Similar to Vpr, Vpx is associated with the nucleocapsid 
and is essential for replication of SIV and HIV-2 in non-dividing macrophages. However 
the role of Vpx in the HIV-1 life cycle is less clear.  The current hypothesis for the role of 
Vpx is that it interacts with a ubiquitin ligase complex to inactivate a restrictive host 
factor in macrophages (6). The final accessory protein Vpu is unique to HIV-1 and 
SIVCPZ and is involved in viral release and degradation of CD4 (2, 3). 
 HIV-1 LIFE CYCLE 
HIV-1 entry is mediated by the envelope (Env) glycoproteins gp120 and gp41. 
Entry is a multistep process that begins with binding of gp120 on the virion surface to the 
receptor CD4 on the surface of the target cell. This gp120-CD4 interaction induces 
conformational changes in the gp120/gp41 complex that expose coreceptor binding 
regions of gp120 and regions of gp41 necessary for insertion into the membrane. Next, 
one of two chemokine coreceptors, CCR5 or CXCR4, is localized to the binding site and 
gp120 binds the coreceptor, leading to dissociation of gp120 and gp41. Subsequently the 
fusion peptide gp41 is inserted into the target membrane leading to establishment of the 
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fusion pore and pore expansion (4, 7).  The process by which HIV-1 virions enter the host 
cell will be discussed in great detail below. 
Once fusion occurs and the NC is released inside the cell, viral uncoating occurs, 
revealing the reverse transcription complex. This complex includes the diploid viral 
positive sense RNA genome, tRNAlys primer, RT, IN, MA, NC, Vpr and various host 
proteins. Phosphorylated MA then facilitates docking of this complex on actin 
microfilaments which is necessary for DNA synthesis.  Completion of reverse 
transcription results in double stranded DNA that assembles with IN, MA, Vpr, RT, and 
host proteins to form the preintegration complex (PIC), which is then transported on 
microtubules to the nucleus. The PIC has a 28nm radius making it approximately the 
same size as a ribosome and making it twice the size of the center aqueous channel in the 
nuclear pore, indicating that nuclear import is not a simple process. Many of the proteins 
in the PIC have nuclear targeting signals, so these proteins could be functioning in a 
cooperative manner to facilitate import or they could be playing unique roles based on the 
target cell. Once the PIC is inside the nucleus, integration of viral DNA into the host 
chromosome is mediated by IN, and this establishes a functional provirus. Alternatively, 
the ends of the viral DNA may be joined to form 2-LTR circles, the virus may undergo 
homologous recombination resulting in a single LTR circle, or the viral DNA may auto-
integrate into itself. None of these processes result in production of infectious virus; 
however these circular forms may be transcriptionally active leading to production of Tat 
and Nef (2, 3).  
Once the viral DNA is integrated, it is transcribed into proviral mRNAs, and the 
mRNA is transported to the cytoplasm.  Transcription of viral DNA into mRNA is a 
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multi-step process involving both host and viral proteins. First, the host-cell transcription 
machinery transcribes short nonpolyadenylated transcripts that form an RNA stem loop 
called the transactivation response (TAR) element. In association with the cellular protein 
cyclin T1, the viral protein Tat binds TAR and recruits cyclin-dependent kinase 9 (Cdk9) 
and other activating host proteins to the HIV LTR, where they form the positive 
transcription-elongation factor b (P-TEFb) complex. The P-TEFb complex positively 
regulates the host RNA polymerase II, allowing efficient elongation of the viral genome. 
During the transcription process, more than a dozen specific transcripts are generated. 
Some of these transcripts are unspliced or singly sliced and they stay in the nucleus, 
whereas the multiply spliced transcripts that encode Nef, Tat, and Rev are transported 
into the cytoplasm early in infection (2, 3).  
Once transcribed, the small shuttling protein Rev binds to the Rev response 
element (RRE) in the env gene and in association with host proteins exports the unspliced 
and singly spliced transcripts from the nucleus to the cytoplasm (2, 3). The singly spliced 
transcripts encode the structural and accessory proteins Env, Vif, Vpr, and Vpu, whereas 
the unspliced transcripts encode the viral RNA genome, Gag-Pol mRNA, and pre-
mRNA.  Once in the cytoplasm Gag and Gag-Pol polyprotein precursors are translated by 
cytoplasmic ribosomes, Env mRNA is translated by ribosomes bound to the endoplasmic 
reticulum (ER), and full-length RNA molecules become encapsidated as progeny viral 
genomes. Gag and Gag-pol precursors are transported to the plasma membrane by 
multivesicular bodies, whereas the Env proteins are transported through the Golgi 
apparatus where they are glycosylated and cleaved to form the mature gp120 + gp41 
complex, and delivered to the plasma membrane.  At the plasma membrane myristoylated 
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Gag associates tightly with the inner leaflet of the membrane, oligomerizes with 
additional Gag molecules, and recruits Env gp120 and gp41 proteins as trimers to the site 
of assembly. Also recruited to the site of assembly are two copies of the viral RNA 
genome, Vpr, and Nef which are then encapsidated. Formation of the immature HIV 
capsid requires approximately 1,500 Gag polyproteins. The host protein human ATP-
binding protein HP68 acts a molecular chaperone for Gag, mediating conformational 
changes in Gag necessary for the assembly of HIV capsid. Once assembled at the plasma 
membrane the virions bud from the surface of the cell. This process involves the host-cell 
budding machinery and is directed by Gag. At this point the immature virion is 
noninfectious; maturation requires that PR cleave Gag and Gag-Pol, at which point Gag 
molecules rearrange to form mature infectious virus which involves condensation of the 
virion cores (2, 3).  
HIV-1 ENTRY 
 HIV-1 enters cells by fusion at the plasma membrane and endocytosis, and it is 
thought that only fusion at the plasma membrane leads to productive infection (2). 
However, a recent study has shown that complete HIV-1 fusion can occur in endosomes 
resulting in efficient infection (8). Fusion at both the plasma membrane and in endosomes 
is mediated by the Env glycoproteins expressed on virions and CD4 and coreceptors 
expressed on the target cell surface. On the virion gp120 is organized into trimeric spikes 
that  associate noncovalently with trimeric gp41 which anchors gp120 into the viral 
membrane (4). HIV-1 fusion is a complicated process that is dependent on actin 
cytoskeleton rearrangements in the target cell and multiple conformational changes in 
Env. The initial attachment of the mature virion to the target cell is due to the interaction 
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of positively charged regions on Env with negatively charged heparan sulfate 
proteoglycans. This attachment brings gp120 into close proximity to the primary receptor 
CD4 (4, 9). Gp120 then binds to CD4 and this engagement induces conformational 
changes in the gp120/gp41complex and actin cytoskeleton rearrangements in the target 
cell. Multiple regions of gp120 undergo conformational changes upon binding to CD4.  
One set of conformational changes results in exposure of the coreceptor binding domain 
on gp120. This domain includes conserved epitopes near or within the bridging sheet and 
the V3 loop. CD4 binding has been implicated in promoting exposure of the bridging 
sheet by moving the V2 loop. Additional conformational changes occur in the C1-C4/5 
regions of gp120 that are occluded due to gp41 interactions. CD4 binding also promotes 
conformational changes in gp41 that induce formation and exposure of the gp41 pre-
hairpin intermediate (4). The actin cytoskeleton rearrangements induced in the target cell 
by CD4 binding promotes recruitment of chemokine receptors CXCR4 or CCR5, 
cholesterol, ganglioside GM1, adhesion molecules, and GPI-anchored proteins to contact 
sites (10, 11). Once the coreceptor binding site on gp120 is exposed and the coreceptor is 
in close proximity gp120 can bind to coreceptor. Binding of gp120 to the coreceptor 
induces signaling through the coreceptor that results in actin cytoskeleton rearrangements 
necessary for fusion. Binding to the coreceptor also induces additional conformational 
changes in gp41 and subsequent insertion of the hydrophobic N-terminus of gp41 into the 
target membrane (4, 12).   
To follow gp41 progression through intermediate conformations, the 
formation/exposure of novel gp41 epitopes has been assessed by antibody reactivity or by 
binding measurment of gp41-derived peptides that are complementary to the heptad 
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repeat region (HR) 1 and HR2 domains of gp41 (7, 13-21). Intermediate conformations 
where HR domains are exposed after binding to CD4 and coreceptor and prior to six-
helix bundle (6HB) formation are referred to as pre-bundles (7). During fusion gp41 folds 
into three intermediate prebundle conformations that mediate different steps of membrane 
fusion before folding into a stable 6HB as depicted in Figure 1. The first gp41 early 
prebundle forms after gp120 binding to CD4. Further conformational changes in gp120 
and gp41 occur after binding to coreceptors which result in dissociation of gp120 and 
gp41. At this stage HR1 and HR2 of gp41 are exposed. Additional folding of gp41 results 
in formation of a second bridging prebundle that inserts itself into the target cell’s plasma 
membrane and further folding of gp41 into the fusogenic intermediate results in 
hemifusion (lipid mixing). The energy from the final folding of gp41 into the 6HB 
conformation is thought to facilitate pore formation and enlargement while the 6HB, 
which forms after pore formation, is though to prevent pore closure. In the 6HB 
conformation the HR2 domains are packed in antiparallel orientation against the trimeric 
HR1 coiled coil and this interaction forms a thermodynamically stable 6HB structure (7, 
22, 23). The actin cytoskeleton rearrangements induced by Env signaling via coreceptor 
in cooperation with folding of multiple gp41 intermediates into 6HBs mediates the pore 
formation and enlargement necessary to allow delivery of the nucleocapsid to the 
cytoplasm (7). 
The initial steps of Env binding to and forming ternary complexes with CD4 and 
coreceptor can occur at blocked temperatures (below 18°C when membrane fusion does 
not occur) without promoting hemifusion or fusion. HR1 and HR2 domains of gp41 are 
also exposed after receptor binding at blocked temperatures. The formation of the Env-
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CD4-coreceptor complexes and the intermediate gp41 conformations at this lower 
temperature is referred to as temperature arrested stage (TAS). The next stage of lipid 
mixing which occurs at optimal temperature can be blocked by lyso-lipids that inhibit 
fusion by disfavoring monolayer bending. This arrested stage is termed lipid-arrested 
stage (LAS) and is used to identify the gp41 intermediate structure that forms directly 
before membrane merger (7).  At this stage the gp41-derived peptides inhibit fusion 
demonstrating that the 6HB has not yet formed. The gp41 conformations formed at 
optimal temperature but prior to membrane merger (LAS) directly engage the target 
membrane and gp41 folding into 6HB is completed after but not before pore formation 
(7). Based on these observations it is thought that gp41 pre-bundles can form small 
nascent fusion pores and 6HBs play a role in stabilizing and possibly expanding the pore. 
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Fig. 1.  Model of intermediate steps of HIV-1 Env-induced fusion progressing 
through early, bridging, and fusogenic prebundles toward 6-helix bundles that form 
after opening of the fusion pore adapted from Melikyan 2008 (7). As mentioned in 
the text actin cytoskeletal rearrangements are necessary in the target cell first to localize 
the coreceptor to the site of gp120-CD4 binding and then again at a post-binding step 
most likely to facilitate pore formation and enlargement. 
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THE ACTIN CYTOSKELETON AND HIV-1 ENTRY 
 In the case of HIV-induced membrane fusion as well as other types of membrane 
fusion, actin remodeling is probably required for at least 3 steps in the membrane fusion 
process (12, 24). The actin filament capping drug that interferes with actin assembly, 
Cytochalasin D (CD), inhibits Env-CD4-coreceptor complex formation (25) but has little 
to no effect on fusion post-binding (12, 25). Jasplakinolide (JP), an actin filament 
stabilizing drug and Lactrunculin A (LA), a monomer sequestering drug both inhibit 
HIV-1 induced membrane fusion at a post-binding step (12).  
 Rho GTPases are involved in multiple cell signaling pathways leading to 
cytoskeleton rearrangements, cell adhesion, cell polarity, endocytosis, vesicle trafficking, 
progression through the cell cycle, differentiation, oncogenesis, and gene transcription 
(26, 27).  Rho GTPases are regulated by three groups of proteins, guanine nucleotide 
exchange factors (GEFs), which increase exchange of GDP for GTP, GTPase activating 
proteins (GAPs), which stimulate intrinsic GTPase activity, and guanine nucleotide 
dissociation inhibitors (GDIs), which inhibit the dissociation of GDP from GTPases (27-
30). Membrane fusion is mediated by Rho GTPase activation of multiple downstream 
effector complexes involved in cytoskeletal rearrangement  (24). There are three main 
subfamilies of Rho GTPases, each controlling a signal transduction pathway connecting 
membrane receptors to assembly and disassembly of the actin cytoskeleton. Members of 
the Rho subfamily stimulate myosin based contractility resulting in stress fibers and focal 
adhesions. The Rac subfamily stimulates lamellipodia and membrane ruffles and the 
Cdc42 subfamily stimulates the formation of filopodia (27, 29, 31, 32).   
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Upon incubation with HIV-1 R5 Env expressing cells, target cells expressing CD4 
and CCR5 underwent changes to the membrane structure resulting in membrane ruffles, 
lamellipodia and filapodia extensions, indicating activation of Rac and Cdc42 in target 
cells (12). However, only the downstream effects of Rac are required for Env-induced 
membrane fusion, as expression of dominant negative (DN) Rac completely abolished 
fusion but DN Cdc42 had no effect. On the other hand, expression of DN Rho, in target 
cells caused a 40% reduction in syncytium formation and cell fusion as measured by dye 
transfer, but no stress fibers were observed in cells incubated with HIV R5 Env 
expressing cells (12). In addition, both Rac and Rho have been shown to be activated in 
target cells incubated with HIV R5 Env expressing cells or with HIV-1, respectively (12, 
33).  
The study demonstrating Env-mediated RhoA activation also showed a 50% 
reduction in single cycle infection and cell-cell fusion with cells expressing DN RhoA 
(33). A more recent study described a role for Env-mediated filamin-A association with 
CD4 and coreceptor in Env-CD4-coreceptor complex formation. Interaction of filamin-A 
with CD4 and coreceptor induces phosphorylation and inactivation of cofilin through a 
RhoA and ROCK dependent mechanism (11). The activation of Rac and Rho by HIV-
Env and the inhibition of fusion by blocking this activation is evidence that HIV-1 
induced signaling to Rho GTPases is required for fusion. However, the studies with CD, 
LA and JP demonstrated that actin cytoskeleton rearrangement is necessary at multiple 
steps in the membrane fusion process (12, 25). Therefore it is unclear whether Rac and 
Rho are required for the same or different steps in the fusion process. 
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Rho activation mediates integrin clustering and  promotes actin polymerization, 
however the level of actin polymerization in response to Rho is relatively small (27). 
Outside of integrin clustering Rho activation has been shown to have a stabilizing effect 
on the actin cytoskeleton. Its activation leads to suppression of cofilin, an actin 
depolymerizing protein, and enhancement of myosin activity which results in a rigid 
cortex (27, 34, 35). On the other hand, Rac is a potent activator of polymerization and has 
been shown to activate multiple actin remodeling proteins leading to nucleation of actin 
polymerization, and uncapping of actin filaments (35). Stimulation of Rac has also been 
shown to actively antagonize Rho resulting in disassembly of stress fibers and focal 
adhesions (27, 36).   
Rho has also been shown to mediate inactivation of Rac via the filamin-A-binding 
Rac GAP, FilGAP. FilGAP antagonizes Rac in response to phosphorylation by the 
RhoA-activated ROCK, and the binding of FilGAP to filaminA is thought to position 
FilGAP where upstream factors can activate and inactivate it (37). This study and the 
2007 Jimenez-Baranda study describing a role for filamin A, RhoA and ROCK in Env-
CD4-coreceptor complex formation, suggest that RhoA activation is required at this 
initial step. Interestingly another study has shown that the C terminus of gp41 interacts 
with and inhibits p115 Rho GEF, suggesting that Rho is turned off and unnecessary for 
fusion events after gp41 insertion (38). Therefore it seems likely that Rho is involved in 
the initial step of Env-induced fusion (Env-CD4-coreceptor complex formation) before it 
is inactivated by the C-terminus of gp41, and active Rac can then mediate later steps in 
membrane fusion. 
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HIV-1 Env induces multiple signaling pathways through CD4 and the coreceptors 
that could potentially lead to Rac activation and actin cytoskeleton reorganization (27, 32, 
39-43). Preliminary studies from our lab indicate that Env-induced Rac activation is 
mediated by the coreceptor as determined by inhibition of Rac activation with the CCR5 
small molecule inhibitor TAK779, and the inability of X4 Env to induce Rac activation in 
CCR5 expressing cells (12). Additional studies with cells lacking expression of CD4 
indicate that CD4 also plays a role in Env induced Rac activation (preliminary studies in 
chapter 5). Also, as described in chapter 2, a small molecule inhibitor (Rac GEF 
Inhibitor) that blocks recognition of Rac by Rac GEFs dependent on a specific Rac 
tryptophan (Trp56) eliminated Env-dependent fusion (44, 45). The Rac GEFs shown to 
be sensitive to this inhibitor are the Rac specific GEF Tiam-1 and the Rac and RhoG 
specific GEF Trio (44). Rac can also be activated and stimulated to promote actin 
rearrangements by an unconventional Rac GEF DOCK180/Elmo/CrkII/p130Cas 
(DOCK180 complex) (28, 39, 46-48). The DOCK180 complex requires cooperation with 
multiple proteins to mediate Rac activation including RhoG and Trio, suggesting that this 
GEF, in addition to Tiam-1 and Trio, would also be inhibited by the Rac GEF inhibitor 
and is possibly required for Env-induced Rac activation and fusion (39).  
CHEMOKINE RECEPTORS CXCR4 AND CCR5 
Chemokines were first identified as chemoattractant cytokines that regulated 
leukocyte trafficking to sites of inflammation. However chemokines are involved in more 
than just chemotaxis. Chemokines have been shown to be involved in angiogenesis, 
hematopoiesis, embryonic development, and metatasis (40) . Some chemokines and 
chemokine receptors are highly specific for each other, but in general chemokine 
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receptors can bind to more than one chemokine and chemokines can interact with more 
than one receptor (49). CXCR4 and its ligand, stromal cell derived factor (SDF-
1/CXCL12) are highly specific for one another, whereas CCR5 is associated with four 
inflammatory chemokines MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), and 
MCP-2 (CCL8), and each of these chemokines can also associate with other receptors 
including CCR1, CCR4,and CCR2B (49, 50).  
Activation of CXCR4 by SDF-1 induces several signaling pathways that lead to 
chemotaxis, migration, and secretion of angiopoietic factors. CXCR4 is expressed by 
many cell types and SDF-1, a member of the alpha family of chemokines, is a potent 
lymphocyte chemoattractant but is also constitutively secreted by fibroblasts in bone 
marrow, lymph nodes, lung, liver, and muscle. During embryogenesis signaling through 
CXCR4 is involved in both hematopoiesis and organogenesis (51). CXCR4 is also 
involved in the homing and retention of hematopoietic/lymphopoietic stem cells, pre T 
and B lymphocytes in the bone marrow, and the trafficking of these cells to sites of tissue 
inflammation and damage. A recent study provides evidence that SDF-1 may also signal 
through another chemokine receptor, CXCR7/RDC1, but its role in cell trafficking and 
migration remains undefined (51). 
CCR5 is expressed on subpoplations of lymphocytes and monocytes/macrophages 
in blood, primary and secondary lymphoid organs and in non-inflamed tissues. CCR5 is 
also expressed in the central nervous system on astrocytes, neurons, and microglia and in 
other tissue on epithelium, endothelium, vascular smooth muscle, and fibroblasts (52). 
Unlike CXCR4 the role of CCR5 in vivo is not very well understood. Studies in knockout 
mice have shown only minor defects in cell mediated immune responses and individuals 
 18 
that lack CCR5 surface expression on their cells due to a 32-base pair deletion in the 
CCR5 gene are seemingly healthy. However, recent results show a role for CCR5 in 
control of infection by West Nile virus (WNV). WNV is a mosquito-borne flavivirus that 
primarily infects birds but can also infect humans. It was first isolated in humans in 
Uganda in 1937 and has caused periodic outbreaks of encephalitis in Africa and Asia 
since then. The first reported case in North America was in a flamingo in 1999 and by 
2005 it had caused 19,369 cases of human symptomatic illness and 782 deaths in the US 
alone. Symptoms associated with the virus include mild-flu like illness, and more rarely 
meningitis, encephalitis, acute flaccid paralysis, and post-neurologic conditions (53, 54).  
In CCR5 knockout mice, infection was uniformly fatal, in constrast to wildtype 
mice where the majority of infected mice survived. In humans with the CCR5∆32 
homozygous mutation, two association studies were performed with a total of four 
cohorts. These studies showed that the majority of CCR5∆32 individuals infected with 
WNV became symptomatic. In one of the cohorts homozygous CCR5∆32 was also 
associated with death. This study also suggested that CCR5 controls WNV infection by 
mediating leukocyte recruitment to the infected central nervous system (53, 55). These 
studies with WNV were the first to associate an antimicrobial function with CCR5 in 
humans, however in mouse models of infection CCR5 has been implicated in defense 
against Trypanosoma cruzi, Toxoplasma gondii, Cryptococcus neoformans, Chlamydia 
trachomatis and herpes simplex virus 1 and 2 (54).  
CHEMOKINE RECEPTORS AND HIV 
Although there are many different chemokine receptors that could potentially act 
as coreceptors for HIV, CXCR4 and CCR5 are the receptors preferentially used in the 
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human host. CCR5 is used by macrophage-tropic viral isolates (R5 viruses) and CXCR4 
is used by T-cell tropic isolates (X4 viruses). Transmission of HIV is mediated by R5 
viruses which are present in early stages of the disease, and preferentially infect CCR5-
expressing macrophages and dendritic cells. R5 viruses are particularly abundant in the 
gut-associated lymphoid tissue, one of the primary sites of HIV and SIV replication. X4 
viruses are present at later stages of disease progression when virus preferentially infects 
CD4+ T cells (2, 56, 57).   
The switch from CCR5 to CXCR4 usage by HIV-1 strains late in the infection 
course is likely due to selective pressure of endogenous CCR5 chemokines. There is not 
always a complete switch meaning that viruses can use both CCR5 and CXCR4, and 
patients may harbor R5 viruses, X4 viruses, and dual-tropic (R5X4) viruses that can use 
both CCR5 and CXCR4. In a subset of patients, during the terminal stages of disease, R5 
and dual-tropic viruses seem to be lost and are replaced by pure X4 viruses. X4 variants 
emerge in only about 40-60% of HIV-1 positive individuals. X4 variants are associated 
with expanded cell tropism, increased viral replication rate, faster disease progression, 
and the onset of AIDS. It is still not clear whether the X4 phenotype is a cause or 
consequence of HIV disease progression. 
HIV-1 ENTRY INHIBITORS 
Currently there are two entry inhibitors, approved by the FDA for treatment of 
HIV-1, maraviroc (Selzentry, Pfizer) an antagonist of CCR5, and enfuvirtide (Fuzeon, 
Roche) also known as T-20, which competitively binds to HR1 on gp41 preventing 
association of HR1 with HR2. The efficacy of enfuvirtide is limited by the delivery route 
(subcutaneous injection) and cost. In addition, enfuvirtide is only prescribed in 
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combination with HAART because it has also been shown to drive viral evolution and 
resistance (9, 58, 59). There are many others entry inhibitors including attachment 
inhibitors, co-receptor binding inhibitors, and fusion inhibitors that are currently in 
clinical trials (9, 58, 59). The risk with inhibitors that block chemokine receptors and 
CD4 is that they could also block natural ligand binding and signaling, inhibiting 
essential immune cell functions.  
Most coreceptor inhibitors either approved by the FDA or in clinical trials target 
CCR5. The CCR5 inhibitors that are in clinical trials or beyond, block binding of CCR5 
to its chemokine ligands and block CCR5-mediated signaling events. CCR5 is thought to 
be a better drug target than CXCR4 because individuals harboring the naturally occurring 
mutation CCR5∆32 have no known health defects due to this deletion. However as 
mentioned above, CCR5 has been associated with defense against infection with WNV 
and has been implicated in defense against  Trypanosoma cruzi, Toxoplasma gondii, 
Cryptococcus neoformans, Chlamydia trachomatis and herpes simplex virus 1 and 2 (54). 
These results demonstrate that complete blockade of CCR5 could put patients at an 
increased risk for numerous infections some of which are potentially fatal. In addition 
there is the possibility that treatment with CCR5 antagonists would promote emergence 
of X4 viruses, thereby accelerating disease progression. 
Development of antagonists of CXCR4 is also complicated due to its role in 
multiple processes including cerebral development, embryonic survival and B-cell 
lymphopoiesis (51, 60, 61). In addition, investigations with the X4 inhibitor AMD3100 
revealed that CXCR4 blockade releases myeloid cells and CD34+ stem cells from the 
bone marrow into the blood, and the backup compound AMD-11070 causes abnormal 
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liver histology in animals during long term dosing studies (9, 58, 59). These results show 
that there are many possible disadvantages to blocking the normal functioning of 
coreceptors. In addition, it is well known that the envelope glycoprotein is among one of 
the most variable HIV proteins with diverse phenotypes making evolution of entry 
inhibitor-resistant viruses likely.  Therefore, a better understanding of chemokine 
receptor and CD4 signaling, function, and mechanism of action, in response to natural 
ligands and in response to infectious diseases is necessary to develop novel approaches to 
limiting HIV entry without impairing the normal immune functions of CD4 and 
chemokine coreceptors. 
CD4 SIGNALING 
 The primary cellular receptor for HIV-1, CD4, is a component of the molecular 
complex that facilitates the interaction of the T cell receptor (TCR) with MHC class II 
molecules and is involved in TCR signaling (43, 62).  The CD4 molecule is a 58 kDa 
transmembrane (TM) glycoprotein that consists of a 370 amino acid containing 
extracellular region, a 25 amino acid containing TM region, and a cytoplasmic tail of 38 
amino acids. The extracellular region is folded into four distinct domains, D1-D4. CD4 is 
post-translationally modified by formation of disulfide bonds that stabilize D1, D2, and 
D4, and by N-linked glycosylation of D3 and D4. There is extensive species conservation 
of the cytoplasmic tail of CD4, indicating that it is functionally important. In addition to 
T lymphocytes, CD4 is expressed on monocytes/macrophages, B cells, and certain 
specialized cells of the central nervous system (63). In CD4+ T cells, CD4 plays multiple 
roles in response to antigens. The binding site on MHC II for CD4 is distinct from the 
binding site for the TCR so CD4 can interact with the MHC class II antigen presenting 
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complex (APC) at the same time as the TCR increasing responsiveness to any particular 
antigen. Upon binding, CD4 undergoes conformational changes that lead to activation of 
the constitutively associated Src tyrosine kinase Lck. Activated Lck phosphorylates 
immunoreceptor tyrosine activation motifs (ITAMs) located on accessory chains of the 
T-cell receptor complex. Once ITAMs are phosphorylated, they can bind the Syk family 
kinase ZAP-70 which is then phosphorylated and activated by Lck.  Once activated ZAP-
70 phosphorylates the linker of activation in T cells (LAT) and SLP-76. 
Once these proteins are activated there are three downstream pathways that can be 
induced. LAT and SLP-76 bind to and activate Tec kinases, which phosphorylate and 
activate phospholipase C-γ (PLC-γ). PLC-γ then cleaves inositol phospholipids to 
generate diacylglycerol (DAG) and inositol trisphosphate (IP3). LAT binds to the adaptor 
protein GADS, a homolog to Grb2, which then recruits the Ras guanine nucleotide GEF 
SOS-1 that then activates Ras. Another GEF, Vav, also binds to SLP-76 and LAT and 
this association leads to Rac activation.  Ras is also activated downstream of PLC-γ by 
the GEF Ras-GRP which is activated by DAG and phorbol esters. Other downstream 
effectors of PLC-γ include protein kinase C (PKC) and Calcineurin. Once activated, 
PKC, Calcineurin, Ras, and Rac mediate activation of transcription factors that influence 
cell proliferation and differentiation and activation of proteins involved in actin 
cytoskeleton reorganization (43).  Lck is not expressed in non-lymphocytes, but CD4 
induces signaling through unknown proteins that lead to Ca+ flux, PLC and 
phospatidylinositol-3-kinase (PI3K) activation (64).  
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CHEMOKINE RECEPTOR SIGNALING 
The chemokine coreceptors belong to a family of seven-transmembrane (TM)-
spanning-receptors termed G-protein coupled receptors (GPCRs). GPCRs share a 
common structural theme that consists of an extracellular amino (N) terminal segment, a 
seven TM α-helical segment forming the transmembrane core, three extracellular loops 
(ECL) three intracellular loops (ICL) and a carboxy (C) terminal cytoplasmic segment. 
Chemokine receptors contain an acidic N terminus, the amino acid sequence 
DRYLAIVHA in ICL2, a short basic ICL3, and a cysteine in each of the 4 extracellular 
domains (49). GPCRs associate with heterotrimeric (het) G proteins. The GDP bound 
inactive form of Gα interacts with Gβγ and the GPCR which upon ligand binding acts as 
a GEF and causes dissociation of GDP from Gα. This results in immediate association of 
Gα with GTP, which leads to dissociation from Gβγ and activation of downstream 
effectors of both Gα and Gβγ. Signaling is ended by hydrolysis of GTP to GDP.  
There are four classes of Gα proteins including Gαi, which is sensitive to ADP 
ribosylation by pertussis toxin (PTX), Gαs, Gαq, and Gα12/13. Dissociation of Gαi and 
Gβγ leads to signaling by both subunits.  Gαi signaling results in inhibition of adenylyl 
cyclases (ACs) and subsequent inhibition of cAMP production, activation of potassium 
(K+) ion channels, inhibition of Ca2+ channels, and activation of phosphodiesterases. 
Signaling through the Gβγ subunit associated with Gαi also results in activation of K+ ion 
channels, and inhibition of Ca2+ channels. Unlike the Gαi subunit, Gβγ activation can 
also stimulate PI3K activation, PLC-β activation, activation of some ACs, and can recruit 
Rho and Rac to the plasma membrane. Signaling through Gβγ is usually observed only at 
high agonist concentrations. Gαs-mediated signaling results in activation of ACs and 
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stimulation of cAMP production, stimulation of c-Src, and activation of the GTPases 
activity of tubulin. Gαq-mediated activation of PLC-β, results in production of IP3 and 
DAG, which then stimulate intracellular Ca2+ release and PKC activation. The 
downstream effectors of the Gα12/13 subunits mediate activation of multiple Rho GEFs, 
stimulate E-cadherin and activate a GAP of Ras (65-69).  A few of the signaling effectors 
of each class are illustrated  in figure 2
 
(49)
.
   
While many GPCRs are known to associate with only one class of het G proteins, 
some are capable of interacting with several classes of het G proteins. Different agonists 
for one receptor and different concentrations of agonist can result in different active 
states of the GPCR which are recognized by different G proteins (65). GPCRs are also 
capable of signaling independently of het G proteins through interactions with β-arrestin, 
a scaffolding protein involved in internalization of GPCRs, or by direct binding with the 
PDZ domain of GEFs, and various other binding partners (67, 70).  
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Fig. 2. Signaling effectors activated by ligation of G-protein-coupled receptors 
adapted from Marinissen and Gutkind 2001 (71). 
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HIV-1 SIGNALING THROUGH CD4 AND CORECEPTORS  
Our lab and others have shown that HIV-1 Env mediated signaling is necessary 
for membrane fusion and entry (12, 25, 33, 72-74). Although multiple signaling 
components are known to be activated by HIV-1 Env through the chemokine coreceptors 
and through CD4, many of these components are not required for Env-induced fusion. 
Multiple studies with soluble CD4 and CD4 tailless have shown that signaling through 
CD4 is not essential for Env-induced fusion (75, 76). However these studies were done in 
cell lines where CD4 and coreceptor were over-expressed. More recent studies done in 
primary cells and cell lines expressing physiologically relevant levels of CD4 and 
coreceptor have shown that signaling through CD4 is required to promote formation of 
the Env-CD4-coreceptor complex (10, 11, 25, 53, 54, 77).   
PTX experiments as well as mutational studies have shown that Env-induced 
fusion is independent of signaling pathways mediated by Gαi, and either the conserved 
DRY motif in ICL2 or the C terminus of the coreceptors (78-85). Therefore, the receptor 
signaling events that mediate fusion are induced by Env, independent of Gαi. CXCR4 
and CCR5 are capable of inducing multiple PTX-insensitive pathways either through G 
proteins coupled to ICL3 or ICL1, or β-arrestin. Some PTX-insensitive signaling events 
that are induced by Env engagement of chemokine coreceptors or CD4 are 
phosphorylation and activation of proline-rich tyrosine kinase 2 (pyk2) and p38 MAPK in 
both T cells and primary macrophages (41, 78, 86-93). PTX insensitive p38 MAPK has 
also been shown to be activated by Env in B cells (94). Env-induced pyk2 
phosphorylation is dependent on coreceptor signaling and on extracellular Ca2+ flux (88). 
CCR5 and focal adhesion kinase (FAK) phosphorylation in T cells is also PTX 
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insensitive and CD4 signaling dependent (89). Furthermore, chemokine mediated PTX-
sensitive pathways are blocked by Env, but PTX-insensitive signaling to p38MAPK is 
not (90, 94-97) suggesting that PTX-insensitive signaling pathways are important for 
HIV-1 infection.  
The signaling mediators required for the Env-mediated activation of these 
pathways are unknown, and it is also unknown whether these pathways lead to Rac 
activation and fusion. Various studies have shown that distinct intracellular signals are 
elicited by Env stimulation in different cells, by Env engagement of different coreceptors, 
and by Env versus the receptors’ natural ligands (49, 92, 98, 99). For example, signaling 
through R5 Env but not X4 Env induces elevations of Ca2+ in lymphocytes (100). Neither 
CXCL12 nor the natural ligands of CCR5 activate nonselective cation ion channels that 
are opened by X4 and R5 Env (98). In addition Env activated Cl- currents more 
frequently and Ca2+ activated K 
 
currents less frequently than the corresponding 
chemokines (98). Futhermore, co-engagement of CD4 along with coreceptors may induce 
unique signals not elicited by either receptor alone and/or the presence of CD4 may serve 
to enhance signaling through coreceptors or vice versa. In previous literature it has been 
shown that CD4 constitutively interacts with CCR5 and this interaction leads to 
modulation of signaling via CCR5 (101, 102). CXCR4 has also been shown to interact 
with CD4 in the presence and absence of Env, however the physiological role of this 
interaction has not been fully determined (60, 103, 104). In addition, signaling through 
CD4 via Env or via IL16 has also been shown to inhibit natural ligand mediated 
chemotaxis via CXCR4 and CCR5 without altering expression of either receptor (95, 
102, 105).  
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 It is also possible that the necessary signaling for fusion can occur through either 
CD4 or coreceptor as both are capable of eliciting similar signaling pathways (49). In fact 
unpublished data from the Broder lab demonstrated diminished Env-mediated syncytia in 
cells expressing both tailless CD4 and tailless CXCR4 (49). In conclusion, it is possible 
that although Env mediated signaling appears to be different for CXCR4 vs. CCR5, there 
are similar components activated by both coreceptors that are required for Rac activation 
and fusion. As demonstrated in chapter 3, X4 and R5 Env-mediated fusion with primary 
cells expressing CXCR4 and CCR5 was dependent on the same pathway. It is also likely 
that the interaction of CD4 with CXCR4 or CCR5 is necessary not only to facilitate 
binding of Env and exposure of the fusion peptide domain but also to facilitate signaling 
distinct from that induced by chemokines. Therefore, Env-induced Rac activation and 
subsequent fusion could be dependent on signaling components activated by ligation to 
CD4 and CXCR4 or CCR5 that are not activated by chemokines or required for host 
coreceptor functions.  
CONCLUSION  
In conclusion, the current treatment for HIV, HAART, although effective at 
suppressing the virus, does not cure the infection, it must be maintained for life, and 
prolonged use often results in significant toxicity. Interruption in HAART treatment 
results in the rapid rebound of replicating virus which can lead to drug resistance (2). In 
addition, due to its high cost, HAART therapy is not available to 31% of the people in 
immediate need of these life-saving AIDS drugs. This information clearly shows that 
current treatment strategies are not enough and understanding the molecular biology of 
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HIV and its relationship with the host is required to make further progress in drug 
discovery. 
 New drug development targets the steps in entry. There are many entry inhibitors 
including attachment inhibitors, co-receptor binding inhibitors, and fusion inhibitors that 
are currently approved for treatment or in clinical trials (9, 58, 59). The risk with 
inhibitors that block chemokine receptors and CD4 is that they could also block natural 
ligand binding and signaling, inhibiting essential immune cell functions. In addition, it is 
well known that the envelope glycoprotein is among one of the most variable HIV 
proteins with diverse phenotypes making evolution of entry inhibitor-resisitant viruses 
likely.  Therefore, a better understanding of signaling through CD4 and chemokine 
receptors in response to natural ligands and in response to HIV-1 Env is necessary to 
develop novel approaches to limiting HIV entry without impairing the normal immune 
functions of CD4 and chemokine coreceptors.  
In chapter 3 we provide evidence that siRNA and inhibitors targeted to Gαq and 
its downstream effectors prevent HIV-1 infection of TZM-BL cells as well as Env-
dependent membrane fusion in U87.CD4.CCR5 cells and PBLs and virus-dependent 
membrane fusion of U87.CD4.CCR5 cells. In chapter 4, we show that the Rac mediated 
actin cytoskeletal rearrangements necessary for fusion are dependent on Abl and the 
Wave2 signaling complex. These results confirm and extend the implication of Rac-
mediated actin cytoskeletal rearrangements in HIV-1 infection, and point to new potential 
target molecules of HIV-1 inhibitory drugs. This strategy of using inhibitors that disable 
host signaling proteins essential for pathogen survival may have a general efficacy in 
developing drugs to combat pathogens that acquire drug resistance.  
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Abstract 
 A virus-dependent fusion assay was utilized to examine the activity of a panel of HIV-1, 
-2, and SIV isolates, of distinct coreceptor phenotypes.  This assay allowed identification 
of entry inhibitors, and characterization of an antagonist of a Rac guanine nucleotide 
exchange factor, as an inhibitor of HIV-mediated fusion. 
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Introduction  
    HIV infection is initiated by binding of envelope surface protein (SU or gp120) to CD4 
and coreceptor, usually either chemokine receptor, CCR5 or CXCR4 (106).  This results 
in conformational changes in transmembrane envelope protein (TM or gp41), resulting in 
insertion of the fusion peptide into the cell membrane, and subsequent fusion of viral and 
cell membranes.  HIV envelope acts as a chemokine mimic, stimulating responses such 
as chemotaxis, gene transcription, and phosphorylation (107).   
     One target of this signaling pathway is the actin filament network (108).  
Reorganization of the actin cytoskeleton is a critical feature of HIV-induced fusion (12).  
This is mediated by activation of Rho family GTPases, especially Rac (27).  Rac 
regulates diverse cellular processes, including intercellular adhesion, cytoskeletal 
membrane ruffling and lamellipodia formation, proliferation, and gene transcription.  The 
active, GTP-bound form of Rac is negatively regulated by Rac GTPases (GAPs) and 
positively regulated by Rac guanine nucleotide exchange factors (GEFs).  Tiam1 is a 
GEF specific for Rac, while others are more promiscuous in activating multiple Rho 
GTPases.   
     In order to further elucidate the role of Rac activation in HIV fusion, we made use of a 
novel virus-dependent fusion assay (12, 109-111).  This is based on the ability of virus 
particles to bridge at least two cells and allow transfer of cytoplasmic contents.  In this 
assay, we use U87 glioma cells expressing CD4 and CCR5 or CXCR4, as well as 
vaccinia virus expressing T7 polymerase.  The second population of U87 glioma cells, 
with CD4 and CCR5 or CXCR4, is infected with a vaccinia virus with a β-galactosidase 
gene under the regulation of the T7 promoter.  A three hour incubation of these two cell 
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populations in the presence of fusion-competent virus particles allows fusion, quantified 
by β-galactosidase activity.  Sensitivity of the assay was found to be enhanced by serum 
starvation for 24-48 hrs prior to fusion.  We show here that this assay is rapid, flexible, 
and applicable to a wide range of lentivirus isolates.  Moreover, this assay is useful for 
examining the activity of inhibitors of receptor or co-receptor binding, fusion peptide 
activity, as well as subsequent fusion activities, including Rac activation. 
Results 
Comparison of virus-dependent fusion and infection assays and the env-dependent 
fusion assay 
     The virus-dependent fusion assay was directly compared to the env-dependent fusion 
assay (Fig 1).  For the env-dependent fusion assay, a macrophage-tropic virus, derived 
from the YU2 envelope (WT), was compared to one with a mutation in gag, resulting in 
substitution of L12E within the MA protein, resulting in a defect in envelope 
incorporation in virus particles (112, 113).  Both proviral clones expressed similar 
amount of cell-surface envelope, as demonstrated by the fusion assay (Fig 1, left-hand 
bars).  However, in the virus-dependent fusion assay the WT virus is capable of inducing 
fusion, whereas the L12E virus, defective in envelope incorporation, fails to induce 
fusion activity in this assay (Fig 1, right-hand bars).   
     The virus-dependent fusion and infection assays were also compared with isogenic 
viruses that differed only in the sequence of their V3 envelope domain (Fig 2) (114).  
Virus p2027 includes the V3 loop from R5 strain SF162.  In contrast, virus IDI has a V3 
loop derived from X4 strain HXB2, with the exception of substitutions at positions 27, 
29, and 30 of the V3 loop that are found in SF162.  Virus EIDI is identical to virus IDI 
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with the exception of an additional substitution at position 25.  Twenty or 50 ng of virus 
was tested in the virus-dependent fusion assay, as described above.  In contrast, 10 or 50 
ng of virus was tested for infection of Magi.CD4.CCR5 cells (115).  The viruses 
exhibited dose-dependent levels of infection and fusion in these assays, and the results 
were quite similar.   
     The virus-dependent fusion and infection assays were also tested with a panel of 40 
primary HIV isolates with differences in coreceptor tropism, as well as viruses derived 
from 14 HIV-1 molecular clones, 2 HIV-2 molecular clones, and 2 SIV molecular clones 
(Table 1, Fig 3).  For this purpose, fusion assays were performed with U87.CD4.CCR5 
and U87.CD4.CXCR4 cells, whereas infection assays were performed with Magi.CD4 or 
Magi.CD4.CCR5 cells (which also express CXCR4).  In each case, the virus-dependent 
fusion and infection assays gave comparable results, demonstrating the utility of this 
assay to screen a wide variety of laboratory and primary isolates.     
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Table 1 
   Panel of Isolates Tested with Virus-Dependent Fusion Assay and Magi Assay  
Virus or Panel Coreceptor Usage Novel Properties 
Primary Isolates   
BaL, SF162 R5  
LAI, 8 primary isolates X4 Isolates from diverse clades from NIH AIDS Repository 
89.6, MN R5 X4  
Sequential Isolates R5→ X4 27 longitudinal isolates from 6 HIV-infected MACS subjects 
Molecular Clones   
ADA, BaL, SF162, YU2 
(V3 mutant HXB2 
chimeras) 
Variable R5 
Env chimeras and mutants that express V3 loop 
or minimal sequence determinants for CCR5 
usage in HXB2 backbone 
HXB2 X4  
HIV-2 (ES, ROD10) R5 X4  
SIV (mne, pbj) R5 X4  
Luciferase Reporters   
ADA, SF162, YU2 
chimeras R5 
Multiple mutants with minimal sequence 
determinants for R5 use 
HXB2 X4  
SF2, 89.6 R5 X4  
 
Use of virus-dependent fusion assay for studies of HIV entry inhibitors 
     The virus-dependent fusion and infection assays were compared in studies of entry 
inhibitors that specifically block SU-mediated CD4 binding (Sim2) or CCR5 binding 
(2D7), or TM-mediated fusion (T20, Fig 4).  U87.CD4.CCR5 cells were pre-incubated 
with antibody or drug, at the indicated concentrations for 12 hrs.  For fusion assays, the 
cells were also infected with either vaccinia viruses expressing β-galactosidase or T7 
polymerase, as described above.  The cells were then exposed to 100 ng of HIV-luc virus 
(YU2-derived), for either 3 hrs for the fusion assay or 24 hrs for the infection assay (116).  
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Fusion activity was determined by β-galactosidase activity, as described above.  
Infectious virus was quantified by luciferase activity.  In each case, a similar 
concentration-dependence was seen for inhibition, although the infection assay was 
slightly less sensitive than the fusion assay at high concentrations of the anti-CCR5 
antibody (2D7, Fig 4a).  Similar assays were carried out with two different preparations 
of T-20, a TM-fusion inhibitor, and inhibitory concentrations identified in the fusion 
assay were similar to those reported previously using infection assays (Fig 4b) (117).      
Identification of a Rac GEF inhibitor that blocks HIV entry 
     The virus-dependent fusion assay was utilized to identify novel HIV entry inhibitors.  
Based on previous observations of a role of Rac activation during HIV fusion, we 
examined an inhibitor of the Rac 1 GEFs, Trio and Tiam, NSC23766 (44).  This drug 
blocked HIV fusion, as measured by the Env-dependent fusion assay (Fig 5a,b), infection 
(Fig 5c), or virus-dependent fusion (Fig 5d).  The concentration range of HIV inhibitory 
activity was similar to that required to block Rac activation (not shown). 
     In order to examine the specificity of the effects of the Rac GEF inhibitor, a 
constitutively active Rac mutant, RacV12, was used to overcome the inhibitor effects by 
activating the signaling pathway downstream of the Rac GEFs.  RacV12  overcame the 
effects on Rac activation as measured by the amount of Rac-GTP in cell lysates resulting 
from HIV Env-mediated fusion (Fig 6a).  No effects of RacV12 were seen on Rho 
activation resulting from HIV Env mediated fusion (not shown).  Moreover, RacV12 
overcame the effects on Env-mediated fusion of the Rac GEF inhibitor (Fig 6b).     
Conclusions 
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         The virus-dependent fusion assay provides a rapid, sensitive, flexible method to 
examine the biological activity of laboratory or natural isolates of HIV-1, -2, or SIV, and 
may have applications to many other viruses that mediate pH-independent fusion.   It 
compares favorably with other assays of virus, such as one that depends upon transfer of 
a virus core containing a Vpr-β-lactamase fusion protein into a target cell, which requires 
a longer incubation time and FACS analyses (118, 119).  It is likely that the virus-
dependent fusion assay can also examine pseudotyped HIV particles, to identify 
inhibitors of other viral glycoproteins, as shown with the β-lactamase assay (120).  This 
assay has advantages over various env-dependent fusion assays, since it utilizes relevant 
levels of virus-associated glycoprotein and does not require multiple receptor contacts for 
initiating the activity (121).      
     The rapidity of the virus-dependent assay is ideal for screening panels of potential 
HIV entry inhibitors, and is readily adaptable for high throughput screens.  The assay is 
effective at identifying inhibitory small molecules and antibodies.  It may have 
applications for studies of neutralizing antibodies directed against HIV-1.  Lastly, 
differences in results of virus-dependent fusion and infection assays may provide new 
insights into biological differences between different virus isolates.   
     Rac activation is critical in other aspects of HIV biology besides entry.  HIV-1 Nef 
binds the DOCK-ELMO complex and p21-activated kinase 2 complex to initiate Rac 
activation, inhibit lymphocyte chemotaxis, and induce merlin phosphorylation (122, 123).  
Rac activation is also important for other viruses.  Rho and cdc42 mediate adenovirus 
endocytosis (124).  Early steps in herpes simplex virus type 1 infection are dependent 
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upon regulated Rac and Cdc42 signalling (125).  In contrast, Rho activation facilities 
Kaposi’s sarcoma herpesvirus entry (126).   
     The activity of the inhibitor of Rac GEF, Trio, further substantiates the role of Rac 
activation in the fusion process.  Additional studies of downstream mediators of Rac 
activity in HIV fusion have shown no effects of chemical inhibitors of NADPH oxidase, 
MEK, PI-3 kinase, or myosin light chain kinase, or dominant-negative inhibitors of Pak-2 
or PI-3 kinase (our unpublished findings).  It is quite possible that Rac activation through 
the WAVE, Arp 2/3 complex is important for HIV fusion.  Further studies of the entire 
signaling pathway involved in HIV-fusion should be informative in developing new 
strategies to block infection.   
Materials and methods 
Inhibitors 
     The CCR5 and CD4 monoclonal antibodies 2D7 and Sim.2, and T-20 drugs were 
obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, 
National Institute of Allergy and Infectious Diseases (117, 127, 128). 
Viruses 
     Recombinant vaccinia viruses expressing β-galactosidase (vCB21R), T7 polymerase 
(vPT7-3), and CD4 (vCB-3) were obtained from the AIDS Research and Reference 
Reagent Program, vaccinia viruses encoding an uncleaved HIV envelope (UNC; vCB-
16), ADA envelope (vCB-39), and HXB2 envelope (vSC60) as well as wild type vaccinia 
virus (vWT) were gifts from Dr E Berger, vaccinia viruses encoding the YU2 envelope 
(vSP-5) and constitutively active Rac GTPase (vRacV12) were gifts from Drs C Broder 
and S Wei, respectively.  HIV virus stocks were prepared by lipofection of plasmid DNA 
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encoding full-length proviral molecular clones, with the Env gene of the R5 YU2, ADA, 
or SF162 strains or the X4 HXB2 strain in the HIV NL4-3 backbone (12, 116), or with a 
mutation in the Gag gene at residue 12 (L12E; our unpublished data).  HIV Luc viruses 
encode the firefly luciferase gene in place of Nef.  Transfected 293T cell supernatants 
were harvested after 48 hrs, filtered, and tittered for p24 antigen content by ELISA.  
Twenty-seven low-passage isolates obtained at serial visits from participants in the 
Baltimore site of the Multicenter AIDS Cohort Study (MACS) are also included (129). 
Fusion and infection assays 
     The HIV-1 envelope-mediated fusion assay was modified from that developed by Dr 
Berger (130).  The U87 cell lines were serum-starved for 36 hrs, then infected overnight 
at 37oC with vCB21R at MOI=10, and in some cases recombinant vaccinia virus 
encoding the constitutively active GTPase RacV12 mutant (vRacV12).  Fusion partner 
BSC40 cells were infected overnight with vPT7-3 and vCB-39 encoding the ADA 
envelope.  Alternatively, in some experiments 106 BSC40 cells were transfected with 5-
10 ug of proviral plasmids and infected after 1 hr with vPT7-3.  Cells were then lightly 
trypsinized, washed, and incubated with or without the Rac GEF inhibitor for 1 hr at 
37oC.  Cells (105) of each type are then mixed 1:1 in triplicate wells, incubated for 3 hrs 
at 37oC, and fusion stopped by the addition of NP-40 to a final concentration of 1% and 
freeze thawing at -20oC.   β galactosidase activity was determined using chlorophenol 
red-β-d-galactopyoranoside (CPRG, Calbiochem) and the absorbance of each sample 
determined at 579 nm (116).    
     The virus-dependent fusion assay was performed with free virus particles obtained 48 
hrs after transfection of 293T cells (116).  Virus was incubated in the presence of 20 
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ug/ml DEAE-dextran with 105 U87.CD4.CCR5 cells infected for 18 hrs with vPT7-3 and 
105 U87.CD4.CCR5 cells infected for 18 hrs with vCB21R.  Assays were performed in 
triplicate wells.   Fusion activity was quantified as described above. 
     Infection assays were performed with Magi.CD4 or Magi.CD4.CCR5 cells and 
number of blue foci determined 2 days post-infection (115).  Alternatively, for some 
assays, viruses with luciferase expressed in place of Nef were utilized, and luciferase 
activity measured 1-2 days after infection. 
Rac and Rho Activation Assays 
     These assays were performed with 2x106 serum starved U87.CD4.CCR5 cell mixed at 
a ratio of 1:1 with BSC40 cells infected with vaccinia virus expressing Env or vWT.  In 
some cases, one population of U87.CD4.CCR5 cells was infected with vRacV12.  Rac 
GEF inhibitor was added at the indicated concentrations to the target cells 1 hr prior to 
mixing and again at the time of mixing.  Reactions were incubated at 37oC for 30 min, 
washed two times with ice cold PBS, and cells lysed.  Lysates were snap frozen and later 
equal amounts of protein per well were analyzed using a G-LISA Rac activation or Rho-
A activation assay kit according to the manufacturer’s instructions (Cytoskeleton, 
Denver, CO).      
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Figures 
Fig. 1. Comparison of Env-dependent and virus-dependent fusion assays, using an 
Env packaging-defective mutant proviral clone (L12E).  Virus particles from HIV-1 
MA mutant L12E have diminished levels of envelope incorporation and demonstrate 
little virus-dependent fusion activity.  In contrast, transfection of these proviral clones 
into BSC40 cells result in similar levels of Env-induced fusion when cells are mixed with 
U87-CD4 cells.   
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Fig. 2. Virus-dependent fusion assay results are comparable to levels of infection of 
HeLa.CD4.CCR5 cells containing an LTR-lacZ reporter using viruses with Env V3 
mutations.  These viruses include amino acid substitutions in the V3 envelope domain 
that affect their efficiency of use of CCR5 (114). 
 
 45 
Fig. 3. Virus dependent fusion assay and infection results with HIV-2 and SIVmne.  
Different amounts of virus produced from infectious molecular clones by transfection of 
293T cells, were used in fusion assays with U87.CD4.CCR5 cells or infection assays with 
Magi.CD4.CCR5 cells.   
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Fig. 4.  Inhibition of virus-dependent fusion with antibodies or peptide inhibitors. a) 
Antibody neutralization studies were performed with anti-CCR5 antibody 2D7 or anti-
CD4 antibody Sim2.   Virus-dependent fusion assays (top) are compared to infection 
assays performed for 24 hrs with U87.CD4.CCR5 cells (bottom).  b)  Dose-dependent 
inhibition of virus-dependent fusion with T-20 was examined.  Two different sources of 
T-20 were obtained from the NIH AIDS Research and Reference Repository, derived 
originally from DAIDS (with free N and C-terminal amino acids) and Trimeris (N-
acetylated derivative).  RLU, relative light units. 
a 
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Fig. 5. Dose dependent inhibition of R5-Env dependent fusion or infection of 
U87.CD4.CCR5 cells using a Rac GEF inhibitor.  a) Rac GEF inhibitor was added at 
the time of cell mixing or b) target U87 and/or HIV-1 ADA Env-expressing BSC40 cells 
were pretreated for 1 hr, washed, and mixed prior to measuring fusion activity by β-
galactosidase activity.  c) Cells were infected with 10 ng p24 of HIVluc derived from 
HIV-1 ADA, with drug added at the time of virus addition.  Luciferase activity was 
determined 16 hr post-infection, expressed as relative light units (RLU).  d) Rac GEF 
inhibitor was added at the time of virus in a virus-dependent fusion assay.  Experiments 
were repeated 3 times and representative data shown.    
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Fig. 6.  Constitutively active RacV12 overcomes the effects of the Rac GEF inhibitor.  
a) Effects of RacV12 on the ability of the Rac GEF inhibitor to block the ability of HIV 
ADA mediated fusion to activate Rac activation, as measured by the level of Rac-GTP in 
the cells.  b) Effects of RacV12 on the ability of the Rac GEF inhibitor to block HIV-1 
ADA Env-dependent fusion. 
  
 
 
 
 
 51 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
 
HIV Envelope Induction of the Gαq Signaling Cascade 
 
Is Required for Virus Entry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 
 
Preface to Chapter 3 
Chapter 3 was published in the September 15, 2008 Journal of Virology. In Volume 82, 
Issue 18, Pages 9191-9205 by Brooke Harmon and Lee Ratner. All experiments and data 
were performed and collected by Brooke Harmon. Suzanne Pontow and Nancy A. 
Campbell gave important technical guidance for completion of the study and Intelly Lee 
gave technical assistance with one experiment shown in figure 11A. 
 
 
 
 
 
 
 
 
 
 
 
 53 
 
 
 
 
HIV Envelope Induction of the Gαq Signaling Cascade 
 
Is Required for Virus Entry 
 
Brooke Harmon and Lee Ratner 
 
Division of Molecular Oncology, Washington University 
School 
 
of Medicine, St Louis, Missouri 
 
 
Corresponding Author: Lee Ratner MD PhD, Box 8069, 660 S Euclid Ave, St Louis, MO 
63110 
 314-362-8836, Fax: 314-747-2120; Email: LRATNER@IM.WUSTL.EDU 
 
Key Words: HIV, Gαq, Rac, Fusion, Ras 
 
Running Title: Gαq Signal Cascade for HIV Entry 
 
 
 
 54 
Abstract 
 
Binding of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) 
with the primary receptor CD4 and one of two coreceptors, CXCR4 or CCR5, activates a 
signaling cascade resulting in Rac GTPase activation and stimulation of actin cytoskeletal 
reorganizations critical for HIV-1 mediated membrane fusion.  The mechanism by which 
HIV-1 Env induces Rac activation and subsequent actin cytoskeleton rearrangement is 
unknown. In this study, we show that Env-mediated Rac activation is dependent on the 
activation of Gαq and its downstream targets. Fusion and Rac activation are mediated by 
Gαq and phospholipase C (PLC), as shown by attenuation of fusion and Rac activation in 
cells either expressing siRNA targeting Gαq or treated with the PLC inhibitor U73122. 
Rac activation and fusion were also blocked by multiple protein kinase C (PKC) 
inhibitors, by inhibitors of intracellular Ca2+ release, by Pyk2 targeted siRNA, and by the 
Ras inhibitor S-trans,trans-farnesylthiosalicylic acid (FTS). Fusion was blocked without 
altering cell viability or cell surface localization of CD4 and CCR5. Similar results were 
obtained when cell fusion was induced by Env expressed on viral and cellular membranes 
and when cell lines or primary cells were the target. Treatment with inhibitors and siRNA 
specific for Gαi or Gαs signaling mediators had no effect on Env-mediated Rac activation 
or cell fusion, indicating that the Gαq pathway alone is responsible. These results could 
provide a new focus for therapeutic intervention, with drugs targeting host signaling 
mediators, rather than viral molecules, a strategy which is less likely to result in 
resistance. 
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Introduction 
Entry of HIV-1 is mediated by sequential binding of the trimeric HIV envelope 
glycoprotein (Env) to CD4 and one of two primary chemokine coreceptors, CXCR4 or 
CCR5. This binding triggers a series of conformational changes in Env that expose the 
fusion peptide, which then induces the merger of viral or infected cell membranes with 
target membranes (2, 4, 49). The HIV-1 Env interaction with CD4 and coreceptor also 
stimulates various intracellular signaling events, similar to those initiated by their natural 
ligands, such as phosphorylation of Pyk2, Ca2+ mobilization, activation of RhoGTPases, 
and actin cytoskeleton rearrangements (12, 33, 49, 86, 87, 89, 99). Actin cytoskeletal 
remodeling and RhoGTPases play a central role in regulating fusion of biological 
membranes (24, 27). In the case of HIV-1-induced membrane fusion, activation of the 
RhoGTPase Rac and subsequent actin cytoskeletal reorganizations are required for 
efficient virus entry and infection (12, 25). The exact mechanism of Env-induced Rac 
activation that mediates actin cytoskeletal rearrangements and induces membrane fusion 
has not been investigated.  
Binding of both CD4 and the coreceptors elicit signaling pathways that result in 
Rac activation. However, previous results suggest that Env-induced Rac activation is 
mediated via the coreceptor rather than CD4 (12). The coreceptor CCR5 is the principal 
receptor for HIV-1 transmission, whereas CXCR4 binding viral isolates are primarily 
found in late stages of disease (131). Coreceptors CCR5 and CXCR4 belong to a family 
of seven-transmembrane-spanning receptors termed G-protein coupled receptors 
(GPCRs). Ligand induced conformational changes in GPCRs leads to activation of 
heterotrimeric (het) G proteins (40, 49, 67, 69). GPCRs associate with four classes of het 
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G proteins, Gαi, which is sensitive to ADP ribosylation by pertussis toxin (PTX), Gαs, 
Gαq, and Gα12/13 (49, 67). Most documented signaling through chemokine receptors goes 
through the PTX sensitive Gαi, however fusion has been shown to be PTX insensitive 
(78, 82-85).  Additional studies have shown that mutation of the DRY domain of the 
second intracellular loop of CCR5, the domain thought to interact with Gαi, also had no 
effect on HIV-1 induced membrane fusion and entry (78, 79, 82-85). These results 
suggest that Env-induced fusion is independent of signaling pathways mediated by Gαi.  
However, GPCRs can induce PTX-insensitive pathways by activating other het G 
proteins; by signaling independently of het G proteins through interactions with β-
arrestin, a scaffolding protein involved in internalization of GPCRs; or by direct binding 
with the PDZ domain of guanine nucleotide exchange factors (GEFs), and various other 
binding partners (67, 70).  
The signaling method utilized depends on multiple factors, including cell type, 
receptor, the activation state of the cell, and availability of signaling partners. In addition 
to Gαi, CCR5 has been shown to couple to Gαs and Gαq and the interaction with Gαq has 
been mapped to the third intracellular loop of CC chemokine receptors (49, 80, 132). 
Signaling through Gαs leads to activation of adenylyl cyclase, calcium (Ca2+) channels 
and cyclic AMP (cAMP)-dependent protein kinase A (PKA), whereas signaling though 
Gαq results in activation of phospholipase Cβ (PLCβ), Ca2+channels, and protein kinase C 
(PKC). Signaling components that participate in both Gαs and Gαq mediated pathways 
and het G protein-independent pathways are activated by HIV-1 Env interaction with 
CCR5 (87, 88, 133, 134). Since the likely domains involved in G protein dependent and 
independent signaling pathways are also required for normal surface expression, 
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generation of CCR5 molecules unable to couple with signaling intermediates was not 
possible. In addition, similar signaling pathways are activated via CD4 and CCR5 
suggesting that required signaling may occur through one receptor if the other is impaired 
(49, 64, 89).  In this study, we utilized small interfering RNA (siRNA) and various small 
molecule inhibitors to determine which signaling processes are required for Rac 
activation and subsequent membrane fusion (Fig. 1). The data presented demonstrate that 
HIV-1 Env mediates activation of the Gαq pathway via CCR5 and this activation is 
critical for HIV-1 induced cell-cell fusion. 
 
Materials and Methods 
 
Cell Lines. U87.CD4.CCR5 is an astroglioma cell line engineered to express CD4 and a 
CCR5 construct that is tagged at its C terminus with green fluorescent protein (GFP). The 
maintenance of BSC40 cells (African green monkey kidney cells), U87.CD4.CCR5 cell 
lines and peripheral blood lymphocytes (PBLs) has been described (116). The TZM-BL 
(also known as JC53-BL) reporter cell line was a gift from John C. Kappes. This is a 
HeLa cell clone that expresses CD4, CCR5 and CXCR4 and was engineered to express 
Escherichia coli β-galactosidase (β-Gal) and firefly luciferase under the transcriptional 
control of the HIV-1 long terminal repeat (LTR) as described (135). TZM-BL cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM) containing 4 mM L-
glutamine, 1 mM sodium pyruvate, 100 units of penicillin per ml, 100 µg of streptomycin 
per ml (complete DMEM; Mediatech) supplemented with 15% fetal bovine serum 
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(FCIII). Unless noted, tissue culture supplies were obtained from Mediatech, Manassas, 
VA.  
 
Reagents. The control siRNA constructs (non-targeting 20-25 nt siRNA designed as a 
negative control), the siRNA contructs targeted to Gαq, Gαi Gαs Pyk2 and Rac and the 
rabbit anti-Gαq/11, rabbit anti-Gαi, goat anti-Gαs, goat anti-Pyk2, goat anti-actin, and HRP 
conjugated donkey anti-goat antibodies were obtained from Santa Cruz Biotechnology, 
Inc (Santa Cruz, CA,). The siRNA constructs were transfected using GeneEraser siRNA 
Transfection Reagent according to the manufacturer's instructions (Stratagene, La Jolla, 
CA). The rabbit anti-Pyk2 antibody and thapsigargin were obtained from Sigma (St. 
Louis, MO). The monoclonal anti-human CCR5 antibody (MAB182) was obtained from 
R&D systems (Minneapolis, MN). The rabbit polyclonal anti-Pyk2 (pYpY579/580) 
phosphospecific antibody and Cytochalasin D (CD) were obtained from Invitrogen 
(Carlsbad, CA). 100X GDP, 100X GTPγS, and anti-Rac and anti-Ras antibodies were 
obtained from Millipore (Billerica, MA). U73122 was obtained from Tocris Bioscience 
(Ellisville, MO), U73343 and the cyclopiazonic acid were obtained from BioMol 
International (Plymouth Meeting, PA), Xestospongin C was obtained from Cayman 
Chemical (Ann Arbor, MI) dantrolene was obtained from Axxora (San Diego, CA), and 
all other inhibitors were obtained from EMD Chemicals (San Diego, CA).  
 
Viruses. Wild-type (WT) vaccinia (WR strain) and recombinant vaccinia viruses 
expressing β-galactosidase (vCB21R), and T7 polymerase (vPT7-3) were obtained from 
the AIDS Research and Reference Reagent Program . Vaccinia viruses encoding an 
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uncleaved HIV envelope (UNC; vCB-16), ADA envelope (vCB-39), and HXB2 envelope 
(vSC60), were gifts from Edward Berger, and the vaccinia virus encoding the HIV 
envelope from the YU2 (vSP-5) strain and constitutively active Rac GTPase (vRacV12) 
were gifts from Drs C Broder and S Wei, respectively (45). The HIV stocks used in the 
following assays are prepared by the lipofection of plasmid DNA encoding full-length 
proviral molecular clones, which contain the Env gene of the R5 YU2 strain in the 
HIVNL4-3 backbone. To produce pseudotyped HIV-1, either amphotropic MLV (A-MLV) 
envelope or vesicular stomatitis virus G (VSV-G) expressing plasmids were cotransfected 
with the proviral DNA of HIV-1. Transfected 293T cell supernatants are harvested 48 
hours postlipofection, filtered, and assayed for p24 antigen content by enzyme-linked 
immunosorbent assay (116). 
Envelope-dependent fusion assay. The HIV-1 envelope-mediated fusion assay used was 
a modification of the assay developed by Dr. Berger's laboratory (130). The target cells 
(PBMCs or U87.CD4.R5 cells) were serum starved for 36 hours (h) then infected 
overnight with vCB21R or with recombinant vaccinia virus encoding the constitutively 
active GTPase RacV12 mutant (vRacV12). Fusion partner BSC40 cells were co-infected 
with vPT7-3 and vaccinia virus expressing HIV-1 Env. Cells were infected overnight 
(multiplicity of infection [MOI], 10 for U87.CD4.R5 cells and BSC40 cells and MOI of 
200 for PMBCs) at 37°C in complete media. The next day infected cells were lightly 
trypsinized, and washed with PBS prior to mixing. Unless otherwise indicated inhibitors 
were added at the indicated concentrations to U87.CD4.CCR5 cells 1 h prior to mixing 
and again at the time of mixing. To allow fusion, 105 cells were mixed 1:1 with a fusion 
partner in triplicate wells and incubated 3 h at 37°C. To account for any effect of 
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inhibitors on vaccinia virus infection and/or on T7 polymerase function, vCB21R and 
vPT7-3 co-infected cells were similarly treated with inhibitors. Concentration curves 
were performed with all of the inhibitors to determine the concentration that resulted in 
the maximum decrease in fusion without altering vaccinia virus infection or T7 
polymerase activity. Cells were lysed by addition of NP-40 to a final concentration of 1% 
and freeze thawing at -20°C.  β-galactosidase activity of reaction lysates is determined 
using chlorophenol red–β-d-galactopyranoside (CPRG, Calbiochem) and the absorbance 
of each sample is determined at a wavelength of 570nm (12).  
Western Blot Analysis. Cell lysates were prepared using mammalian cell lysis buffer 
(50mM Tris-Cl, PH 8, 5mM EDTA, 100mM NaCl, 0.5% Triton X100 plus protease and 
phosphatase inhibitors. Fifty micrograms of lysate was separated by 12% SDS-PAGE for 
siRNA transfected samples and by 10% SDS-PAGE for Pyk2 samples and transferred to 
PVDF membranes, blocked with 0.01% Tween 20 and 5% dry milk in TBS, and probed 
overnight with rabbit polyclonal anti-Pyk2 (pYpY579/580) antibody (1:1,000) or for 2h 
with anti-Gαq (1:500), anti- Gαi (1:500),anti-Gαs (1:500), anti-Pyk2 (1:500) or anti-Rac 
(1:2,000) antibodies. After washing with 150 mM NaCl, 10 mM Tris-HCl, pH 7.5 (TBS), 
horseradish peroxidase-labeled secondary antibody was added (1:1,000 donkey anti-goat 
IgG; Santa Cruz, 1:2,000 dilution, goat anti-rabbit IgG; Pierce, or 1:10,000 dilution anti-
mouse IgG; Amersham). Proteins were visualized in an Alpha Innotech (San Leandro, 
CA) imager by using supersignal west femto sensitivity substrate (Pierce). The blots were 
then stripped for 30 minutes at 50 degrees in stripping buffer (2% SDS, 6% Tris-Cl, PH 
7.5, 0.7% β-mercaptoethanol in H2O), washed 3X in TBS, blocked and probed with anti-
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actin (1:500) or anti-Pyk2 (1:1,000) overnight, washed, and appropriate secondary 
antibodies were added prior to visualization on Alpha Innotech imager. 
Rac and Ras Activation Assay. Rac and Ras activation assays were performed with 
2 × 106 serum-starved U87.CD4.CCR5 cells or 1 x 107 serum-starved U87.CD4.CCR5 
cells per sample respectively. These cells were mixed at a ratio of 1:1 with BSC40 cells 
which were infected with vCB-39 (HIVADA Env), vSC60 (HIVHXB2 Env), or WT vaccinia 
virus (no Env) as described above. Inhibitors were added at the indicated concentrations 
to the target cells 1 h prior to mixing and again at the time of mixing unless otherwise 
noted. Reactions were incubated at 37 °C for 30 min, washed two times with ice cold 
PBS, and cells were lysed. Lysates were snap frozen and later equal amounts of protein 
per sample (determined by Bio-Rad Protein Assay, Bio-Rad Laboratories, Hercules, CA) 
were analyzed using a G-LISA Rac activation assay kit (Cytoskeleton, Denver, CO) or 
Ras activation assay kit according to the manufacturer's instructions (Cell Biolabs,  San 
Diego, CA), with equal amounts of protein for column loading (Bio-Rad).  
Virus-dependent fusion assay. The virus-induced cell fusion assay was performed as 
previously described (45). Briefly, U87.CD4.CCR5 cells were infected with vCB21R or 
vPT7-3 cultured overnight, harvested by trypsin treatment, washed with PBS, and 105 
cells were mixed (1:1) with DEAE-dextran (20ug/ml) and 100ng p24 HIVYU2. The assay 
was performed in triplicate using a 96-well microtiter plate. Unless otherwise indicated 
inhibitors were added at the indicated concentrations to both populations of 
U87.CD4.CCR5 cells 1 h prior to virus addition and again at the time of virus addition. 
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Fusion reactions were incubated for 3 h at 37°C and reactions were assayed for β-
galactosidase activity as described  (12).  
 
JC53-BL assay. JC53BL cells were serum starved for 12h then plated overnight in 
complete media in 96 well plate at 1X104 cells per well. Cells were treated for 1h with 
indicated concentrations of inhibitors prior to addition of media alone or 150ng p24 of 
HIVYU2 or VSVG or A-MLV-pseudotyped HIV in the presence of 20ug/ml DEAE-
dextran for 3h at 37°C. After 3h cells were washed 3 times with PBS and inhibitors were 
added in fresh media. Following a 24h incubation cells were lysed and luciferase units 
determined. Infected wells and uninfected wells with inhibitor were compared to wells 
with no inhibitor. 
cAMP assay. cAMP assay was performed with 5 x 106 serum-starved U87.CD4.CCR5 
cells  per condition. Half of the U87.CD4.CCR5 cells were pre-treated with 200ng/ml 
pertussis toxin (PTX) for 18h prior to treatment with 1uM forskolin (EMD Chemicals) 
and 500ng/ml CCL4 (PreproTech Inc., Rocky Hill, NJ), for 30 minutes and cAMP assay 
was performed with equal amounts of protein per sample (Bio-Rad) according to 
manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI). 
PKA assay. PepTag assay for nonradioactive detection of cAMP-dependent protein 
kinase (Promega) was used with whole cell lysates prepared from U87.CD4.CCR5 cells 
treated with indicated inhibitors for 1h. The assay was performed in the presence of 
inhibitors with equal amounts of protein per sample (Bio-Rad) according to the 
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manufacturer's protocol. PKA activity was quantitated by scanning densitometry of 
phosphorylated peptide substrate resolved in 0.8% Tris · HCl agarose (pH 8.0).  
Flow Cytometry and Confocal microscopy. U87.CD4.CCR5 cells were treated with 
indicated concentrations of inhibitors for 3h. For detection of CD4 and CCR5, 
Phycoerythrin (PE)-conjugated anti-CD4 (Q4120, Sigma), and monoclonal anti-human 
CCR5 antibodies (MAB182, R&D systems, Minneapolis, MN) were used at 1:20 fold 
dilution and 10ng/ml respectively. Cells were detached by incubation in 5 mM EDTA (in 
PBS) for 5min at 37 °C. The incubation time for the primary and secondary (goat anti-
mouse PE conjugated IgG F(ab)2, R&D systems) antibodies was 30 minutes on ice for 
CCR5 and room temperature (RT) for CD4. Cells were then fixed with 1% 
paraformaldehyde and analyzed using FACS Calibur flow cytometer (BD Biosciences) 
with CellQuest software (BD Biosciences). 
For confocal microscopy analysis, U87.CD4.CCR5 cells were plated on coverslips at 
2X105 cells per well in 6 well plate. The next day cells were treated with indicated 
concentrations of inhibitors for 3h and with CD for 15 minutes. Cells were fixed with 4% 
paraformaldehyde for 30 minutes at RT, blocked with 5% BSA in PBS and stained with 
anti-CD4-PE for 1h at RT (CCR5 has C-terminal GFP tag). Cells were washed with PBS 
and incubated with 1:500 dilution of TO-PRO3 (Invitrogen) in permeabilization buffer 
(0.2% saponin, 5% BSA in PBS) for 15 minutes. Cells were washed three times in PBS, 
mounted on slides using Gold Anti-fade mounting media (Invitrogen), and 10 random 
fields recorded for each condition. Cells were analyzed by confocal fluorescence 
microscopy using a 510 Meta LSM confocal microscope (Zeiss, Thornwood, NY). 
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Statistical Analysis. Raw data for fusion and infectivity assays were compared using 
two-tailed t-test. P values are considered significant when they are <0.05, and very 
significant when they are <0.01. 
Results 
HIV-1 Env induces Rac activation and membrane fusion via a PTX-insensitive and 
PKA- independent pathway.  In order to determine whether HIV-1 Env-dependent Rac 
activation is mediated by Gαi/o family members, U87.CD4.CCR5 cells were pretreated 
with 200ng/ml PTX, 18 hours prior to incubation with BSC40 cells expressing Env from 
R5 HIVADA strain or cells lacking Env. Exposing cells to HIVADA Env in the presence or 
absence of PTX resulted in a 2.25 fold increase in Rac activation as determined by 
quantitation of levels of GTP-bound Rac1 purified by Rac-G-LISA (Fig. 2A). Activity of 
PTX was confirmed by demonstrating that MIP-1β-mediated inhibition of forskolin-
induced cAMP formation was sensitive to PTX (not shown). In addition, Env-dependent 
cell-cell fusion was also unaffected by treatment with PTX  (78, 82-85). These results 
indicate that HIV-1 stimulates Rac activity and Env-dependent cell-cell fusion by a 
pathway that does not involve Gαi/o proteins.  
      Next, we investigated the importance of PTX-resistant G proteins Gαs and Gαq. The 
major downstream effector of Gαs is adenylyl cyclase, which results in increased cellular 
levels of cAMP and leads to activation of cAMP-dependent PKA. PKA is a likely 
candidate for the pathway described in this study, because its activity is stimulated by 
HIV-1 Env and PKA has been shown to be upstream of Rac activation and subsequent 
cell migration (133). To test the role of PKA, U87.CD4.CCR5 cells were pre-treated with 
two different inhibitors of PKA, inhibitory peptide PKA-I (14-22) and chemical inhibitor 
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H89 and the effects were studied in a quantitative Env-dependent cell-cell fusion assay. 
Although these PKA inhibitors effectively inhibited PKA activity, there was no effect on 
Env-mediated cell fusion (Fig 2B). These data confirm a previous report that synthesis of 
an early product of reverse transcription is not affected by PKA inhibition (136). In this 
study none of the inhibitors had an effect on vaccinia virus infection or on T7 polymerase 
activity at the concentrations described (not shown). In addition, H89 had no effect on 
Env-dependent Rac activation (Fig 2C). In this experiment, controls included a mis-
matched X4 Env that did not induce Rac activation in U87.CD4.R5 cells, and a CCR5-
inhibitor, TAK-779, that completely inhibited Rac activation (12).  These data suggest 
that although the cAMP-dependent PKA pathway is activated by HIV-1 Env, it is not 
required for Env-dependent Rac activation and cell-cell fusion.  
 
HIV-1 Env mediates Rac activation and membrane fusion via G proteins from the 
Gαq/11 family.  In addition to Gαs, the Gαq/11 family of PTX-resistant G proteins are 
known to associate with CCR5, (40, 49). To investigate the importance of the Gαq/11 
family of G proteins, Gαq expression was down-regulated by RNAi in U87.CD4.CCR5 
cells. Gαi and Gαs were also down-regulated to confirm that these proteins do not play a 
role in Env-mediated fusion and to show that knockdown of irrelevant pathways has no 
effect on Env-mediated fusion.  siRNA expressing cells were then mixed with BSC40 
cells expressing different Env subtypes. Maximal Rac activation was measured after 30 
min, whereas maximal Env-dependent fusion was measured after 3 h (12). Transfection 
of cells with Gαq-directed siRNAs decreased levels of Env-dependent cell-cell fusion by 
an average of 73±3.6% for both HIV-1 R5 and Dual-tropic Env subtypes (Fig. 3A left 
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panel). There was no significant fusion observed with cells expressing the X4 Env and 
U87.CD4.R5 target cells with or without siRNA expression as was expected. Rac 
activation was similarly decreased in cells transfected with Gαq-directed siRNAs (Fig 
3C), whereas siRNA directed against Gαi and Gαs had no effect on Env-induced cell-cell 
fusion or Rac activation (Fig 3A and 3C). The decrease in levels of fusion and Rac 
activation correlated well with the decreased steady state level of Gαq and each siRNA 
specifically downregulated its target protein with no effects on expression of the other Gα
 
proteins as detected by immunoblot (Fig. 3B). Vaccinia virus infection and T7 
polymerase activity was also measured in siRNA transfected cells and Env-dependent 
cell-cell fusion in these cells was normalized accordingly. In order to determine if Gαq 
acts upstream of Rac in Env-mediated cell-cell fusion, a constitutively active Rac mutant, 
RacV12, was used (Fig. 3A right panel). RacV12 overcame the effects on Env-mediated 
fusion resulting from siRNA targeted to Gαq (Fig. 3A). These results show that the 
effects of the siRNA are overcome by expression of a downstream signaling component. 
Thus the Gαq/11 proteins are involved in HIV-1 Env-dependent cell-cell fusion upstream 
of Rac activation.  
 
HIV-1 Env-induced Rac activation and cell-cell fusion depends on PLC activation 
     Activation of the Gαq leads to activation of inositol phospholipid-specific 
phospholipase C beta (PLCβ) which catalyzes the hydrolysis of phoshatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) to produce the secondary messenger molecules 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (137). To test for the 
involvement of PLC in HIV-1 induced fusion and Rac activation, U87.CD4.CCR5 cells 
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were pretreated for 1h with 3µM of the PLC inhibitor U73122, or the inactive analog 
U73343 prior to mixing with HIV-1 Env-expressing cells, and measurement of cell-cell 
fusion and Rac activation (Fig. 4). This concentration of U73122 has previously been 
shown to be specific for PLC (138), and does not increase intracellular Ca2+, whereas 
higher concentrations of U73122 inhibit PLC and also lead to a release of Ca2+ from 
intracellular stores (139). The PLC inhibitor U73122 suppressed Env-dependent cell-cell 
fusion by an average of 73 ± 7.6% (Fig. 4A top panel) and Rac activation by 62 ± 1.5% 
(Fig. 4B). The same concentration of the inactive analog U73343 had no significant 
effect on fusion or Rac activation (Fig. 4).  Inhibitory effects of U73122 were overcome 
by expression of constitutively active RacV12 (Fig. 4A bottom panel). The 
phosphatidylinositol-specific PLC inhibitor ET-18-OCH3 also suppressed Env-dependent 
cell-cell fusion and Rac activation by approximately 45% (data not shown). To validate 
the effects of U73122 and U73343 on Env-mediated fusion in a relevant HIV-1 target 
cell, peripheral blood lymphocytes (PBLs) which express both CCR5 and CXCR4 were 
used as the target cell in a quantitative Env-dependent cell-cell fusion assay. PBLs were 
pretreated with U73122, U73343 and TAK-779 for 1h prior to mixing with BSC40 cells 
expressing different HIV-1 Env subtypes and measurement of cell-cell fusion. The PLC 
inhibitor U73122 suppressed Env-dependent cell-cell fusion in PBLs by an average of 74 
± 12.8% and U73343 had no effect (Fig 4C). U73122 inhibited fusion mediated by HIV-1 
R5 Envs, Dual-tropic Envs and X4 Envs suggesting that PLC is required for Env-induced 
fusion mediated by both CCR5 and CXCR4. TAK-779, as expected completely inhibited 
fusion mediated by HIV-1 R5 Env-expressing cells but inhibited fusion mediated by the 
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Dual-tropic Env by only 59 ±5.4% and had no significant effect on fusion mediated by 
X4 Env. 
 
Intracellular Ca2+ release is required for Env-dependent cell-cell fusion and Rac 
activation.  The second messengers IP3 produced by hydrolysis of PtdIns(4,5)P2 
activates the IP3 receptor (IP3R) on the membrane of the sarcoplasmic/endoplasmic 
reticulum (SER) which opens a Ca2+ channel resulting in intracellular Ca2+ release. This 
Ca2+ release leads to activation of the ryodine receptor (RyR)-operated Ca2+ channel 
leading to a further increase in intracellular Ca2+. It has been shown previously that HIV-
1 Env interaction with chemokine receptors results in a PTX-insensitive elevation of 
intracellular Ca2+ (89). However the role for intracellular Ca2+ release in HIV-1 Env-
mediated fusion is unknown. To test for the involvement of intracellular Ca2+ release, 
multiple inhibitors of intracellular calcium release were utilized. These inhibitors include 
xestospongin C (XC), which specifically blocks IP3R-induced Ca2+ release and 
dantrolene, which blocks RyR-induced intracellular Ca2+ release. In addition, 
thapsigargin (TG) and cyclopiazonic acid (CPA), irreversible and reversible inhibitors, 
respectively, of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps, 
were used to deplete internal Ca2+ stores. Inhibition of the SERCA pumps prevents Ca2+ 
from being sequestered in the ER and it is gradually lost from the cell via passive leakage 
into the cytosol and subsequent extrusion through the plasma membrane. TG and CPA 
are structurally different and are unlikely to elicit similar cellular responses unless 
specifically acting on SERCAs (140).  
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Target cells were pretreated for 1hr with 100uM dantrolene, 10uM CPA, 2uM 
TG, or 5uM XC. The cells were subsequently incubated with HIV-1 Env expressing cells 
and cell-cell fusion and Rac activation were measured. Dantrolene, CPA, TG and XC 
treatment reduced Env-mediated cell-cell fusion by an average of 93±2.2%, 79±2.5%, 
97±2.6%, and 76±3.5% respectively in U87.CD4.CCR5 cells which is similar to the 
inhibition observed in PBLs (Fig. 5A, left panel, Fig 5C). In the case of PBLs this 
inhibition was observed with both CCR5 and CXCR4 tropic Envs. The effects of these 
intracellular Ca2+ modulators on Env-induced Rac activation in U87.CD4.CCR5 cells 
also correlate with their effects on Env-induced cell-cell fusion. Although all of these 
intracellular Ca2+ modifiers inhibit Env-dependent Rac activation and cell-cell fusion to 
similar degrees, the effects on cell-cell fusion were not completely reversed by 
expression of RacV12 (Fig 5A, bottom panel). Env-dependent cell-cell fusion in cells 
treated with dantrolene, CPA, TG, and XC and expressing RacV12 was 50±1.6%, 
40±2.7%, 25±2.6%, and 32±6%, that of untreated cells, suggesting a role for intracellular 
Ca2+ flux both upstream and downstream of Rac activation.  
 
HIV-1 Env mediates Rac activation and cell-cell fusion via a PKC-dependent 
pathway. Production of the second messenger DAG and the IP3 induced Ca2+ release 
facilitate membrane translocation and activation of the serine/threonine kinase, PKC.  To 
investigate the role of PKC, U87.CD4.CCR5 cells were pre-treated for 1h with small 
molecule inhibitors of PKC, Bisindolylmaleimide I (Bis I), Calphostin C, and 
Chelerythrine Chloride (Ch Ch).  These cells were then incubated with HIV-1 Env 
expressing cells, and cell-cell fusion was measured. The PKC inhibitors Calphostin C and 
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Ch Ch reduced Env-mediated cell-cell fusion by 87±2% and 89±2% respectively whereas 
Bis I only reduced fusion by 55±11% (Fig 6A, left panel). Concentration curves were 
performed with all of the inhibitors used in this study to determine the concentration that 
resulted in the maximum decrease in fusion without altering vaccinia virus infection or 
T7 polymerase activity (data not shown). At higher concentrations Bis I had a greater 
effect on Env-induced cell fusion, however at these concentrations Bis I is no longer 
specific for PKC (141) (data not shown). Effects of PKC inhibition on fusion were 
overcome with constitutively active RacV12 (Fig 6A, right panel).  
 To determine which isoform of PKC is involved in Env-mediated Rac activation 
and cell-cell fusion, PKC inhibitors were used that are specific for conventional isoforms, 
PKCα, PKCβ, and PKCγ, which depend on Ca2+ and DAG as well as a phospholipid for 
activation. The specific PKC inhibitors used were Ro-32-0432 which is most specific for 
PKCα, Go-6976 which specifically inhibits Ca2+ dependent PKC, particularly PKCα and 
PKCβI, and the inhibitory peptide, PKC-I (20-28), which is a pseudosubstate that 
specifically blocks PKCα and PKCβ activation. U87.CD4.CCR5 cells were pre-treated 
with these inhibitors for 1h prior to mixing with HIV-1 Env-expressing cells, and 
measurement of cell-cell fusion. Pretreatment with Ro-32-0432, Go-6976, and PKC-I 
(20-28) decreased Env-mediated cell-cell fusion by 73±4.4%, 70±3.6% and 93±3.5% 
respectively (Fig 6B, left panel). Expression of the constitutively active Rac mutant, 
RacV12 overcame the effects of these PKC inhibitors on HIV-1 Env-mediated cell-cell 
fusion (Fig 6B, right panel).   
To determine the effects of PKC inhibitors on Rac activation U87.CD4.CCR5 
cells were pre-treated with Calphostin C, Ch Ch, Go-6976 and PKC-I (20-28) for 1h prior 
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to mixing with HIV-1 Env-expressing cells. Levels of suppression of Env-dependent Rac 
activation correlated with levels of inhibition of Env-dependent cell-cell fusion (Fig. 6C).  
In this experiment, controls included the CCR5-inhibitor, TAK-779 and a specific 
RacGEF inhibitor, both of which inhibited Env-induced Rac activation (44, 45). In 
addition to the data with RacV12, this suggests that PKCα and/or PKCβ is required 
upstream of Rac in Env-mediated cell fusion.  
To validate the effects of both general and specific PKC inhibitors on Env-
mediated fusion in a relevant HIV-1 target cell, PBLs were pretreated with Ch Ch and 
Go-6976 for 1h prior to mixing with HIV-1 Env-expressing cells, and measurement of 
cell-cell fusion. Pretreatment with Ch Ch and Go-6976 decreased Env-mediated cell-cell 
fusion with HIV-1 R5 Envs, Dual-tropic Env and X4 Env by an average of 98±2.9%, and 
75±2% respectively (Fig. 6D). As with the above experiments with the PLC inhibitor and 
Ca2+ inhibitors these results suggest that PKC is required for Env-induced cell-cell fusion 
in both cell lines and primary cells regardless of Env coreceptor preference. 
 
 HIV-1 Env-induced Pyk2 activation mediated by intracellular Ca2+ release is 
required for Env-dependent cell-cell fusion and Rac activation.  Previous studies have 
shown that HIV-1 Env-induced intracellular Ca2+ release results in activation of the focal-
adhesion-related-kinase Pyk2, a downstream target of PKC (88, 89). Pyk2 is a non-
receptor tyrosine kinase that can be activated by growth factors, chemokines, and GPCR 
ligands and provides a link between these ligands and multiple downstream cellular 
events such as modulation of the cytoskeleton (88, 93, 142, 143).  There are no available 
inhibitors specific for Pyk2 so to test the role of Pyk2 in Env-induced Rac activation and 
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cell-cell fusion, Pyk2
 
expression was down-regulated by RNAi in U87.CD4.CCR5 cells. 
RNAi to Rac was used as a positive control for down-regulation of fusion. siRNA 
expressing cells were then mixed with BSC40 cells expressing different Env subtypes. 
Transfection of cells with Pyk2- and Rac-directed siRNAs decreased levels of Env-
dependent cell-cell fusion by an average of 77±5.4% and 73±2.3% respectively (Fig. 7A 
left panel) and Rac activation by 83±2.5 and 81±0.6 respectively (Fig. 7C). The decrease 
in levels of fusion and Rac activation correlated well with the decreased steady state level 
of Pyk2 and Rac protein, and each siRNA was specific for its target protein as detected 
by immunoblot (Fig. 7B). Vaccinia virus infection and T7 polymerase activity was also 
measured in siRNA transfected cells and Env-dependent cell-cell fusion in these cells 
was normalized accordingly. RacV12 overcame the effects on Env-mediated fusion 
resulting from siRNA targeted to Pyk2 or Rac (Fig. 7A right panel) indicating that Pyk2 
acts upstream of Rac in Env-mediated cell-cell fusion and that the effects of the siRNA 
are overcome by Rac over-expression. 
 
HIV-1 Env-induced Rac activation and cell-cell fusion depend on Ras activation. 
Pyk2 can lead to Rac activation via multiple signaling partners; however previous data 
suggests that Env-dependent Rac activation and cell-cell fusion are mediated by a Rac-
specific GEF (45). The Rac-specific GEF Tiam1 is directly activated by Ras and is 
involved in actin cytoskeletal reorganization (42, 144). In addition, Pyk2 activates Ras 
via Src downstream of Gαq providing a link between Pyk2 and Rac activation (142). To 
test the role of Ras, U87.CD4.CCR5 cells were pretreated with the Ras inhibitor S-
trans,trans-farnesylthiosalicylic acid (FTS), which blocks membrane association of Ras, 
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thus preventing Ras activation. FTS inhibition of Env-dependent cell-cell fusion was dose 
dependent (Fig. 8A, left panel), and concentrations of FTS shown to abolish Env-
dependent cell-cell fusion in U87.CD4.CCR5 cells similarly inhibited Env-dependent 
Rac activation and Env-dependent cell-cell fusion induced by BSC40 cells expressing all 
HIV-1 Envs with target PBLs (Fig. 8B and Fig. 8C). However, FTS inhibition of cell-cell 
fusion was not completely reversed by expression of RacV12, suggesting a role for Ras 
both upstream and downstream of Rac activation (Fig. 8A, right panel).  
       Ras activation downstream of the chemokine receptor CCR5 has not been shown in 
previous studies. To determine if Ras is activated via HIV-1 Env interaction with CCR5 
and to determine if FTS inhibits this activity, U87.CD4.CCR5 cells were pretreated for 
1hr with DMSO alone or with the indicated concentrations of FTS prior to mixing with 
HIV-1 Env-expressing cells for 30 minutes, and measurement of Ras activation. The 
activation state of Ras in cell lysates was determined by utilizing Raf-1 binding to 
separate Ras-GTP from total Ras (Fig. 8D). There was a 3.6 fold increase in activated 
Ras when U87.CD4.CCR5 cells were mixed with cells expressing Env from R5 HIVADA 
strain (lane 6) versus U87.CD4.CCR5 cells mixed with cells expressing no HIV Env 
(lane 3), or expressing Env from X4 HIVHXB2 strain (lane 4). The increase in levels of 
activated Ras was prevented by TAK-779 (lane 5), suggesting that the Env interaction 
with coreceptor, rather than CD4 alone, mediates Ras activation. Env-induced Ras 
activation was inhibited by FTS in a dose dependent manner that correlates with 
inhibition of Env-dependent cell-cell fusion (Fig. 8A, 8D lanes 7, 8, 9). These data 
suggest that HIV-1 Env-induced Ras activation is required for Env-dependent Rac 
activation and cell-cell fusion.  
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HIV-1 Virus-dependent cell fusion and infection of TZM-BL cells is dependent on 
the Gαq signaling pathway. The Env-induced cell fusion assay is a rapid, sensitive, and 
flexible method used to solely study the HIV-1 Env-mediated fusion step of virus 
infection. However, this assay involves over-expression of Env on the cell surface of 
BSC40 cells and does not involve actual virus particles and may not reflect all the factors 
that mediate fusion. Therefore, we used a virus-dependent fusion assay that is based on 
the ability of virus particles to bridge two cells and allow transfer of cytoplasmic content 
(45). This assay has advantages over the Env-induced cell fusion assay since it utilizes 
relevant levels of virus-associated glycoprotein and is representative of virus-cell fusion 
versus cell-cell fusion. In this assay we use two populations of U87.CD4.CCR5, one 
population is infected with vaccinia virus expressing T7 polymerase and the second 
population is infected with a vaccinia virus expressing the β-galactosidase gene under the 
regulation of the T7 promoter. Both populations of U87.CD4.CCR5 cells were treated 
with TAK-779, U73122, U73343, Ch Ch, Go-6976, PKC-I (20-28) dantrolene, CPA, TG, 
XC, and FTS, for 1h prior to addition of fusion-competent R5 virus HIVYU2 for 3h. In this 
experiment, controls included untreated and inhibitor treated cells that were not incubated 
with virus (subtracted as background) and the CCR5-inhibitor, TAK-779, that completely 
inhibited HIV-1 virus-dependent cell fusion. Like Env-dependent fusion, virus-induced 
fusion was reduced by 73±5% in U73122 treated cells versus cells treated with DMSO 
alone, and the inactive analog U73343 had no effect (Fig. 9A). The PKC inhibitors, 
dantrolene, CPA, TG, XC and FTS also inhibited virus-dependent fusion at levels 
comparable to inhibition seen with the Env-dependent fusion assay (Fig. 9A).   
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The inhibitory effects of the various inhibitors to the downstream mediators of 
Gαq on HIV-1 Env-induced cell-fusion and virus-dependent cell fusion suggest an 
inhibition of virus entry. However, both the Env-dependent and virus-dependent fusion 
assay only measure the initial step of virus infection, and do not look at the effect of 
blocking the Gαq pathway, and subsequently fusion, on the entire virus life cycle. It is 
also unknown whether the inhibitors used in this study specifically block fusion induced 
by HIV-1 Env or if they block virus-induced membrane fusion and infection in general. 
To test the specificity of these inhibitors for HIV-1 Env-induced entry and infection we 
performed the following assay with wildtype HIVYU2 particles or with VSV-G and A-
MLV-pseudotyped HIV-1 virus particles. HIV-1 enters cells by inducing virus-cell 
membrane fusion at the cell surface. When HIV-1 is pseudotyped with VSV-G or A-
MLV Env, the route of viral entry becomes clathrin-mediated or caveola-mediated 
endocytosis (145, 146). To analyze the effects of these inhibitors on infection with each 
of these viruses, we performed a single-cycle HIV-1 infection assay using TZM-BL 
indicator cells (also known as JC53-BL cells), a derivative of HeLa cells, which express 
surface levels of CD4, CCR5, and CXCR4 comparable to levels produced by peripheral 
blood mononuclear cells (PBMC) (117). These cells have also been engineered to express 
-galactosidase and luciferase under the control of the HIV-1 LTR, which allows 
quantitative measurement of virus infectivity. TZM-BL cells were pretreated with TAK-
779, U73122, U73343, Ch Ch, Go-6976, dantrolene, CPA, TG, XC, and FTS, for 1hr 
prior to incubation with R5 virus HIVYU2, VSV-G-pseudotyped HIV-1 or A-MLV-
pseudotyped HIV-1 for 3hrs. Ammonium chloride (NH4Cl) (inhibits clathrin mediated 
endocytosis) and okadaic acid (OA) (inhibits caveola-mediated endocytosis) were 
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included as controls for inhibition of VSV-G and A-MLV-mediated entry respectively. 
After 3hrs virus was washed off, the same concentration of inhibitor was added back to 
the wells, and the cells were incubated at 37° for 24hrs. Figure 9B shows that the 
reduction in infection with HIVYU2 in the presence of PKC inhibitors, Ca2+ inhibitors, and 
FTS was comparable to the reduction in Env-dependent and virus-dependent cell fusion 
(Fig. 9B, upper left panel). The stronger inhibitory effect of U73122 seen in the reporter 
gene virus infectivity assay, suggests that PLC could also play a role in post-fusion steps 
in the virus life cycle (Fig. 9B, upper left panel). Interestingly, VSV-G HIV-1 infected 
inhibitor-treated cells, with the exception of U73122 and NH4CL-treated cells, at 
efficiencies equal to DMSO treated cells (Fig. 9B, right panel). Similarly, A-MLV HIV-1 
infected inhibitor-treated cells, with the exception of U73122 and OA-treated cells, as 
efficiently as it did DMSO-treated cells (Fig. 9B, lower left panel). These data indicated 
that the PKC inhibitors, Ca2+ inhibitors and FTS were unable to block HIV-1 infection 
when HIV-1 entered cells through VSV-G–mediated or A-MLV-mediated endocytosis. In 
other words reverse transcription and nuclear import were able to proceed in the presence 
of these inhibitors. VSV-G HIV-1 and A-MLV HIV-1 infection in U73122-treated cell 
was inhibited by 57±8.9% and 64±3.6% respectively (Figure 9B). These results support 
the suggestion PLC plays a role in post-fusion steps in the virus life cycle.  
To analyze the effects of the siRNAs targeted to Gαq, Gαi ,Gαs, pyk2 and Rac on 
HIV-1 infection and to show that the effects are not cell-type specific, we performed a 
single-cycle HIV-1 infection assay using TZM-BL indicator cells transfected with control 
siRNA and siRNA targeted to Gαq, Gαi ,Gαs, Pyk2 and Rac. Figure 9C shows that the 
reduction in infection with HIVYU2 in cells expressing siRNA directed against Gαq, pyk2, 
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and Rac versus cells expressing control siRNA was comparable to the reduction in Env-
dependent cell-cell fusion and Rac activation (Fig. 3 and Fig. 7). Whereas, the siRNA 
targeted to Gαi and Gαs had no effect (Fig. 9C). The decreased steady state level of Gαq, 
Gαi ,Gαs, pyk2 and  Rac protein in TZM-BL cells expressing targeted siRNA versus 
control siRNA,  was similar to that observed in U87.CD4.R5 cells (Fig. 3B and Fig. 7B), 
and each siRNA was specific for its target protein, as detected by immunoblot (data not 
shown). 
 
Inhibitor treatment does not alter CD4/CCR5 receptor expression or surface 
localization. Suppression of Env-dependent Rac activation and cell-cell fusion in the 
presence of inhibitors could also be explained by a change in CD4/CCR5 receptor 
localization or surface expression. To confirm that there were no changes in CD4/CCR5 
receptor localization; U87.CD4.CCR5 cells were incubated with the inhibitors for 3h and 
were analyzed by confocal microscopy. No gross differences in cell surface localizations 
of CD4 or CCR5 were observed (Fig 10A). Blocking CCR5, with TAK-779 and Rac 
activation with the RacGEF Inhibitor also had no effect on CD4/CCR5 localization. In 
contrast, CD4 and CCR5 localization could be disrupted by treating cells with the actin 
assembly inhibitor Cytochalasin D (CD). U87.CD4.CCR5 cells treated with inhibitors 
reconstituted in DMSO were compared to DMSO treated cells, and the cells treated with 
inhibitors reconstituted in H2O were compared to untreated cells.  
To determine the effect of inhibitors on surface expression of the CD4/CCR5 
receptors we used flow cytometric analysis (FACS). Incubation of U87.CD4.CCR5 cells 
with U73122, U73343, Calphostin C, Ch Ch, PKC-I (20-28), dantrolene, FTS, and 
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RacGEF Inhibitor for 3h had no effect on cell surface expression of CD4 or CCR5 (Fig. 
9B). In this experiment, U87 cells that do not express CD4 or CCR5 were used as a 
negative control and untreated cells were used as a positive control. TAK-779 a CCR5 
inhibitor that interacts with the same domain as the anti-CCR5 antibody blocked CCR5 
staining but had no effect on CD4 staining. These results confirm that at the 
concentrations used in this study these inhibitors do not alter CD4/CCR5 cell surface 
expression or localization. 
 
Inhibitor treatment results in specific inhibition of target molecules.  Next we 
examined whether the decrease in Env-dependent Rac activation and cell-cell fusion in 
the presence of inhibitor is due to specific inhibition of the target molecule by 
determining effects on PKA activity and Pyk2 phosphorylation. To measure the effect on 
PKA activity, U87.CD4.CCR5 cells were pretreated for 1h with U73122, U73343, 
Ch,Ch, Dantrolene, or FTS then lysed and total lysates were analyzed in the presence of 
inhibitors using the PepTag assay for the non-radioactive detection of cAMP-dependent 
protein. PKA activity in U73122, U73343, ChCh, and FTS-treated cells was similar to 
that in untreated cells (Fig. 11A). PKC inhibitors Bis I, Calphostin C, Go-6976, and Ro-
32-0432 were also tested with similar results (data not shown). Treatment of 
U87.CD4.CCR5 cells with dantrolene decreased PKA activity by 30% suggesting a role 
for intracellular Ca2+ release in maintaining endogenous PKA activity. This decrease is 
minimal compared to the 75% reduced PKA activity in cells treated with H89 (Fig. 10A). 
In addition, dantrolene treated cells show a 90% decrease in Env-induced Rac activation 
 79 
and 98% decrease in cell-cell fusion whereas PKA inhibition has no effect (Fig. 6, Fig. 
2B).  
To determine the effect of inhibitors on HIV-1 Env-induced Pyk2 activation, 
U87.CD4.CCR5 cells were pretreated with U73122, U73343, PKC inhibitors Calphostin 
C, Ch Ch, Go-6976 and PKC-I (20-28), dantrolene, or FTS for 1h prior to mixing with 
HIV-1 Env expressing cells for 5 min and measurement of Pyk2 phosphorylation. As 
expected, inhibitors targeted to PLC, PKC and intracellular Ca2+ release that are required 
upstream of Pyk2 decreased the amount of Env-induced Pyk2-phosphorylation whereas 
FTS had no effect (Fig 11B).  
Table 1 summarizes the effects of the PLC inhibitor, general and specific PKC 
inhibitors, intracellular Ca2+ release inhibitors and FTS on Env-induced cell-cell fusion, 
Rac activation, virus-dependent cell-cell fusion, infection of TZM-BL cells, PKA 
activation and Pyk2 phosphorylation. These results confirm that at the concentrations 
used in this study these inhibitors are specific for their target molecules. 
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Table 1. Summary of studies with inhibitors 
 
Reagent 
(uM) 
Target % EDFa 
% 
EDFb 
with 
RacV12 
% Rac 
Activation 
% 
VDFc %Infection 
% PKA 
Activation 
% 
Pyk2-P 
H89 (10) PKA 95±2 NTd 100±2 NT NT 24±0.6 NT 
U73122 (3) PLC 27±1 108±0.2 27±2 28±5 0.8±1 105±5 19 
U73343 (3) 
Inactive 
analog for 
U73122 
95±1 105±0.4 104±4 99±14 96±10 111±4 97 
Bis I (10) PKC 45±11 107±8 NT NT NT NT NT 
Calphostin 
C (0.5) PKC 13±2 97±7 14±1 NT NT NT 16 
Ch Ch (50) PKC 11±2 116±9 17±0.4 7±4 10±2 99±4 14 
Go 6976 
(1) 
Ca2+ 
dependent 
PKC 
21±4 99±3 27±1 24±6 33±3 NT 26 
Ro-32-
0432 (10) 
Specific for 
PKC α & β 27±4 108±5 NT NT NT NT NT 
PKC-I (20-
28) (100) 
Specific for 
PKC α & β 7±3 114±5 6±1 0±3 2±0.2 NT 0 
Dantrolene 
(100) 
RyR-
Intracellular 
Ca2+ 
release 
7±2.2 50±1.6 10±5 9±1.8 10±1.2 70±2.5 0 
CPA (10) SERCA 21±2.5 40±1.6 19±1.2 14±3 13± 1.7 NT NT 
TG (2) SERCA 3±2.6 25±1.6 21±2.2 9±1.1 0.6±0.5 NT NT 
XC (5) 
IP3R-
Intracellular 
Ca2+ 
release 
24±3.5 32±1.6 25±1.3 20±6.6 3±0.5 NT NT 
FTS (50) Ras 0± 0.2 40 ±4 20±4 0±9 0.3±2 92±24 97 
a. Values are percentages for treated reactions compared to those determined for 
reactions with untreated controls.  
b. EDF, Env-dependent fusion (percent fusion is the average of reactions from cells 
incubated with HIVADA, HIVYU2, and HIV89.6 Env-expressing cells). 
c. VDF, virus-dependent fusion 
d. NT, not tested 
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Discussion 
Earlier studies using PTX and/or mutant CD4 and coreceptors supported the view 
that signaling is not required for HIV-1 Env-mediated fusion (78, 82-85). However, it is 
now apparent that signaling via CD4 and the coreceptors is far more intricate than was 
thought previously. The studies suggesting that signaling is dispensable for HIV-1 entry 
focused mostly on signaling through Gαi and did not show that Gαi-independent pathways 
were similarly dispensable. A recent study reported that HIV-1 Env-mediated Rac 
activation and subsequent reorganization of the actin filament network are required to 
facilitate membrane fusion (12). Another study reported a block of entry and post-entry 
events with the B oligomer of PTX, which modulates signaling independent of Gαi (147). 
Additional studies reported that the tyrosine kinase inhibitor genistein blocks HIV-1 
infection in primary macrophages and that RhoA and filamin A are required for the actin-
dependent clustering of CD4 and coreceptor required for membrane fusion (11, 148, 
149). These findings indicate that HIV-1 Env-induced signaling plays a crucial role in 
Env-mediated membrane fusion. 
In the current study, we elucidate that the signal transduction pathway of Env-
dependent Rac activation and membrane fusion is Gαq, PLC-β, PKC, Pyk2, and Ras 
dependent (Fig 1). Env-mediated Rac activation and membrane fusion were attenuated in 
cells expressing siRNA targeted to Gαq and Pyk2 and in cells treated with the PLC 
inhibitor U73122 but not in cells treated with its inactive analog U73343 or in cells 
expressing siRNA targeted to Gαi and Gαs. Rac activation and fusion were also blocked 
by multiple PKC inhibitors, by inhibitors of intracellular Ca2+ release, and by the Ras 
inhibitor FTS. The observation that siRNA and inhibitors targeting the Gαq pathway were 
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inhibitory but inhibitors and siRNA targeting the Gαi or the Gαs pathway were not 
indicates that this pathway is both necessary and sufficient to mediate membrane fusion. 
Using a constitutively active Rac mutant, RacV12, we have shown that Gαq, PLC-β, PKC 
and Pyk2, are necessary upstream of Rac whereas Ras activation and intracellular Ca2+ 
release are required for cell-cell fusion both upstream and downstream of Rac activation. 
Importantly, the inhibitor concentrations employed in our experiments did not alter levels 
of surface expression or localization of CD4 and CCR5 and also did not show any 
nonspecific effects on vaccinia virus infection and T7 polymerase or on other signaling 
pathways. Inhibitors to PKC, intracellular Ca2+ release and Ras suppressed Env-
dependent and virus-dependent fusion as well as HIVYU2 infection of TZM-BL cells to 
comparable levels. On the other hand, VSV-G HIV-1 or A-MLV HIV-1 infection of 
TZM-BL cells was not blocked by the PKC, intracellular Ca2+ release, and Ras inhibitors, 
confirming that the block is specific to HIV-1 Env-mediated membrane fusion. The PLC 
inhibitor U73122 had a greater effect on HIVYU2 infection of TZM-BL cells than on Env-
dependent and virus-dependent fusion and also decreased VSV-G HIV-1 or A-MLV 
HIV-1 infection. Taken together this data suggests that while all the inhibitors suppress 
fusion and therefore infection, U73122 can also suppress post-fusion steps in the virus 
life-cycle.  
It has been shown previously that binding of CCR5 by HIV-1 gp120 activates 
several signaling pathways including those involving PLC and PKC activation, Ca2+ 
elevation, Pyk2 phosphorylation, and Rac activation (12, 90, 99). In the present study we 
show that Env interaction with CCR5 also results in Ras activation. Env-induced Ras 
activation is mediated specifically by CCR5, and not by CD4, because no increase in 
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RasGTP was observed in U87.CD4.CCR5 stimulated with X4 Env or TAK-779 treated 
cells stimulated with R5 Env. Env-dependent Ras activation provides a link between 
CCR5 stimulation and Rac activation. We have shown previously that Env-mediated Rac 
activation is dependent on a Rac specific GEF most likely Tiam-1 (45, 144), and Ras has 
been shown to mediate Rac activation via a direct interaction with Tiam-1 or via 
phospatidylinositol 3-OH kinase-mediated activation of Tiam-1 . The Env-mediated 
activation of Ras upstream of Rac indicates that Tiam-1 is the RacGEF responsible for 
Env-mediated Rac activation. Rac-GEFs and their interacting proteins play an important 
role in selection of downstream effectors of Rac leading to regulation of different cellular 
processes (150-152). Therefore, discovery of the Rac-GEF and of downstream targets of 
Rac required for fusion will provide information on the mechanism of fusion and 
additional targets for therapeutic intervention.  
In summary, we provide evidence that siRNA and inhibitors targeted to Gαq and 
its downstream effectors prevent HIV-1 infection of TZM-BL cells as well as Env-
dependent membrane fusion in U87.CD4.R5 cells and PBLs and virus-dependent 
membrane fusion of U87.CD4.R5 cells. HIV-1 Env interaction with CCR5 stimulates a 
signaling cascade involving Gαq, PLC, PKC, intracellular Ca2+ release, Pyk2 and Ras that 
allows activation of Rac and subsequent actin cytoskeleton rearrangements necessary for 
fusion. These results confirm and extend the implication of Rac in HIV-1 infection, and 
point to new potential target molecules of HIV-1 inhibitory drugs. Multiple PKC 
inhibitors are in clinical trials or are approved for clinical use to treat cancer and diabetes 
including Go-6976 and Bis I used in this study (153).  Multiple studies in mice with the 
Ras inhibitor FTS have given promising results for the treatment of various types of 
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cancer, neurofibromatosis, and kidney disease (154, 155). In addition, FTS is currently in 
phase I clinical trials for hematologic malignancies (155, 156). The ability of these 
inhibitors to specifically down-regulate their target molecules without adverse side 
effects suggests that these inhibitors might be appropriate drugs for treatment of HIV-1 
and other infectious microbes that manipulate this pathway. This strategy of using 
inhibitors that disable host signaling proteins essential for pathogen survival may have a 
general efficacy in developing drugs to combat pathogens that acquire drug resistance.  
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Figures 
Fig. 1.  Model of signal transduction pathway elicited by Env interaction with CCR5 
required for Rac activation and membrane fusion. This study establishes the role of 
various signaling molecules during HIV-1-induced membrane fusion by examining the 
effects of selective inhibitors and siRNA targeting the Gαq pathway using Rac activation, 
virus entry and infection assays. Signaling molecules previously shown to be activated by 
gp120 are shown in bold, and confirmed pathways are shown with a solid line (12, 87, 
134, 141, 144). Suspected factors that may be involved are shown in normal font, and 
potential pathways are shown with dotted lines. Ras is shown in black because it was 
shown to be activated by Env in this study. Open boxes represent siRNA or selective 
small molecule inhibitors used to inhibit Gαq and molecules downstream of Gαq.  
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Fig. 2. Env-mediated Rac activation and cell-cell fusion are PTX-insensitive and 
PKA independent. (A) U87.CD4.CCR5 cells were treated with 200ng/ml PTX for 18h 
prior to and during 30 min incubation with BSC40 cells expressing no Env (grey) or Env 
from HIV-1 strain ADA (black). Whole cell lysates were then analyzed by Rac specific 
G-LISA activation assay (average A490 of duplicate wells ± standard deviation; data are 
representative of results from three similar experiments). (B) Actin-dependent cell fusion. 
Average fusion compared to untreated control reactions and detected by ß-galactosidase 
activity ± standard deviation is shown. U87.CD4.CCR5 cells were infected with vaccinia 
virus expressing ß-galactosidase (vCB21R) overnight, then these cells were pretreated 
with DMSO alone (black) and the PKA inhibitors PKA 14-22 (grey) and H89 (black) at 
indicated concentrations (uM) for 1h. A portion of these cells was mixed 1:1 with 
HIVADA or HIVUNC Env-expressing cells (subtracted as background) for 3h in the 
presence of inhibitors. Data are representative of results from three similar experiments 
performed in triplicate. Cell fusion was normalized using untreated cells as incubated 
with HIVADA Env as 100%. The rest of the cells were lysed and whole cell lysates were 
analyzed for PKA activity in the presence of inhibitors. PKA (ng) based on standard 
curve of A570nm of varying amounts of PKA. Results representative of three 
independent experiments performed in duplicate. (C) U87.CD4.CCR5 cells were treated 
for 1h with 1uM TAK-779 or 10uM H89 prior to and during 30 min incubation with 
BSC40 cells expressing no Env (subtracted as background), HIVADA Env (open bars) or 
HIVHXB2 Env (solid bars). Whole cell lysates were then analyzed by Rac specific G-LISA 
activation assay. Average A490 of duplicate wells ± standard deviation; data are 
representative of results from three similar experiments (*, P < 0.01).  
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Fig. 3. Gαq down-regulation with siRNA reduces Env-mediated cell-cell fusion. (A) 
Average fusion compared to untreated control reactions and detected by ß-galactosidase 
activity ± standard deviation are shown. U87.CD4.CCR5 cells were transfected with 
100nM control siRNA (control) or 100nM siRNA targeted against Gαq, Gαi or Gαs. 24h 
post-transfection U87.CD4.CCR5 cells were serum starved. 48h post transfection the 
cells were infected with vCB21R alone or with vaccinia virus encoding the constitutive -
active point mutant RacV12 (vRacV12) in complete media. 72 h post-transfection the 
transfected U87.CD4.CCR5 were incubated with HIVUNC (subtracted as background) 
HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are 
representative of results from three similar experiments performed in triplicate (**, P < 
0.05). Cell fusion was normalized using control siRNA transfected cells incubated with 
HIVADA Env as 100%. (B) 2X105 of each population of transfected cells were lysed and 
whole cell lysates were analyzed by western blot. There are three immunoblots, the lysate 
from cells transfected with 100nM control siRNA (lane1) or 100nM siRNA targeted to 
Gαq (lane 2), Gαi (lane 3), or Gαs (lane 4), were loaded on each immunoblot and were 
initially probed with anti-Gαq (left), anti-Gαi (middle), or anti-Gαs (right),  then all blots 
were stripped and probed with anti-actin (bottom). The relative reduction index (RI) was 
calculated as the quotient of the densitometry signal for the Gαq, Gαi or Gαs band and that 
for actin (shown below), and then normalized by the ratio obtained with control siRNA 
(defined as 1). Data represent results from 1of 3 experiments with similar results. (C) 
U87.CD4.CCR5 cells were transfected with 100nM control siRNA (solid bars), 100nM 
Gαq siRNA, Gαi siRNA, or Gαs siRNA (open bars) as described above. 72h post-
transfection cells were incubated for 30 min with BSC40 cells expressing no Env 
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(subtracted as background), or HIVADA Env. Whole cell lysates were then analyzed by 
Rac specific G-LISA activation assay. Average A490 of duplicate wells ± standard 
deviation; data are representative of results from three similar experiments (**, P < 0.05). 
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Fig. 4. PLC-β is required for Env-mediated fusion upstream of Rac. Average fusion 
compared to untreated control reactions and detected by ß-galactosidase activity ± 
standard deviation are shown. (A) Serum starved U87.CD4.CCR5 cells were infected 
with vCB21R alone, or with vRacV12 in complete media overnight. These cells were 
then pretreated with DMSO alone, or 3uM of PLC-β inhibitor U73122 and its negative 
analog U73343 for 1h and the inhibitors were also present during the incubation with 
HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-
expressing cells for 3h. Data are representative of results from three similar experiments 
performed in triplicate (*, P < 0.01, **, P < 0.05).  Cell fusion was normalized using 
DMSO treated cells incubated with HIVADA Env as 100%. (B) U87.CD4.CCR5 cells 
were treated for 1h with 1uM TAK-779, 3uM U73122, 3uM U73343 (open bars), or 
DMSO alone (solid bars) prior to and during incubation for 30 min with BSC40 cells 
expressing no Env (subtracted as background), or HIVADA Env. Whole cell lysates were 
then analyzed by Rac specific G-LISA activation assay. Average A490 of duplicate wells 
± standard deviation; data are representative of results from three similar experiments (*, 
P< 0.01, **, P < 0.05). (C) Serum starved PBLs were infected with vCB21R in complete 
media overnight. These cells were then pretreated with DMSO alone, 1uM TAK-779 or 
3uM of PLC-β inhibitor U73122 and its negative analog U73343 for 1h and the inhibitors 
were also present during the incubation with HIVUNC (subtracted as background) 
HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are 
representative of results from three similar experiments performed in triplicate (*, P < 
0.01, **, P < 0.05).  Cell fusion was normalized using DMSO treated cells incubated with 
HIVADA Env as 100%. 
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Fig. 5. Intracellular Ca2+ release is required for Env-mediated fusion upstream & 
downstream of Rac. Average fusion compared to untreated control reactions and 
detected by ß-galactosidase activity ± standard deviation are shown. (A) Serum starved 
U87.CD4.CCR5 cells were infected with vCB21R alone, or with vRacV12 in complete 
media overnight. These cells were then pretreated with DMSO alone or 100uM 
dantrolene, 10uM cyclopiazonic acid (CPA), 2uM thapsigargin (TG), or 5uM 
Xestospongin C (XC) for 1h and the inhibitors were also present during the incubation 
with HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-
expressing cells for 3h. Data are representative of results from three similar experiments 
performed in triplicate (*, P < 0.01). Cell fusion was normalized using DMSO treated 
cells incubated with HIVADA Env as 100%.  (B) U87.CD4.CCR5 cells were treated for 1h 
with DMSO alone (solid bars), 1uM TAK-779, 100uM dantrolene, 10uM CPA, 2uM TG, 
5uM XC, or 100uM RacGEF inhibitor (open bars) prior to and during incubation for 30 
min with BSC40 cells expressing no Env (subtracted as background), or Env from 
HIVADA Env. Whole cell lysates were then analyzed by Rac specific G-LISA activation 
assay. Average A490 of duplicate wells ± standard deviation; data are representative of 
results from three similar experiments (*, P < 0.01). (C) Serum starved PBLs were 
infected with vCB21R in complete media overnight. These cells were then pretreated 
with DMSO alone or 100uM dantrolene, 10uM cyclopiazonic acid (CPA), 2uM 
thapsigargin (TG), and 5uM Xestospongin C (XC) for 1h and the inhibitors were also 
present during the incubation with HIVUNC (subtracted as background) HIVADA, HIVYU2, 
HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are representative of results from 
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three similar experiments performed in triplicate (*, P < 0.01). Cell fusion was 
normalized using DMSO treated cells incubated with HIVADA Env as 100%.   
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Fig. 6. PKC is required for Env-mediated fusion upstream of Rac. Average fusion 
compared to untreated control reactions and detected by ß-galactosidase activity ± 
standard deviation are shown. (A, B) Serum starved U87.CD4.CCR5 cells were infected 
with vCB21R alone or with vRacV12 overnight in complete media.  These cells were 
then pretreated with DMSO alone or the PKC inhibitors Bisindolylmaleimide I (Bis I, 
10uM), Calphostin C (0.5uM), and Chelerythrine Chloride (Ch Ch, 50uM) for 1h (A) or 
pretreated with the specific PKC inhibitors Go-6976( Ca2+-dependent, 1uM), Ro-32-0432 
(selective for α & β, 10uM), and PKC-I (20-28) (myristolated peptide inhibitor specific 
for α & β, 100uM) for 1h (B). The inhibitors were also present during the incubation with 
HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-
expressing cells for 3h. Data are representative of results from three similar experiments 
performed in triplicate (*, P<0.01, **, P < 0.05). Cell fusion was normalized using 
DMSO treated cells incubated with HIVADA Env as 100%. (C) U87.CD4.CCR5 cells 
were treated for 1h with DMSO alone (solid bars), 1uM TAK-779, 0.5uM Calphostin C, 
50uM Ch Ch, 1uM Go 6976, 100uM PKC-I (22-28) and 100uM RacGEF inhibitor (open 
bars) prior to and during incubation for 30 min with BSC40 cells expressing no Env 
(subtracted as background), or HIVADA Env. Whole cell lysates were then analyzed by 
Rac specific G-LISA activation assay. Average A490 of duplicate wells ± standard 
deviation; data are representative of results from three similar experiments (*, P < 0.01). 
(D) Serum starved PBLs were infected with vCB21R overnight in complete media.  
These cells were then pretreated with DMSO alone or the PKC inhibitors Ch Ch, (50uM) 
or Go-6976for 1h. The inhibitors were also present during the incubation with HIVUNC 
(subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells 
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for 3h. Data are representative of results from three similar experiments performed in 
triplicate (*, P<0.01). Cell fusion was normalized using DMSO treated cells incubated 
with HIVADA Env as 100%. 
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Fig. 7. Env-induced fusion and Rac activation are dependent on Pyk2. (A) Average 
fusion compared to untreated control reactions and detected by ß-galactosidase activity ± 
standard deviation are shown. U87.CD4.CCR5 cells were transfected with 100nM control 
siRNA (control) or 100nM siRNA targeted against Pyk2 or Rac. 24h post-transfection 
U87.CD4.CCR5 cells were serum starved. 48h post transfection the cells were infected 
with vCB21R alone or with vaccinia virus encoding the constitutive -active point mutant 
RacV12 (vRacV12) in complete media. 72 h post-transfection the transfected 
U87.CD4.CCR5 were incubated with HIVUNC (subtracted as background) HIVADA, 
HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are representative of 
results from three similar experiments performed in triplicate (*, P < 0.01). Cell fusion 
was normalized using control siRNA transfected cells incubated with HIVADA Env as 
100%. (B) 2X105 of the each population of transfected cells were lysed and whole cell 
lysates were analyzed by western blot. There are two immunoblots, the lysate from cells 
transfected with 100nM control siRNA (lane1) or 100nM siRNA targeted to Pyk2 (lane 
2) or Rac (lane 3) were loaded on each immunoblot and were initially probed with anti-
Pyk2 (left) or anti-Rac (right),  then all blots were stripped and probed with anti-actin 
(bottom). The relative reduction index (RI) was calculated as the quotient of the 
densitometry signal for the Pyk2
 
or Rac band and that for actin (shown below), and then 
normalized by the ratio obtained with control siRNA (considered 1). Data represent 
results from 1of 3 experiments with similar results. (C) U87.CD4.CCR5 cells were 
transfected with 100nM control siRNA (solid bars), 100nM Pyk2 or 100nM Rac siRNA 
(open bars) as described above. 72h post-transfection cells were incubated for 30 min 
with BSC40 cells expressing no Env (subtracted as background), or HIVADA Env. Whole 
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cell lysates were then analyzed by Rac specific G-LISA activation assay. Average A490 
of duplicate wells ± standard deviation; data are representative of results from 1 of 3 
similar experiments (**, P < 0.05). 
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Fig. 8. Ras is required for Env-mediated fusion upstream & downstream of Rac. 
Average fusion compared to untreated control reactions and detected by ß-galactosidase 
activity ± standard deviation are shown. (A) Serum starved U87.CD4.CCR5 cells were 
infected with vCB21R alone, or with vRacV12 in complete media overnight. These cells 
were then pretreated with DMSO alone or indicated concentrations of Ras inhibitor FTS 
for 1h and inhibitor was also present during the incubation with HIVUNC (subtracted as 
background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are 
representative of results from three similar experiments performed in triplicate (*, P < 
0.01). Cell fusion was normalized using DMSO treated cells incubated with HIVADA Env 
as 100%. (B) U87.CD4.CCR5 cells were treated for 1h with DMSO alone (solid bars), 
1uM TAK-779, 50uM FTS, and 100uM RacGEF inhibitor (open bars) prior to and during 
incubation for 30 min with BSC40 cells expressing no Env (subtracted as background), or 
Env from HIVADA Env. Whole cell lysates were then analyzed by Rac specific G-LISA 
activation assay. Average A490 of duplicate wells ± standard deviation; data are 
representative of results from three similar experiments (*, P < 0.01, **, P <0.05). (C) 
Serum starved PBLs cells were infected with vCB21R in complete media overnight. 
These cells were then pretreated with DMSO alone, 50uM Ras inhibitor FTS, or 100uM 
RacGEF inhibitor for 1h and inhibitor was also present during the incubation with 
HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-
expressing cells for 3h. Data are representative of results from three similar experiments 
performed in triplicate (*, P < 0.01). Cell fusion was normalized using DMSO treated 
cells incubated with HIVADA Env as 100%. (D) Ras activation assay. Western blot 
analysis of Raf-1 binding fractions from lysates of U87.CD4.CCR5 cells mixed with 
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BSC40 cells expressing no Env (lane 3), HIVHXB2 Env (lane 4) or HIVADA Env (lanes 5-
9). 1uM TAK-779 was included to inhibit CCR5-Env binding (lane 5). Cells were 
pretreated with DMSO alone (lane 6) and indicated concentrations of FTS to inhibit Ras 
(lane 7-9) for 1hr and during the 30 min incubation with Env-expressing cells. Positive 
(lane 1) and negative (lane 2) controls were generated by GTPγS- and GDP-loading of 
reaction lysates, respectively. Increases (n-fold) in the amount of Ras-GTP compared to 
lane 3 were determined by densitometry (normalized to lysate loading control) and are 
indicated below the blot. Data represent results from 1of 3 experiments with similar 
results. 
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Fig 9. Effect of inhibitors on virus-dependent cell fusion with HIV-1 R5 virus and 
infection of TZM-BL cells with HIV-1 R5 virus or A-MLV- pseudotyped and VSV-
G pseudotyped HIV-1 virus. (A) Average fusion compared to untreated control 
reactions and detected by ß-galactosidase activity ± standard deviation are shown. One 
population of serum starved U87.CD4.CCR5 cells was infected with vCB21R and the 
other population of U87.CD4.CCR5 cells was infected with vPT7-3 in complete media 
overnight. These cells were then mixed (1:1) in triplicate wells of 96 well plate and 
pretreated with DMSO alone, TAK-779 (1uM), U73122 and U73343 (3uM), Ch Ch 
(50uM), Go-6976 (1uM), PKC-I (20-28) (100uM), dantrolene (100uM), CPA (10uM), 
TG (2uM), XC (5uM) and FTS (50uM) for 1h. Inhibitors were also present during 
incubation with 100ng of HIVYU2 per well for 3h at 37°C. Data are representative of 
results from three similar experiments (*, P < 0.01). Cell fusion was normalized using 
DMSO treated cells mixed with HIVYU2 as 100%. (B) JC53BL cells were pre-incubated 
with DMSO alone, TAK-779 (1uM), U73122 and U73343 (3uM), Ch Ch (50uM), Go-
6976 (1uM), dantrolene (100uM), CPA (10uM), TG (2uM), XC (5uM), FTS (50uM), 
NH4Cl (50mM), and OA (100nM) for 1h and inhibitors were also present during 3h 
infection period with 150ng of HIVYU2, A-MLV-pseudotyped HIV-1 or VSV-G-
pseudotyped HIV-1 per well. Virus and inhibitor were then washed off the cells and the 
cells were incubated in the same concentration of inhibitor at 37°C overnight. Luciferase 
activities in the infected cell lysates were measured at 24h post-infection and were used 
to calculate virus infectivity relative to that of the control.  Data are representative of 
results from 1 of 3 similar experiments performed in triplicate (**, P < 0.05). Cell 
infection was normalized using DMSO treated cells as 100%. 
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Fig 10. Gαq inhibitors do not affect surface expression and localization of CD4 and 
CCR5.GFP. (A) Confocal micrographs of U87.CD4.CCR5 cells untreated, treated with 
DMSO alone, TAK-779 (1uM), U73122 (3uM), U73343 (3uM), Calphostin C (0.5uM), 
Chelerythrine Chloride (50uM), PKC-I 20-28 (100uM), dantrolene (100uM), FTS 
(50uM) and RacGEF Inhibitor (100uM) for 3h, and CD (1uM) for 15 min, fixed and 
stained with anti-CD4-PE antibodies (red) and counterstained with TO-PRO3 (blue). The 
green GFP signal and red PE signal have been merged to show areas of colocalization 
(yellow).  Data are representative of results from 3 experiments. Images were collected 
using an oil objective (magnification X63). (B) U87.CD4.CCR5 cells were incubated 
with all the inhibitors listed in (A) except CD for 3h and detached by treatment with 
5mM EDTA. U87 cells and untreated and treated U87.CD4.CCR5 cells were labeled for 
surface expression of CD4 and CCR5 and analyzed by flow cytometry. Unlabeled 
U87.CD4.CCR5 cells were used to compensate for GFP. Data are expressed as 
percentage of surface expression based on DMSO treated cells as 100%. 
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Fig 11. Pretreatment with inhibitors results in specific effects on target molecules. 
(A) U87.CD4.CCR5 cells were treated with the PKA inhibitor H89 (10uM), PLC 
inhibitor U73122 and its negative analog U73343 (10uM), PKC inhibitor Ch Ch (50uM), 
Intracellular Ca2+ inhibitor dantrolene (100uM) and Ras inhibitor FTS (50uM) for 1h. 
Whole cell lysates were then analyzed for PKA activity in the presence of inhibitors. 
PKA (ng) based on standard curve of densitometry of varying amounts of PKA. Results 
representative of two independent experiments performed in duplicate (*, P < 0.01, **, P 
<0.05). (B) Western blot analysis of phosphorylated Pyk2 from lysates of 
U87.CD4.CCR5 cells mixed with BSC40 cells expressing no Env (lane 1) or Env from 
HIV-1 strains HXB2 (lane 3), or ADA (lanes 2, 4-12) at 37°C for 5 min. Cells were 
pretreated with DMSO alone (NI, lane 1-3), 1uM TAK-779 (lane 4), 3uM U73122 and 
U73343 (lane 5-6), 0.5uM Calphostin C (lane 7), 50uM Ch Ch (lane 8), 1uM Go-6976 
(lane 9), 100uM PKC-I (20-28) (lane 10), 100uM dantrolene (lane 11) and 50uM FTS 
(lane 12) for 1hr and during the 5 min incubation with Env-expressing cells. Cell lysates 
were resolved by 10% SDS-PAGE, transferred to a nitrocellulose membrane, and probed 
with anti-Pyk2 phosphospecific [pY579/580] antibody (upper panel, P-Pyk2). The same 
blot was then stripped and reprobed with an antibody specific for total Pyk2 (lower 
panel). Blots shown are representative of 3 independent experiments.  
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Abstract 
Entry of human immunodeficiency virus type 1 (HIV-1) commences with binding of the 
envelope glycoprotein (Env) to the receptor CD4, and one of two coreceptors, CXCR4 or 
CCR5. Env-mediated signaling through coreceptor results in Gαq-mediated Rac 
activation and actin cytoskeleton rearrangements necessary for fusion. In this study, we 
show that the mechanism of Env-induced Rac activation is mediated by the Rac guanine 
nucleotide exchange factor Tiam-1, which associates with the adaptor protein IRSp53 to 
link Rac to the Wave2 complex and activates the actin polymerization complex Arp2/3. 
Env-mediated fusion and HIV-1 infection are dependent on Tiam-1, IRSp53, Wave2, and 
Arp3 as shown by attenuation of fusion and infection in cells expressing siRNA targeted 
to these signaling components. Env-dependent cell fusion and HIV-1 infection were also 
inhibited by siRNA to Abl and Abl kinase activity inhibitors, imatinib, nilotinib, and 
dasatinib. Fusion was blocked by these inhibitors without altering cell viability or surface 
expression of CD4 and CCR5. Similar results were obtained when cell-cell fusion was 
induced by Env expressed on viral or cellular membranes and when cell lines or primary 
cells were the target. Using membrane curving agents and fluorescence microscopy, we 
showed that inhibition of Abl kinase activity arrests fusion at the hemifusion step, 
suggesting a role for actin remodeling in pore formation and expansion. These results 
also suggest a potential use of Abl kinase inhibitors to treat HIV-1 infected patients.  
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Introduction   
     HIV-1 enters cells by fusion at the plasma membrane and endocytosis (1-3). HIV-1 
entry requires multiple conformational changes in the HIV-1 glycoprotein, and 
rearrangement of the actin cytoskeleton. These events are triggered by binding of the 
viral envelope (Env) surface subunit gp120 to the primary receptor, CD4, and one of two 
chemokine coreceptors, CCR5 or CXCR4 (2, 12). This interaction activates signaling 
events similar to those initiated by natural ligands, such as Ca2+ mobilization, activation 
of RhoGTPases, and phosphorylation of tyrosine kinases, pyk2, Zap70 and p56lck (12, 
49, 73).  The Rho GTPase sub-family stimulates myosin based contractility and drives 
the formation of stress fibers and focal adhesions. The Rac GTPase sub-family stimulates 
lamellipodia and membrane ruffles, and the Cdc42 subfamily stimulates the formation of 
filopodia (26, 27, 157). We showed  that HIV-1 Env binding to target cells activates Rac, 
stimulates membrane ruffles and lamellipodia, and fusion is inhibited by dominant 
negative Rac (12, 45). Furthermore, HIV-1 Env-induced Rac activation depends on 
activation of Gαq, phospholipase C (PLC), Ca2+ mobilization, protein kinase C (PKC), 
pyk2 and Ras (73). In the current study we identified the fusion-specific effectors of Rac 
required for actin cytoskeleton rearrangements that mediate membrane fusion and entry.  
     Rac GTPase is regulated by guanine nucleotide exchange factors (GEFs) (26, 27, 
157). HIV-Env induced Rac activation is mediated by a Rac-specific GEF, either Tiam-1 
or Trio (44, 45). GEFs not only facilitate the GDP to GTP switch for their targeted 
GTPase, but they also select downstream effector proteins by participating in scaffold 
protein complexes that organize components of a specific signaling pathway.  
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     There are multiple effectors of Rac, including serine/threonine kinases, lipid kinases, 
actin-binding proteins, and adaptor/scaffold molecules (27, 158). PAK is a downstream 
effector of Rac and Cdc42 that promotes stabilization of actin networks. Another 
downstream effector of Rac that nucleates actin polymerization is the Arp2/3 complex. 
The Arp2/3 complex is activated by the Wave2 complex through  IRSp53, an adaptor 
protein that binds Rac and Wave2 (27). The Wave2 complex includes Rac-associated 
protein 1, Nck-associated protein, Abl-interacting protein 2, and heat shock protein C300. 
Wave2 also associates with Abl, which promotes Wave2 phosphorylation and activation 
(159). In addition to determining which Rac effectors are critical for membrane fusion, 
we studied the steps in the membrane fusion process affected by these signaling 
molecules. These data demonstrate that the Wave2 signaling complex and Abl are 
required for Env-mediated membrane fusion, entry, and infection and that inhibition of 
Abl kinase arrests the fusion process at hemifusion. 
Results 
HIV-1 Env-mediated fusion depends on the Wave2 signaling complex.  
     To determine whether Abl, Trio, or Tiam-1 are required for HIV-1 Env-mediated cell 
fusion, expression of these proteins was downregulated by RNA interference (RNAi) in 
U87.CD4.CCR5 cells. Cells expressing siRNAs were mixed with BSC40 cells expressing 
different Env subtypes and Env-dependent fusion was measured. Transfection of target 
cells with siRNA to Tiam-1 and Abl decreased levels of Env-mediated cell-cell fusion by 
an average of 79 ± 5% and 74 ± 5% respectively for both HIV-1 R5 and dual-tropic Env-
subtypes (Fig 1A, left). There was no significant fusion observed with CCR5 expressing 
target cells and X4 Env expressing cells, as expected. The decrease in the levels of fusion 
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correlated well with the decreased steady-state level of Tiam-1, and Abl as detected by 
immunoblot (Fig. 1C). The siRNA directed against Trio had no effect on Env-induced 
cell-cell fusion despite a 70% reduction in expression of the Trio protein (Fig 1A, C). To 
determine whether Tiam-1 and Abl are acting exclusively upstream of Rac, a 
constitutively active Rac mutant, RacV12 was expressed in siRNA transfected cells. 
Expression of RacV12 reversed the effects on fusion of siRNA to Tiam-1, suggesting that 
Tiam-1 is functioning upstream of Rac (Fig 1A, right). In contrast, levels of fusion in 
cells expressing RacV12 and siRNA to Abl were only 53 ± 1% that of cells expressing 
RacV12 and control siRNA, suggesting a role for Abl upstream and downstream of Rac.  
     Tiam1 binds to the Rac and Cdc42 effector IRSp53, enhancing IRSp53 binding to Rac 
and the Wave2 scaffolding complex (150). To determine the role of these Rac effectors in 
Env-mediated membrane fusion, their expression was downregulated by RNAi in 
U87.CD4.CCR5 cells. The siRNA expressing cells were mixed with Env-expressing cells 
and fusion measured. Expression of siRNAs to Irsp53, Wave2, and Arp3 decreased 
fusion by 74 ± 5% 77 ± 4% and 78 ± 4%, respectively, and this decrease was not 
overcome by expression of RacV12, suggesting that these proteins are required 
downstream of Rac (Fig 1B). The decrease in fusion correlated with the downreguation in 
protein expression as seen by immunoblot (Fig. 1C), and each siRNA was specific for its 
target protein (Fig S1A). Treatment of cells stably expressing siRNA resistant Arp3, with 
Arp3 targeted siRNA had no effect on Env-mediated cell-cell fusion. (Fig. 1D). However, 
treatment of untransfected cells and cells stably expressing siRNA resistant Arp3 with 
siRac decreased fusion by 75 ± 5% and 76 ± 3% respectively (Fig. 1D). These results 
show that the effect of RNAi on fusion is specific to inhibition of target molecules. 
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Small molecule inhibitors of Abl kinase activity inhibit HIV-1 entry.  
     Since treatment of cells with Abl targeted siRNA led to a decrease in fusion, we 
determined whether treatment with Abl kinase inhibitors, imatinib (IMB), nilotinib 
(NIL), and dasatinib (DAS), block fusion and infection. IMB is a relatively specific 
inhibitor of Bcr-Abl, Abl, Arg, and class III receptor tyrosine kinases. NIL is a kinase 
inhibitor 20-50 fold more potent than IMB at inhibiting Abl. DAS, originally designed as 
a Src family kinase inhibitor, also inhibits ephrin and platelet-derived growth factor 
receptor kinases, and kit. DAS is 300 fold more potent than IMB at inhibiting Abl (160, 
161). To determine the concentrations of these Abl kinase inhibitors that inhibit Env-
mediated fusion without non-specific effects, trypan blue analysis, vaccinia virus 
infection, and T7 polymerase activity were measured in addition to Env-dependent cell 
fusion (Fig. S2). Treatment of U87.CD4.CCR5 cells with 10uM IMB, 500nM NIL, and 
300nM DAS for 1h prior to and during 3h incubation with Env-expressing cells 
decreased Env-mediated fusion by an average of 95 ± 2%, 92 ± 5%, and 92 ± 6%, 
respectively, and Abl kinase activity by 85-87% (Fig. 2A, S1B). There was no decrease 
in T7 polymerase activity, or localization of CD4 and CCR5 on the cell surface (Fig. S2, 
S3). Expression of RacV12 in cells treated with IMB, NIL and DAS increased the level 
of fusion by an average of 3.5-fold (**, P < 0.05) compared to treated cells without 
RacV12, suggesting a role of Abl kinase activity upstream of Rac (Fig. 2B). To 
determine the effect of these Abl kinase inhibitors on Env-induced Rac activation, 
U87.CD4.CCR5 cells were treated with inhibitors for 1h prior to mixing with BSC40 
cells expressing no HIV-1 Env, HIV-1 X4 Env, or HIV-1 R5 Env for 30 minutes in the 
presence of inhibitor. The mismatched X4 Env, that does not induce Rac activation in 
 115 
CCR5 expressing cells, and the CCR5 inhibitor TAK-779, which completely blocks Env-
mediated Rac activation in CCR5 expressing cells, were included as controls. Env-
induced Rac activation was abolished in cells treated with TAK-779 and all three of the 
Abl kinase inhibitors (Fig. 2C). To validate these effects in a relevant HIV-1 target cell, 
PBLs which express CD4, CCR5 and CXCR4, were used as the target cell in an Env-
dependent cell fusion assay.  Treatment of PBLs with IMB, NIL, and DAS decreased 
fusion by an average of 92 ± 1%, 92 ± 3%, and 99.5 ± 1%, respectively, for HIV-1 R5, 
dual-tropic and X4 Env subtypes (Fig. 2D). In addition, infection of CD4, CCR5 and 
CXCR4-expressing cells with R5 and X4 HIV-1 was inhibited by treatment with IMB in 
a dose dependent manner (Fig. S2C). These results suggest that Abl is required for Env-
induced fusion mediated by both CCR5 and CXCR4. The CCR5 inhibitor TAK-779, as 
expected, completely blocked fusion and infection mediated by R5 Env-expressing cells, 
inhibited fusion mediated by dual-tropic Env by 56 ± 2%, and had no effect on fusion or 
infection mediated by X4 Env (Fig. 2D, S2C).   
      To confirm these results using virus particles with relevant levels of virus-associated 
glycoprotein, we used a virus-dependent cell fusion assay based on the ability of virus 
particles to bridge two cells and allow transfer of cytoplasmic contents (12, 45). For this 
assay we used two populations of U87.CD4.CCR5 cells, one expressing the T7 
polymerase and the other expressing the β-galactosidase (β-gal) gene under the T7 
promoter. Both populations were incubated with inhibitors for 1h prior to 3h incubation 
with R5 virus HIVYU2. In this assay controls included untreated and inhibitor treated cells 
that were not incubated with virus, TAK-779, and T-20, which blocks entry by inhibiting 
the conformational change in HIV-1 gp41 required for fusion (135). Virus-dependent cell 
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fusion was reduced by an average of 94 ± 3% in cells treated with IMB, DAS, and NIL 
compared to cells treated with DMSO alone, and treatment with TAK-779 and T-20 
completely inhibited fusion (Fig. 2E). To confirm the specificity of these effects, we 
performed an Env-dependent fusion assay with cells stably expressing two different drug 
resistant Bcr-Abl mutants (Y253F and T315I), or expressing wildtype (WT) Bcr-Abl 
(162). Expression of the drug resistant Bcr-Abl mutants but not WT Bcr-Abl resulted in 
recovery of fusion (Fig. 2F), demonstrating that the effects of these inhibitors on Env-
dependent fusion are specific to inhibition of Abl. 
Infection of TZM-BL cells with HIV-1 particles but not particles pseudotyped with 
Amphotropic Murine Leukemia Virus (A-MLV) Env or Vesicular Stomatitis Virus 
Glycoprotein (VSV-G) depend on Abl and the Wave2 signaling complex 
      To determine whether the Wave2 signaling complex and Abl are required exclusively 
for HIV-1 entry, or virus-induced  fusion and infection in general, we examined infection 
with HIV-1 versus A-MLV Env (A-MLV-HIV-1) or VSV-G pseudotyped HIV-1 (VSV-
G HIV-1) using the TZM-BL assay. HIV-1 Env induces virus-cell fusion at the cell 
surface to facilitate entry, whereas viruses pseudotyped with VSV-G or A-MLV Env 
induce clathrin- or caveola-mediated endocytosis, respectively (145). TZM-BL cells, a 
derivative of HeLa cells that express physiological levels of CD4, CCR5, CXCR4, and 
luciferase (luc) under the control of the HIV-1 LTR, were pretreated with the Abl kinase 
inhibitors for 1h prior to incubation with virus for 3h, and a subsequent 24h incubation 
with inhibitor only (117, 135). Ammonium chloride (NH4Cl) which inhibits clathrin 
mediated endocytosis, and okadaic acid (OA), which inhibits caveola-mediated 
endocytosis, were included as controls. Fig. 3A shows that treatment with IMB, NIL, and 
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DAS decreased infection with HIVYU2 virus by 93 ± 10%, 94 ± 0.5%, and 92 ± 14%, 
respectively, comparable to the reductions in Env-dependent and virus-dependent cell 
fusion . The Abl kinase inhibitors had no effect on infection with A-MLV HIV-1 or 
VSV-G HIV-1, but treatment with NH4Cl blocked infection with VSV-G HIV-1, and 
treatment with OA blocked infection with A-MLV HIV-1 (Fig. 3A, middle and bottom). 
These data show that Abl kinase inhibitors were able to block HIV-1 Env-mediated 
fusion specifically, had no effect on infection via clathrin-mediated or caveola-mediated 
endocytosis, and do not affect post-entry steps. 
     To test the effect of Wave2 complex targeted siRNAs on infection, TZM-BL cells 
were transfected with 200nM control or siRNA directed towards Tiam-1, Trio, Abl, 
Irsp53, Wave2 and Arp3.  These cells were incubated with virus for 3h, and media alone 
for 24h. The decreased levels of HIV-1YU2 infection of TZM-BL cells expressing siRNA 
targeted to Tiam-1, Abl, Irsp53, Wave2, and Arp3 was comparable to levels of Env-
mediated cell fusion with U87.CD4.CCR5 cells expressing these siRNAs, whereas the 
siRNA to Trio had no effect (Fig. 3B, 1A, 1B).  Steady state levels of target proteins in 
cells expressing targeted siRNAs were decreased to similar levels as in U87 cells (Fig. 
1C). Infection of TZM-BL cells with A-MLV HIV-1 or VSV-G HIV-1 was not affected 
by expression of the targeted siRNAs (Fig 3B), suggesting that Tiam-1, Abl, Irsp53, 
Wave2, and Arp3 are not necessary for post-fusion steps in the virus life cycle.  
The Abl kinase inhibitors block fusion and infection at a post-hemifusion step  
     HIV-1 Env-induced fusion and release of the viral capsid into the cytosol is a 
multistep process. 1) The surface subunit gp120 binds CD4, and undergoes a 
conformational change, and actin cytoskeletal rearrangements in the target membrane 
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bring the coreceptor CCR5 or CXCR4 into close proximity. 2) Coreceptor binding to 
gp120 triggers conformational changes in gp41 to produce a prebundle conformation that 
inserts into the target cell membrane, allowing lipid mixing or hemifusion, and pore 
formation. 3) Additional conformational changes induce formation of the gp41 6-helix-
bundle which prevents pore closure and facilitates pore enlargement and full fusion (4, 7, 
163). To determine which step(s) in the membrane fusion process are blocked by the Abl 
kinase inhibitors, we examined the effect of membrane curving agents on fusion and 
infection.  Oleic acid (OLA), chlorpromazine (CPZ), dibucaine (DB), and trifluoperazine 
(TFP) are lipid analogs that insert into the inner leaflet of the cell membrane. OLA 
induces curvature in the membrane that promotes formation of a hemifusion intermediate 
but cannot induce pore formation if there is a block at hemifusion. CPZ, DB, and TFP are 
membrane-permeable weak bases that partition into inner leaflets of cell membranes and 
induce curvature and relieve a block at hemifusion (164, 165). To determine the effect of 
inhibitors and lipid analogs on virus-dependent cell fusion, U87.CD4.CCR5 cells were 
treated with TAK-779, IMB, NIL, and DAS for 1h, prior to 30 minute incubation with 
HIVYU2, and treatment with CPZ, DB, and TFP for 1 min or OLA  for 5 min. The lipid 
analogs were washed off, inhibitor and virus were added back, and fusion was measured 
after 3h. Cells were also incubated with the lipid analogs in the absence of HIVYU2 to 
account for the effects of these agents on the cells and on T7 polymerase activity. TAK-
779 mediated inhibition of fusion was not affected by these lipid analogs. The average 
level of fusion for CPZ treated cells, treated with IMB, NIL, and DAS, versus DMSO 
alone was 78 ± 3% versus 5 ± 3% in the absence of any lipid analog (Fig. 4A). Addition 
of the lipid analogs DB and TFP increased levels of fusion in cells treated with Abl 
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kinase inhibitors to 52 ± 3% and 55 ± 2% respectively, in comparison to cells treated 
with DMSO alone. Addition of OLA did not increase fusion in cells treated with any of 
the inhibitors.  
     To confirm these results with another cell type and to show the effect of lipid analogs 
on HIV-1 infection, TZM-BL cells were similarly treated with inhibitors and lipid 
analogs but after the 3h incubation with HIV-1YU2, virus was washed off, inhibitors were 
added back and cells incubated for 24h.  Addition of CPZ and TFP to TZM-BL cells 
treated with Abl kinase inhibitors increased average infection to 56 ± 5% and 59 ± 4% 
respectively, versus DMSO treated cells (Fig. 4B). Infection of TZM-BL cells treated 
with Abl kinase inhibitors in the absence of lipid analogs was only 11 ± 5% that of 
DMSO treated cells.  OLA had no effect on infection (Fig. 4B). These results suggest that 
inhibition of Abl kinase arrests fusion at a hemifusion step, preventing pore formation, 
pore enlargement and content mixing.  
To confirm that Abl kinase inhibitors cause arrest at hemifusion, we used a 
modification of a fusion assay described previously (166). CHO-K1 cells, that lack 
expression of the lipid ganglioside GM1, were engineered to express GFP and the HIV-
1ADA (R5) Env protein. U87.CD4.CCR5 cells were used as the target cell, and lipid 
mixing was detected when GM1, detected by a TRITC-conjugated form of cholera toxin 
β-subunit (CTX-β), was transferred from the target cell to CHO-K1-GFP cells.  Complete 
fusion is detected when cells express GM1, GFP, and are multinucleated. Quantification 
was performed for three independent experiments and percentage of hemifused GFP+, 
GM1+ cells with single nuclei and the percentage of multinucleated fully fused cells was 
enumerated for 68 cells from each condition (Fig. 4C, S4, Table S1). There were 83.1 
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±10.9% hemifused cells with IMB-treated cells mixed with HIVADA-expressing CHO-K1 
cells, compared to DMSO treated cells with 22.3 ± 4.9% hemifused cells and 75.5 ± 6.2% 
fully fused cells (Fig 4C). With no HIV-1 Env or with the addition of TAK-779 there was 
little or no hemifusion or full fusion. These results confirm that Abl kinase activity is 
required at a post-hemifusion step. 
Discussion 
     Dynamic regulation of the actin cytoskeleton is required for fusion of biological 
membranes. For Env-mediated membrane fusion actin rearrangements in the target cell 
are critical for formation of the gp120-CD4-coreceptor complex, as well as post-binding 
steps (11, 12, 25, 33, 44, 45, 73). Our previous data demonstrated that Env-induced Rac 
activation is mediated by Gαq and its downstream effectors, including Ras. We showed 
that a small molecule inhibitor of Rac GEFs, Trio and Tiam-1 eliminated Env-dependent 
fusion (44, 45). Other studies showed that Ras  promotes Rac activation via direct 
interaction with Tiam1, or by phosphatidylinositol 3-kinase (PI3K)-mediated activation 
of Tiam-1 (144). Env-dependent Rac activation likely occurs through the first 
mechanism, since treatment of target cells with PI3K inhibitors had no effect on Env-
dependent cell fusion (167).  
     The non-receptor tyrosine kinase, Abl, modulates actin upstream and downstream of 
Rac (168, 169). In the current study, we show that the activity of Abl kinases is required 
both upstream and downstream of Rac for Env-induced membrane fusion. Env-mediated 
fusion and Rac activation were attenuated in cells treated with siRNA targeted to Abl, or 
Abl kinase inhibitors, IMB, NIL, and DAS, which was only partially overcome by 
expression of RacV12. This inhibition was observed with Env expressed on viral or 
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cellular membranes, and when cell lines or primary cells were the target. The inhibitor 
concentrations employed did not alter levels of CD4 or CCR5 expression or localization 
on the surface of cells nor did they result in nonspecific effects on vaccinia virus 
infection or T7 polymerase activity. The effects of these inhibitors on Env-mediated 
fusion were specific to inhibition of Abl as demonstrated by reversal of inhibition in cells 
expressing drug resistant Abl mutants.  
     Abl kinase has been shown to modulate actin reorganization downstream of Rac by 
phosphorylation and activation of the Wave2 complex. Abl interactor adaptors associate 
with Wave2, and promote membrane translocation and phosphorylation of Wave2 (159, 
170). Wave2 mediates signaling downstream of Rac, through Arp2/3-mediated actin 
polymerization. Tiam1 binds to the adaptor protein IRSp53, and promotes the interaction 
of activated Rac and Wave2. In the current study we demonstrated that IRSp53, Wave2, 
and Arp3 are required downstream of Rac for HIV-1 entry and infection. Env-mediated 
fusion was attenuated in cells expressing siRNA targeted to IRSp53, Wave2 and Arp3 
and this inhibition was not overcome by expression of RacV12. The decrease in fusion 
observed with Arp3 targeted siRNA was overcome by expression of siRNA resistant 
Arp3 suggesting that the effects observed with RNAi were specific. Infection of TZM-BL 
cells with HIV-1 was similarly inhibited in cells expressing Tiam-1, Abl, IRSp53, Wave2 
and Arp3 directed siRNA. HIV-1 infection was also inhibited in cells treated with Abl 
kinase inhibitors. The inhibition of HIV-1 infection by targeted siRNA or Abl kinase 
inhibitors was overcome when virus was pseudotyped with VSV-G or A-MLV Env. 
These results suggest that these signaling mediators are important for HIV-1 Env 
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mediated entry and are not necessary for clathrin or caveola-mediated endocytosis, and 
they are not required at post-entry steps in the virus life cycle.  
     The current study also showed that the block in fusion caused by inhibition of Abl 
kinase occurs after hemifusion and before cytoplasmic mixing. This conclusion was 
based on the 1) confocal microscopy demonstration that addition of IMB to the fusion 
reaction allowed membrane but not cytoplasmic mixing, and 2) observation that lipid 
analogs that overcome a block at hemifusion overcame Abl kinase inhibition of HIV-1 
virus dependent cell fusion and infection. These results support a model whereby HIV-1 
Env binding to CCR5 stimulates activation of Gαq resulting in activation of Ras, via 
pyk2 and Abl phosphorylation of the Ras GEF complex. Activated Ras then mediates 
Rac activation via the Rac GEF Tiam-1, and activated Rac interacts with IRSp53. IRSp53 
promotes Rac activation of the Wave2 complex, which is also activated by Abl, and 
activated Wave2 induces subsequent activation of Arp2/3-mediated actin rearrangements 
which facilitate pore formation, pore enlargement, and entry of HIV-1. 
     Many microbial pathogens depend on Abl family kinases to mediate efficient infection 
of their targeted host, including Shigella flexneri, enteropathogenic Escherichia coli, 
Heliobacter pylori, Anaplama phagocytophilum, coxsackievirus, poxvirus, and murine 
AIDS virus. Abl kinases are involved in pathogen entry, intracellular movement, and exit 
from target cells; proliferation of target cells; and phosphorylation of microbial effectors. 
Many of these processes involve reorganization of the target cell actin cytoskeleton and 
depend on the same signaling pathways as HIV-1 (12, 73, 171). Discovery of these 
signaling mediators as fundamental components of microbial pathogenesis provides new 
targets for therapeutic intervention. The clinical application of IMB, NIL, and DAS, 
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which block deregulated Abl kinases in leukemia patients, demonstrate that inhibition in 
vivo is possible with manageable side effects (160, 161, 172). In addition IMB has been 
shown to be an effective inhibitor of anti-apoptotic pathways induced by HIV-1 in 
macrophages (173). Most current antiviral therapies target viral proteins and mutation of 
the virus leads to therapy resistance. Therefore, using inhibitors that target host signaling 
proteins essential for HIV-1 entry may be an efficient new strategy for treatment of 
infected patients.  
Materials and Methods  
Reagents & Cell Lines. U87.CD4.CCR5 cells are astroglioma cells expressing CD4, 
CCR5-GFP or HA-CCR5. CHO-K1 cells (ATCC) were grown in F-12K media with 10% 
serum and other cells maintained as described (116). pMSCVneo-WT, Y253F, and T315I 
Bcr-Abl were gifts from Dr. R. Van Etten (162). The siRNA resistant mutations were 
generated in Arp3 based on sequences obtained from Santa Cruz Biotechnology Inc 
(SCBT), by PCR-mediated mutagenesis. WT and mutant cDNAs were cloned in 
pcDNA3.1+zeo. IMB, NIL, and DAS were from LC Laboratories and were used at 10uM, 
500nM, and 300nM respectively unless indicated; CPZ (0.5mM), DB (5mM), TFP 
(0.3mM), OA (100nM), OLA (50uM) and NH4Cl (50mM) were from Sigma; TAK-779 
(1uM), and T-20 (10ug/ml) were from the AIDS Research and Reference Reagent 
Program; and siRNA constructs were from SCBT and used at 200nM (73). 
Viruses. WT vaccinia (WR strain) and recombinant vaccinia viruses expressing β-gal 
(vCB21R), T7 polymerase (vPT7-3), constitutively active Rac GTPase (vRacV12), or 
HIV-1 Env proteins were described (116). HIV with R5 YU2 or X4 HXB2 Env in 
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HIVNL4-3 backbone were generated from 293T cells; some were pseudotyped with A-
MLV) or VSV glycoproteins (73). TZM-BL assays were performed as described (73). 
Fusion and hemifusion assays. Envelope-mediated and virus-dependent fusion assays 
were described. Average fusion compared to untreated control reactions were detected by 
ß-gal activity ± standard deviation (73). Hemifusion assays were performed with 2x106 
CHO-K1 cells nucleofected with a GFP expression plasmid, and after 24h infected with 
vaccinia virus expressing HIVADA Env or no Env. After 16h, 4x105 U87.CD4.CCR5.HA 
cells were added for 3h, fixed with paraformaldehyde, stained with TRITC-conjugated 
CTX-β (CTX-555, EMD), and analyzed on a 510 Meta LSM confocal microscope. 
Statistical Analysis. Fusion and infectivity results were compared using a two-tailed t-
test. All p values, unless indicated, were <0.03. 
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Figures 
Fig. 1. Downregulation of Wave2 signaling complex with siRNA reduces HIV-1 Env-
mediated cell fusion and infection. U87.CD4.CCR5 cells were transfected with control 
siRNA (control) or siRNA targeted against (A) Trio, Tiam-1, Abl, Rac, (B) Irsp53, 
Wave2, and Arp3. Cells were serum starved 24h post-transfection (pt), infected with 
vCB21R alone or with vRacV12 48h pt, and 72h pt cells were incubated for 3h with 
HIVUNC (subtracted as background), HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-
expressing cells and β-gal activity was measured (C) Each population of transfected cells 
were analyzed by western blot with antibodies to the designated protein or actin. The 
relative reduction index (RI) is the quotient of the densitometry signal for the target band 
and that for actin, normalized by the ratio obtained with control siRNA. (D) 
U87.CD4.CCR5 cells engineered to express a siRNA resistant clone of Arp3 were 
transfected with control siRNA, or siRNA targeted against Arp3 or Rac. Cell fusion was 
measured by β-gal activity, and was normalized using control siRNA transfected cells 
incubated with HIVADA Env as 100%. All data are representative of results from three 
similar experiments performed in triplicate. 
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Fig 2. Abl kinase is required upstream and downstream of Rac. (A) Serum starved 
U87.CD4.CCR5 cells were infected with vCB21R alone, or with (B) vRacV12 overnight, 
then treated with DMSO alone, TAK-779, IMB, NIL, or DAS for 1h and the inhibitors 
were also present during 3h incubation with HIV-1 Env-expressing cells and β-gal 
activity as measured. (C) U87.CD4.CCR5 cells were treated for 1h with TAK-779, IMB, 
NIL, or DAS and during 30 min incubation with BSC40 cells expressing no Env 
(subtracted as background), HIVADA Env or HIVHXB2 Env. Whole cell lysates were 
analyzed by Rac specific G-LISA activation assay. Average A490 of triplicate wells ± 
standard deviation are shown. (D) Serum starved PBLs were infected with vCB21R in 
complete media overnight, treated with DMSO, TAK-779, IMB, NIL, or DAS for 1h 
prior to addition of HIV-1 Env-expressing cells and β-gal activity was measured. (E) 
U87.CD4.CCR5 cells were infected overnight with vCB21R or vPT7-3, then mixed (1:1) 
in triplicate wells, treated for 1h with DMSO, TAK-779, T20, IMB, NIL, DAS, and with 
100ng of HIVYU2 for 3h at 37°C. β-gal activity was measured and cell fusion was 
normalized using DMSO treated cells mixed with HIVYU2 as 100%(F) U87.CD4.CCR5 
cells engineered to express indicated clones of Bcr-Abl were treated with Abl inhibitors 
and HIVUNC or HIVADA Env as described above or analyzed by western blot with anti-
Abl or anti-actin antibody (inset). All data are representative of results from three similar 
experiments performed in triplicate. 
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Fig. 3.  Infection with HIV-1 particles but not particles pseudotyped with MLV Env 
or VSV-G is dependent on Abl and the Wave2 signaling complex. (A) TZM-BL cells 
were incubated for 1h with DMSO, NH4Cl , OA, IMB, NIL, or DAS and 150ng of 
HIVYU2, A-MLV-or VSV-G-HIV-1 per well was added for 3h, washed, and cells were 
incubated with inhibitors overnight and luc activity was measured. (B) TZM-BL cells 
were transfected with control siRNA or siRNA directed against indicated target proteins 
and 48h later infected with 150ng of HIVYU2, A-MLV- or VSV-G-HIV-1 for 3h, cells 
were washed and incubated overnight, and luc activity measured. Cell infection was 
normalized using (A) DMSO treated cells or (B) cells transfected with control siRNA as 
100%. All data are representative of results from three similar experiments performed in 
triplicate. 
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Fig. 4. Abl kinase inhibitors block virus-dependent fusion and infection at a post-
hemifusion step. (A)  Serum starved U87.CD4.CCR5 cells were infected with vCB21R 
or vPT7-3 overnight, then mixed (1:1) in triplicate wells of 96 well plate, and these cells 
or (B) TZM-BL cells were treated with DMSO, TAK-779, IMB, NIL, or DAS for 1h, (A) 
100ng or (B) or 150ng of HIVYU2 added for 30 min with indicated lipid analogs for 1-5 
min (A) Cells were washed, and virus and inhibitors were added back for 3h and β-gal 
activity was measured or (B) cells were then washed and incubated in inhibitor overnight 
and luc activities were measured. Data are representative of results from three similar 
experiments. Cell fusion and infection were normalized using DMSO treated cells 
infected with HIVYU2 as 100%. (C) CHO-K1 cells that do not express GM1 were 
transfected with a GFP expressing plasmid (green), and 24h later infected with WT 
vaccinia virus or vaccinia virus expressing HIVADA Env. After another 24h, CHO-K1 
cells were overlayed for 3h with U87.CD4.CCR5 cells pre-treated for 1h with DMSO, 
TAK-779, or IMB. Cells were fixed and stained with CTX-555 (red), and counterstained 
with TO-PRO 3 (blue). Images were collected using an oil objective (magnification X63). 
The upper panels are a consolidation of three different images and the lower panels are a 
consolidation of two different images. Images were cropped but relative cell size was 
maintained. The percentage of hemifused cells is listed. 
. 
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Supporting Imformation 
Fig. S1. Abl is activated by HIV-1 Env and Pretreatment with inhibitors and siRNA 
results in specific effects on target molecule. (A) U87.CD4.CCR5 cells were 
transfected with 200nM control siRNA or siRNA directed against Trio, Tiam-1, Abl, 
IRSp53, Wave2, Arp3 and Rac and 48 h later each population of transfected cells was 
lysed and analyzed by western blot with antibodies to the designated protein or actin. The 
relative reduction index (RI) is the quotient of the densitometry signal for the target band 
and that for actin, normalized by the ratio obtained with control siRNA. Data are from 1 
of 3 experiments with similar results. The bottom blot depicting Rac levels in cells 
transfected with the labeled siRNA demonstrates that the siRNAs have no effect on Rac 
expression. (B) Abl kinase activity was measured using PAthScan Bcr/Abl activity assay 
from Cell Signaling. Depicted is western blot analysis of a downstream target of activated 
Abl kinase, phosphorylated CrkL, and loading control eIF4E from lysates of 
U87.CD4.CCR5 cells mixed 1:1 with BSC40 cells expressing no Env (lane 1) or Env 
from HIV-1 strain ADA (lanes 2-5) at 37°C for 20 min. Cells were pretreated with 
DMSO alone (NI, lane 1-2), 1uM TAK-779 (lane 3), 10uM IMB (lane 4), 500nM NIL 
(lane 5), 300nM DAS (lane 6), 100uM Rac GEF Inhibitor (lane 8), for 1hr and during the 
20min incubation with Env-expressing cells. Cell lysates were resolved by 10% SDS-
PAGE, transferred to a nitrocellulose membrane, and probed with phosphospecific 
primary antibody cocktail and anti-rabbit or anti-biotin secondary. Blots shown are 
representative of 3 independent experiments. 
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Fig. S2. Abl kinase inhibitors decrease Env-induced fusion, virus-dependent fusion 
and infection of TZM-BL cells with R5 and X4 virus in a concentration dependent 
manner. Average fusion compared to untreated control reactions was detected by ß-gal 
activity ± standard deviation. (A) Serum starved U87.CD4.CCR5 cells were infected with 
vCB21R alone, or with vRacV12 overnight, then treated with DMSO alone, 1uM TAK-
779 or 1uM, 5uM and 10uM IMB, for 1h and the inhibitors were also present during the 
3h incubation with HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or 
HIVHXB2 Env-expressing cells. (B) U87.CD4.CCR5 cells were infected overnight with 
vCB21R or vPT7-3, then mixed (1:1) in triplicate wells, treated for 1h with DMSO, 1uM 
TAK-779, or 1uM, 5uM and 10uM IMB, and 100ng of HIVYU2 added for 3h at 37°C. 
Cell fusion was normalized using DMSO treated cells mixed with HIVYU2 as 100%. (C) 
TZM-BL cells were incubated for 1 h with DMSO, 1uM TAK-779, 1, 5 and 10uM IMB, 
and 150ng of HIVYU2 or 150ng HIVHXB2 per well was added for 3h, washed, and cells 
were incubated with inhibitors at 37°C overnight. (D) Serum starved U87.CD4.CCR5 
cells were infected with vCB21R alone, or with vRacV12 overnight, then treated with 
DMSO alone, 125, 250 and 500nM NIL, or (E) DMSO alone, 75, 150 and 300nM DAS, 
for 1h and the inhibitors were also present during the 3h incubation with HIVUNC 
(subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells. 
Data are representative of results from three similar experiments.  
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Fig. S3. Abl kinase inhibitors do not affect surface expression and localization of 
CD4 and CCR5.GFP. (A) Confocal micrographs of U87.CD4.CCR5 cells treated with 
DMSO alone, TAK-779 (1uM), IMB (10uM), NIL (500nM), Dasatinb (300nM) and 
RacGEF Inhibitor (100uM) for 3h, and CD (1uM) for 15 min, fixed and stained with anti-
CD4-PE antibodies (Sigma, red) and counterstained with TO-PRO3 (blue). The green 
GFP signal and red PE signal have been merged to show areas of colocalization (yellow).  
Data are representative of results from 3 experiments. Images were collected using an oil 
objective (magnification X63). The NIL panel is a consolidation of 2 separate images. 
(B) U87.CD4.CCR5 cells were incubated with no inhibitor, DMSO alone, TAK-779 
(1uM), IMB (10uM), NIL (500nM), Dasatinb (300nM) and RacGEF Inhibitor (100uM) 
for 3h and detached by treatment with 5mM EDTA. U87 cells, and untreated and treated 
U87.CD4.CCR5 cells, were stained with anti-CCR5 (R&D) or anti-CD4 antibodies 
(Sigma), and goat anti-mouse PE conjugated antibody. Cells were analyzed on a FACS 
Calibur flow cytometer. Unlabeled U87.CD4.CCR5 cells were used to compensate for 
GFP. Data are expressed as percentage of surface expression based on DMSO treated 
cells as 100%.   
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Fig. S4. Abl kinase inhibitors block fusion at a post-hemifusion step. (A) CHO-K1 
cells that do not express GM1 were transfected with a GFP expressing plasmid, and 24h 
later infected with wildtype vaccinia virus or vaccinia virus expressing HIVADA. After 
another 24h, CHO-K1 cells were overlayed for 3h with U87.CD4.CCR5.HA cells pre-
treated for 1h with DMSO, 1uM TAK-779, or 10 uM IMB. Cells were fixed and stained 
with TRITC-conjugated CTX (CTX-555), and counterstained with TO-PRO 3 (blue). 
Images were collected using an oil objective (magnification X63). The upper right middle 
panel (ADA DMSO) is a consolidation of two different images. Images were cropped but 
relative cell size was maintained.  
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SI Table 1. Quantification of cell-cell hemifusion assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV Env Inhibitor % hemifusion ± SD % fusion ± SD 
None       
(n=68) 
DMSO 0 0 
ADA (R5)  
(n=68) 
DMSO 22.3 ± 4.9 75.5 ± 6.2 
ADA (R5) 
(n=68) 
TAK-779 7 ± 4.8 0 
ADA (R5) 
(n=68) 
Imatinib 83.1 ±10.9 14.3 ± 5.1 
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Introduction:  
 Substantial insights into the mechanism used by HIV-1 viral proteins to promote 
fusion have come from numerous studies using cell fusion assays, techniques that 
monitor viral core-associated enzymes into the host cell, and time-resolved imaging of 
single viral particles. The current model for viral protein-mediated fusion has emerged 
from extensive biochemical and functional data using these systems (7, 174-182). Fusion 
commences with binding of trimeric gp120 to CD4 which induces a structural change in 
gp120 that creates the binding site for coreceptor. Upon binding to coreceptor the 
gp120/gp41 complex undergoes additional conformational changes that results in 
dissociation of gp120 and gp41 and insertion of the hydrophobic TM domain of gp41 into 
the target cell membrane (4, 7, 183). In addition to anchoring the viral proteins to the 
target membrane, the fusion peptide also destabilizes lipid bilayers, by reducing the free  
energy barrier required to pass through curved fusion intermediates (182, 184). Next the 
extended trimeric conformation of gp41 that is bridging the viral and target membrane 
folds back on itself forming a hairpin structure and driving membrane merger 
(hemifusion) (7). The energy from the final folding of gp41 into the 6HB conformation is 
thought to facilitate pore formation and enlargement and the 6HB, which forms after pore 
formation, is though to prevent pore closure (7). 
Dilation of fusion pores to a size that is large enough for nucleocapsid delivery 
(~50nm) is required for infection but the mechanism of pore enlargement in not well 
understood. However evidence from our lab demonstrates a role for actin remodeling in 
HIV-1 entry post binding that would support the idea of HIV-1 hijacking cellular 
machinery to create and expand the fusion pore (7, 12). In Chapters 2-4 we sought to 
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determine the mechanism used by Env to mediate actin cytoskeleton rearrangements and 
to establish what role these rearrangements are playing in fusion.  
A previous study from our lab looked at the role of the actin filament network 
during HIV-1 Env-dependent entry and virus dependent syncytium formation, utilizing 
the actin cytoskeleton disrupting drugs JP, LA, and CD (7, 12). Previous studies showed 
that formation of the Env-CD4-coreceptor complexes was inhibited by treatment of target 
cells with the actin filament capping drug CD but the effect of other actin-targeted drugs 
and the role of actin at later stages in entry was not investigated (25, 185). The study 
from our lab went on to show that the actin filament stabilizing drug, JP and the actin 
monomer sequestering drug, LA inhibited cell fusion mediated by X4 and R5 Env  by 80 
to 100% whether  added before or after incubation at 25°C. As was shown previously CD 
was only inhibitory when the drug was added before the 25°C incubation (12, 25, 185). 
These results indicate that modulation of the actin cytoskeleton is necessary for HIV-1 
entry both prior to and after formation of Env-CD4-coreceptor complexes.  
This study then went on to support the role for actin-based structures in HIV-1 
Env-mediated syncytium formation by confocal imaging. Membrane ruffles, 
lamellipodia, and filopodial extensions were observed in target cells mixed with Env-
expressing cells by time-lapse confocal microscopy (12). These actin structures are 
mediated by Rac and Cdc42, while Rho stimulates formation of stress fibers which were 
not observed in the target cell (12, 31). This study went on to show that Rac was 
activated in target cells exposed to Env and that this activation was required for fusion 
and dependent on Env ligation of CCR5. The results from this study indicate that HIV-1 
Env-coreceptor interactions stimulate an intracellular signaling cascade that promotes 
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Rac mediated reorganization of the actin filament network necessary to facilitate 
membrane fusion (12, 25, 185).  
Results 
The data presented in Chapter 2 further substantiated a role for Rac activation in 
membrane fusion.  Treatment of target cells with a Rac GEF inhibitor blocked HIV-1 
fusion as measured by the Env-dependent fusion assay, infection, or the virus-dependent 
fusion assay (45). The concentration of Rac GEF inhibitor that blocked HIV fusion was 
similar to that required to block Env-induced Rac activation. The specificity of the 
inhibitor was examined by expressing a constitutively active Rac mutant, RacV12 in 
target cells treated with inhibitor. Expression of RacV12 overcame the effects of the Rac 
GEF inhibitor on Env-dependent fusion and on Env-dependent Rac activation (45). In 
addition the Rac GEF inhibitor had no effect on Env-dependent Rho activation (data not 
shown). This study also gave insight into the Rac GEF(s) required for Env-mediated Rac 
activation, as Tiam-1 and Trio are the only Rac GEFs known to be sensitive to this 
inhibitor (44). Additional studies looking at the role of downstream mediators of Rac in 
HIV Env-mediated fusion showed no effects of chemical inhibitors of NADPH oxidase, 
MEK, or myosin light chain. Expression of DN PAK-2 and PI3-K in target cells also had 
no effect on Env-mediated fusion (unpublished findings). In addition, a study looking at 
IL-17-mediated HIV permissiveness in quiescent T cells showed that DN PI3Kp110 and 
the PI3-K inhibitor wortmannin had no effect on fusion or infection of cells with HIV 
(186). 
In an effort to identify the role of CCR5-mediated signaling in Env-induced Rac 
activation and membrane fusion we made various mutations in the domains of the 
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intracellular loops (ICLs) and cytoplasmic tail of CCR5 thought to associate with 
different signaling effectors. It has been shown previously that certain intracellular 
domains of CCR5 and CXCR4 can be mutated without affecting HIV-induced membrane 
fusion  (78-85, 187-189). It has also been shown that specific domains of CCR5 associate 
with different Gα proteins and scaffolding molecules such as β-arrestin (40, 49, 80, 132). 
To determine which CCR5 domains and subsequently which signaling molecules were 
required for Env signaling to Rac, U87 CD4 cell lines were established that expressed 
mutations in the ICL2, ICL3 or the cytoplasmic tail of CCR5. The ICL3 mutations made 
in CCR5 were previously made in CCR1, which has 100% sequence homology to CCR5 
in this region. These mutations in ICL3 of CCR1 disrupted CCR1 coupling to Gαq  (80). 
The mutations made in ICL2 replaced the arginine (R) and tyrosine (Y), from the 
conserved DRY motif thought to associate with Gαi and β-arrestin, with glycine (G) and 
alanine (A) (85). The mutation in the C terminus of CCR5 was a truncation of the 
cytoplasmic tail engineered to end with amino acid (aa) 313. This mutation had been 
shown previously to disrupt β-arrestin association and Ca+ flux (83-85). 
 After these cell lines were established they were sorted by GFP for CCR5 
expression equal to that of U87 CD4 cells expressing wildtype CCR5 (wt cells). Upon 
examination of surface expression by flow cytometry with a CCR5 monoclonal antibody 
the mutants were observed to have a drastic reduction in the amount of surface expression 
compared to wt cells. These results were then confirmed by confocal microscope 
analysis. Next these cells were sorted for CCR5 surface expression similar to wt cells 
using a monoclonal antibody to CCR5. However upon examining surface expression of 
CCR5 on these newly sorted cell lines by flow cytometry and confocal microscopy, it 
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became apparent that there was still little to no surface expression of mutant CCR5 
(figure 1).  The sequences for all of the mutants were double checked and are the same as 
the CCR5 expressed in wt cells except for the targeted mutations. These results together 
with the confocal analysis lead to the conclusion that these mutations prevent proper 
surface trafficking of CCR5, as similar levels of CCR5 are synthesized (figure 1B). 
Although these mutations were all made previously in other studies, further investigation 
of the literature confirmed that the mutations do in fact affect surface expression of 
CCR5. (84, 85, 190, 191)  
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Fig 1. Mutations in the ICL2, ICL3, and a deletion in the C-terminus of CCR5.GFP 
prevent its surface expression. (A) Confocal micrographs of U87.CD4.CCR5.GFP cells 
(wildtype CCR5, far left), U87.CD4.CCR5.ICL3.GFP (middle left), 
U87.CD4.CCR5.ICL2.GFP (right center), and U87.CD4.CCR5∆C.GFP (far right), fixed 
and stained with anti-CD4-PE antibodies (red). The green GFP signal and red PE signal 
have been merged to show areas of colocalization (yellow). (B) The mutant CCR5 
constructs were transiently transfected into 293T cells and 48hr post transfection 
untransfected (not shown but used to determine R1) and transfected 293T cells were 
labeled for surface expression of CCR5 (anti-CCR5 primary and anti-mouse PE-
conjugated secondary) and analyzed by flow cytometry. The lower left quadrant are cells 
that do not express CCR5 (R1), the lower right quadrant are cells that express CCR5 as 
determined by expression of GFP but it is not on the surface (R2), and the upper right 
quadrant are cells that express CCR5 at the surface (R4, PE staining). 
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Since generation of CCR5 molecules unable to couple with signaling 
intermediates was not possible, we looked for alternative methods to determine the 
signaling pathway that regulates Env-mediated Rac activation and membrane fusion. In 
chapter 3 we utilized small interfering RNA (siRNA) and various small molecule 
inhibitors to determine the Env-induced signaling pathway required for Rac activation 
and fusion. The results from this study demonstrate that HIV-1 Env mediates activation 
of the Gαq pathway via CCR5 and this activation is critical for HIV-1 induced membrane 
fusion. Expression of Gαq, Gαi, and Gαs was downregulated by siRNA, and Env-mediated 
Rac activation and fusion were measured. Env-induced Rac activation and cell fusion 
were attenuated in cells expressing siRNA targeted to Gαq but not in cells expressing 
siRNA targeted to Gαi, or Gαs (73). Treatment of cells with inhibitors to the Gαq 
downstream effectors, PLCβ, PKC, intracellular Ca2+ release, and Ras, also blocked Env-
mediated Rac activation and membrane fusion. Whereas inhibitors specific for PKA, the 
downstream effector of Gαs, and PTX which blocks signaling via Gαi had no effect on 
Env-dependent Rac activation and cell fusion (73). In addition, Env-dependent Rac 
activation and cell fusion was also attenuated in cells expressing siRNA targeted to pyk2 
which is activated downstream of PKC and intracellular Ca2+ release, and is a mediator of 
Ras activation. Expression of RacV12 overcame the effects of Gαq and pyk2 siRNA as 
well as the effects of inhibitors of PLCβ and PKC on Env-dependent cell fusion, 
suggesting that these signaling mediators are acting upstream of Rac. Whereas levels of 
Env-induced fusion were only partially recovered by expression of RacV12 in cells 
treated with inhibitors to intracellular Ca2+ release and Ras, suggesting they play a role 
both upstream and downstream of Rac (73).  
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Similar results were obtained when cell fusion was induced by Env-expressed on 
viral or cellular membranes and when cell lines or primary cells were the target. 
Furthermore, single cycle infection of HIV-1 was also attenuated when Gαq and its 
downstream signaling mediators were blocked. On the other hand, infection of cells with 
A-MLV Env or VSV-G pseudotyped HIV-1 was not blocked by inhibitors to PKC, 
intracellular Ca2+ release and Ras, suggesting that these signaling mediators are 
specifically required for HIV-1 mediated fusion (73). The PLC inhibitor had a greater 
effect on HIV-1 infection than on Env-dependent fusion and also slightly decreased 
infection of cells with A-MLV-HIV-1 and VSV-G-HIV-1, suggesting that PLC is 
required at a post-fusion step in the virus life cycle (73).  
In summary, chapter 3 provides evidence that HIV-1 Env interaction with CCR5 
stimulates a signaling cascade involving Gαq, PLC, PKC, intracellular Ca2+ release, Pyk2 
and Ras that allows activation of Rac and subsequent actin cytoskeleton rearrangements 
necessary for fusion. These results confirm and extend the implication of Rac in HIV-1 
infection, and elucidate new potential target molecules of HIV-1 inhibitory drugs.  
The data presented in chapter 4 builds upon this pathway and demonstrates the 
role of the Rac GEF Tiam-1, the src tyrosine kinase Abl, and the Wave2 complex in 
mediating Env-induced reorganization of the actin cytoskeleton necessary for membrane 
fusion. This chapter also demonstrates that Abl kinase is required for membrane fusion 
after the hemifusion step, supporting the hypothesis that the virus hijacks cellular 
machinery to facilitate pore formation and enlargement (7). In this study we used siRNA 
to downregulate expression of the Rac GEFs Tiam-1 and Trio. We also used siRNA to 
downregulate expression of the src tyrosine kinase Abl. Abl has been shown previously 
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to modulate the actin cytoskeleton both upstream and downstream of Rac (157, 168-170, 
192-199). Env-mediated cell fusion and HIV-1 infection of TZM-BL cells was attenuated 
in cells expressing siRNA targeted to Tiam-1 and Abl but not in cells expressing siRNA 
targeted to Trio, despite a 70% reduction in protein levels of Trio. Expression of RacV12 
in cells completely overcame the effect of Tiam-1 directed siRNA, but only partially 
recovered levels of fusion in cells expressing Abl directed siRNA. These results support 
the idea that Tiam-1 is required upstream of Rac to facilitate its activation and Abl is 
functioning upstream and downstream of Rac in Env-mediated cell fusion. As mentioned 
previously, different GEFs are induced by specific signaling components and act not only 
as activators of Rac but also control the effectors activated. GEFs participate in 
subsequent signaling by directing localization of the activated Rac GDP to GTP exchange 
and by interacting in scaffold complexes that organize specific downstream signaling 
mediators (27, 28, 31, 42, 44, 144, 150).  
Theses results demonstrate a role for Tiam-1 and Abl, but not Trio, in Env-
mediated Rac activation and membrane fusion suggesting that the downstream effector of 
Rac is the Arp2/3 actin nucleating complex. Arp2/3 is activated downstream of Rac by 
the Wave2 complex which includes five main proteins, Wave2, Sra-1, Nap-1, Abi2, and 
HSP C300. The tyrosine kinase Abl has been shown to associate with the Wave2 
complex via the Abi2 protein and and has been shown to phosphorylate Wave2 
enhancing the ability of Wave2 to activate the Arp2/3 complex. In addition, the adaptor 
protein IRSp53 has been shown to interact with Tiam-1, and this interaction links Rac to 
Wave2 mediated Arp2/3 activation (150). In this study we observed a decrease in Env-
mediated fusion and HIV-1 infection with cells expressing Irsp53, Wave2 and Arp3 
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directed siRNA. This decrease was not overcome by expression of RacV12, 
demonstrating a role for these proteins downstream of Rac in Env-mediated fusion. 
However expression of siRNA reistant Arp3 did overcome the decrease in fusion in cells 
expressing siRNA to Arp3 but not siRNA to Rac, suggesting that the effects observed 
with RNAi were specific. The decrease in fusion and infection observed with siRNA 
targeted to Abl, Tiam-1, IRSp53, Wave2 and Arp3 directly correlated with the decrease 
in protein expression as seen by immunoblot.  
Since treatment of cells with Abl targeted siRNA attenuated Env-dependent 
fusion and HIV-1 infection, we next sought to determine the effects of commercially 
available Abl kinase inhibitors, IMB, NIL and DAS, on fusion and infection. The 
inhibitor concentrations employed did not alter levels of CD4 or CCR5 expression or 
localization on the surface of cells nor did they result in nonspecific effects on vaccinia 
virus infection or T7 polymerase activity. These inhibitors were used in multiple assays 
including Env-dependent cell fusion with cell lines and primary cells as the target, virus-
dependent cell fusion, Infection of TZM-BL cells with both R5 and X4 virus and Rac 
activation assays. The Abl kinase inhibitors completely abolished fusion and infection 
mediated by both R5 and X4 Env. Env-mediated Rac activation and virus dependent cell 
fusion were similarly abolished. Expression of RacV12 partially overcame the inhibitor 
effects on Env-mediated fusion similar to the effects of RacV12 expression seen in cells 
expressing Abl targeted siRNA. Treatment of cells expressing drug resistant clones of 
Bcr-Abl with Abl kinase inhibitors had no effect on Env-mediated fusion suggesting that 
the effects of these drugs on fusion were specific to inhibition of Abl. The inhibition of 
infection of TZM-BL cells expressing Abl, Tiam-1, IRSp53, Wave2 and Arp3 directed 
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siRNA or treated with Abl kinase inhibitors was overcome when HIV-1 virions were 
psuedotyped with VSV-G or A-MLV Env. These results suggest that these signaling 
mediators are necessary for HIV-1 Env mediated fusion and entry but are not necessary 
for clathrin or caveloa-mediated endocytosis, and they are not required at post-entry steps 
in the virus life cycle. An Abl kinase assay was also performed and demonstrated that 
incubation of target cells with HIV-1 Env-expressing cells resulted in a 2 fold increase in 
Abl kinase activity (measured by an increase in phosphorylated CrkL, a downstream 
target of active Abl kinase) and Abl kinase activity is inhibited by IMB, NIL, and DAS.  
To determine what step in the fusion process is dependent on Abl kinase-mediated 
actin cytoskeleton rearrangements we used the membrane-permeable, cationic 
amphipaths, CPZ, DB, and TFP that induce positive spontaneous curvature of the plasma 
membrane, which in turn disrupts the hemifusion intermediate and promotes pore 
formation (176, 200, 201). We also tested the effect of the exogenous cone shaped lipid 
OLA that promotes negative spontaneous curvature of the membrane and lipid mixing 
(165, 202).  Brief exposure of Abl kinase inhibitor treated cells to CPZ, DB, and TFP 30 
min after incubation with virus increased fusion by ten to fifteen fold above the fusion 
observed with inhibitor treated cells not treated with membrane curving agents. Brief 
exposure of TAK-779 treated cells to CPZ, DB, and TFP did not lead to an increase in 
fusion as was expected. Infection of TZM-BL cells was similarly increased for Abl 
kinase inhibitor treated cells upon exposure to CPZ and TFP. OLA did not increase virus-
dependent membrane fusion or infection of HIV-1 in cells treated with Abl kinase 
inhibitors. No increase was observed in cells lacking exposure to virus, or in CCR5 cells 
exposed to X4 virus, indicating that the increase in fusion and infection was dependent on 
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Env. The block was not overcome by the exogenous lipid OLA, which promotes lipid 
mixing and hemifusion suggesting that the inhibitor treated cells are not arrested prior to 
hemifusion. Another assay utilizing confocal microscopy demonstrated that addition of 
IMB to the fusion reaction allowed lipid but not cytoplasmic mixing, confirming that 
inhibition of Abl kinase arrests fusion at the hemifusion stage and that Abl kinases are 
required for pore formation. 
In conclusion the data from chapters 2, 3, and 4 support the role of Env-mediated 
signaling to the actin cytoskeleton in membrane fusion and virus entry. Chapter 2 
confirmed the requirement for Rac activation in membrane fusion and gave clues to the 
Rac GEF mediating Env-dependent Rac activation (45). Chapter 3 demonstrated that the 
signaling pathway activated by Env binding to coreceptor required for Rac activation and 
membrane fusion was the Gαq pathway. This pathway involves multiple signaling 
components including PLCβ, PKC, pyk2 and Ras. Chapter 4 established a role for the 
Rac GEF Tiam-1 and Abl in Env-dependent Rac activation and membrane fusion and 
showed that signaling from Rac to the actin cytoskeleton is dependent on Abl, IRSp53, 
Wave2 and Arp3. Data present in chapter 4 also suggested that Abl kinase-mediated actin 
cytoskeleton rearrangements are required at a post-hemifusion step in the fusion process 
and that HIV-1 membrane fusion and infection can be inhibited by IMB, NIL and DAS. 
 
Future Directions 
The Rac-Wave2-Arp2/3 pathway described in Chapter 4 mediates actin 
polymerization, however actin rearrangement is a dynamic process that not only requires 
actin nucleation but also requires release of monomeric actin, and exposure of barbed 
 153 
ends. In addition to activating Arp2/3, Rac has been shown to regulate actin dynamics  by 
activating ADF/cofilin to accelerate actin turnover, and by regulating proteins such as 
gelsolin that promote the uncapping of actin at filament ends, leading to exposure of 
barbed ends (30, 35). The signaling mediators necessary for release of capping proteins 
and actin monomers in Env-mediated actin cytoskeletal rearrangements are unknown, 
and could provide additional targets for therapeutic intervention.  
A recent study demonstrated a requirement for phosphatidylinositol 4-phosphate 
5-kinase (PI4P5-K) activity, which mediates production of phosphatidylinositol (4,5)-
bisphosphate (PIP2), in HIV-1 membrane fusion and entry (203). The production of PIP2 
is triggered by Env-CD4 interactions and localizes at sites of Env-target cell contact 
along with F-actin. PI4P5-K is a downstream effector of Rac where it mediates focal 
complex assembly and is involved in release of actin capping proteins from barbed ends 
of actin filaments. PI4P5-K is also a downstream effector of Rho and is involved in focal 
adhesion assembly (30).  Another protein implicated in cell motility and Rac-mediated 
actin structures is profilin. When actin barbed ends are free to polymerize, profilin 
promotes actin filament dynamics by catalyzing nucleotide exchange on actin from ADP- 
to ATP, thereby contributing to actin polymerization at the leading edge of lamellipodia 
(204). A role for profilin in HIV-1 cell fusion has recently been demonstrated in 
macrophages (204). Another protein that regulates actin cytoskeletal dynamics 
downstream of Rho GTPases is actin depolymerizing factor ADF/cofilin. ADF/cofilins 
bind to actin-GDP at the ends of aged filaments and promote actin monomer dissociation. 
ADF/coflin can also bind to actin monomers and prevent GDP to GTP exchange. The 
role of ADF/cofilin in HIV-1 entry is slightly ambiguous since some studies suggest that 
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it is phosphorylated and inactivated by Env-mediated ROCK activation (11), and other 
studies suggest that ADF/cofilin is dephosphorylated and activated by Env signaling 
through CXCR4 (205). The role of various downstream effectors of Rho and Rac that 
mediate actin turnover and uncapping of barbed ends in Env-dependent fusion should be 
tested with available siRNA and small molecule inhibitors. 
 Future studies should also address the role of CD4 in Env-induced actin 
cytoskeleton rearrangements necessary for fusion. It is clear based on many published 
articles that gp120 mediates actin-dependent recruitment of CD4 and CXCR4 to sites of 
gp120 binding (10, 11, 25, 77, 104, 206, 207). However it is unclear whether Env 
signaling through CD4 alone or signaling through CD4 and coreceptor is required for 
Env, CD4 and coreceptor clustering. In addition the mechanism of actin-mediated 
clustering of receptors is unclear. Some studies have shown a requirement for CD4 
mediated activation of Ezrin-radixin-moesin (ERM) proteins that is not dependent on  the 
Rho effector ROCK or PKC (77). However, Rho could still play a role in ERM activation 
through PIP2   and another unknown mediator (27). Other studies have shown a role for 
CD4 and coreceptor-mediated filamin-A interactions in receptor clustering that is 
dependent on RhoA and ROCK mediated phosphorylation of ADF/cofilin (11).  
In a previous study our lab demonstrated that expression of DN Rac completely 
attenuated Env-dependent fusion whereas expression of DN RhoA decreased fusion by 
40% (18). Based on results showing a role for Rho activation in HIV-1 entry (11, 12, 33), 
I hypothesize that CD4-mediated RhoA activation is responsible for Env-CD4-coreceptor 
clustering required for binding, and subsequent signaling through coreceptor to Rac is 
necessary for pore formation and enlargement. (35).  Rac and Rho have been shown to 
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actively antagonize one another and mediate different processes (27, 36, 37). The C 
terminus of gp41 interacts with and inhibits p115 Rho GEF, suggesting that Rho is turned 
off and unnecessary for fusion events after gp41 insertion (38). Therefore it seems likely 
that Rho is only involved in the initial steps of Env-induced fusion prior to hemifusion 
and is subsequently inactivated by Rac and/or the C terminus of gp41.  
On the other hand, Env-mediated signaling to Rac and the actin cytoskeleton 
could occur through CD4 or coreceptor or both resulting in enhanced signaling (43, 49, 
64, 89). No studies have been performed in cells expressing mutant CD4 and mutant 
coreceptor incapable of signaling. A signaling pathway similar to the Gαq pathway is 
elicited by activation of CD4 suggesting that signaling necessary for fusion could occur 
through either receptor. The presence of CD4 could also play role in determining the 
signaling pathway elicited and the amount of activation (101, 102).  
We are currently testing these hypotheses by expressing multiple CD4 mutants 
incapable of signaling in target cells and performing assays with lipid analogs and the 
hemifusion assay described in chapter 4.  
 
Preliminary Results: 
U87 cell lines expressing CCR5.GFP alone (U87 CCR5) and U87 cell lines 
expressing CCR5.GFP and tailless CD4 (U87 CD4.401 CCR5) have been established. 
U87 cell lines expressing CD4 mutants that cannot bind to filamin A or p56lck are being 
established. The cell lines expressing CCR5 alone were used in an Env-dependent cell 
fusion assay where they were infected with a vaccinia virus expressing CD4. These cells 
showed similar amounts of fusion to U87 cells expressing wt CD4 and wt CCR5.GFP (wt 
 156 
cells). In addition the surface expression of CCR5 was determined to be equal to 
expression in wt cells via FACS. When this cell line was used in a Rac activation assay a 
significant decrease in the amount of Rac activation was observed in comparison to wt 
cells. These results suggest that CD4 is required for total Env-induced Rac activation. 
Based on these experiments it is still unknown whether CD4 is only required to induce 
the conformational change required for efficient binding to CCR5 or whether its 
cytoplasmic domain is involved in the signaling pathway leading to optimal Rac 
activation.  
To address this question U87 CD4.401.CCR5 cells were engineered and sorted 
for surface expression of CD4 and CCR5 that is similar to wt cells. These cells as well as 
U87.CD4.CCR5, U87.CCR5 and U87.CD4 cells were studied in a quantitative Env- and 
virus- dependent cell fusion assay and Rac activation assay. Although these cells express 
similar levels of receptor at the surface, cell fusion and Rac activation with U87.CD4.401 
CCR5 cells were reduced by 61 ± 7% and 64 ± 2% respectively compared to cells 
expressing wt CD4 and CCR5 (Fig. 2).  
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Fig. 2. Deletion of CD4 C-terminus attenuates Env-dependent fusion and Rac 
activation and virus-dependent fusion. (A) Average fusion compared to untreated 
control reactions and detected by ß-galactosidase activity ± standard deviation are shown. 
U87.CD4.CCR5, U87.CD4, U87.CCR5 and U87.CD4.401.CCR5 were infected with 
vCB21R overnight then incubated with HIVUNC (subtracted as background) HIVADA, 
HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are representative of 
results from three similar experiments performed in triplicate. Cell fusion was normalized 
using U87.CD4.CCR5 cells incubated with HIVADA Env as 100%. (B) Cells were 
incubated for 30 min with BSC40 cells expressing no Env (subtracted as background), or 
HIVADA Env. Whole cell lysates were then analyzed by Rac specific G-LISA activation 
assay. Average A490 of duplicate wells ± standard deviation; data are representative of 
results from three similar experiments. (C) One population of U87.CD4.CCR5 or 
U87.CD4.401.CCR5 cells was infected with vCB21R and the other population of cells 
was infected with vPT7-3 in complete media overnight. These cells were then mixed 
(1:1) in triplicate wells of 96 well plate and incubated with 75, 100, and 150ng of HIVYU2 
per well for 3h at 37°C. Data are representative of results from three similar experiments 
(*, P < 0.01). Cell fusion was normalized using U87.CD4.CCR5 cells mixed with 150ng 
HIVYU2 as 100%. 
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Future studies will include Env- and virus-dependent fusion assays, and Rac and Rho 
activation assays with mutant CD4 cell lines. Kinetic assays and temperature assays will 
also be performed to determine whether the observed attenuation in fusion is at the 
binding step and if allowing increasing amounts of time for binding before raising the 
temperature will increase the levels of fusion with these mutants. Mutant CD4 and CCR5 
localization should also be determined before and after treatment with Env to see if 
disrupting signaling through CD4 is effecting the recruitment of coreceptor to the site of 
Env-CD4 complexes. This can be done by confocal microscopy analysis and by co-
immunoprecipitation assays with antibodies to CD4, coreceptor, and gp120 (Env) (208). 
Cells will also be treated with the small molecule inhibitors damnacanthal (blocks lck 
activity) and piceatannol (blocks syk kinase ZAP-70) and the effects on Env-dependent 
fusion will be measured (205). We will also test Env-dependent fusion with Jurkat cells, 
which like T cells have Lck, or Jurkat derivatives deficient in Lck, ZAP70, or LAT. 
Finally, assays to determine the fusion steps dependent on CD4 will be performed, using 
mutants and inhibitor treated cells in hemifusion assays with lipid analogs and with 
CHO-K1 cells. 
 
Therapeutic Implications and Conclusions 
As mentioned previously the current anti-retroviral therapy, HAART, has 
important limitations, including rapid virus replication rebound after withdrawal, the 
increasing emergence and transmission of multi-resistant viral strains, difficulties in 
patient compliance, severe side effects and high cost that prevents delivery to 
undeveloped countries (2, 57). These considerations underscore the need for further 
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progress in drug discovery. Blocking HIV entry, versus blocking other steps in the virus 
life cycle is an attractive strategy since this would lock HIV outside the cell and thereby 
prevent the virus from replenishing its latent cellular reservoirs, the last hurdle in HIV 
eradication (57). However there are caveats to targeting the Env glycoprotein, as it one of 
the most variable HIV proteins, making evolution of drug resistance likely. 
Drugs that antagonize CD4, CXCR4, or CCR5 are also risky because they could 
interfere with their normal immune signaling functions in the cell. In addition, use of 
inhibitors that block both CCR5 and CXCR4 would be necessary to prevent promiscuous 
coreceptor usage. Although CCR5 and CXCR4 are the only chemokine receptors thought 
to be targeted by HIV in vivo, multiple other chemokine receptors have been shown to be 
functional coreceptors in vitro, suggesting that under selective pressure HIV-1 could 
evolve to use other chemokine receptors (50). An additional concern with the use of 
coreceptor inhibitors is the risk of interfering with the physiology of other GPCRs which 
are widespread. Cross reaction of inhibitors with other GPCRs would cause side effects 
unrelated to interference with the chemokine system (57). 
The discovery of a role for Abl kinase in HIV-1 Env-mediated entry is a 
particularly encouraging result as the development and clinical application of IMB, DAS, 
and NIL that block deregulated Bcr-Abl in chronic myeloid leukemia patients clearly 
shows that inhibition of Abl kinases is possible in vivo with clinically manageable side 
effects (160, 171, 193).  The next step will be to test IMB (Gleevac) in individuals 
infected with HIV-1 that have failed HAART therapy. Patients should be treated and the 
effect of the drug should be monitored by viral loads. In addition viral samples should be 
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taken to monitor resistance of virus to IMB. PBMC and CD4+ T cells should also be 
monitored for virus induced-changes in susceptibility to infection in the presence of IMB. 
 Studies should also been done prior to patient treatment to test for emergence of 
drug resistance. PBMCs should be infected with R5 and X4 viruses in the presence of 3 
different concentrations of IMB, for example 0.1uM, 1uM, and 10uM. These cells should 
be cultured for several weeks and used in entry and infection assays in the presence of 
IMB to test for new susceptibility to infection and fusion. Virus will be retitered on 
MAGI-5 cells in the presence or absence of IMB to test for resistance.  
The Env-mediated signaling pathway to Rac contains multiple factors that could 
be potential drug targets. There are multiple PKC inhibitors in clinical trials or approved 
for clinical use to treat cancer and diabetes (153).  Studies with the Ras inhibitor FTS in 
mice have given encouraging results for the treatment of various types of cancer, 
neurofibromatosis, and kidney disease (154-156). In addition, FTS is currently in phase I 
clinical trials for hematologic malignancies (155). The ability of these inhibitors and the 
Abl kinase inhibitors to specifically down-regulate their target molecules without adverse 
side effects suggests that these inhibitors might be appropriate drugs for treatment of 
HIV-1 and other infectious microbes that manipulate this pathway. In addition, 
determining the other signaling effectors of Rho and Rac that mediate Env-dependent 
fusion could provide additional targets for therapeutic intervention. This strategy of using 
inhibitors that disable host signaling proteins rather than viral proteins, essential for 
pathogen survival, may have a general efficacy in developing drugs to combat HIV-1 and 
other pathogens that acquire drug resistance. 
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